id	sid	tid	token	lemma	pos
aji-160	1	1	_	_	PUNCT
aji-160	2	1	_	_	PUNCT
aji-160	3	1	_	_	PUNCT
aji-160	4	1	_	_	PUNCT
aji-160	5	1	_	_	PUNCT
aji-160	6	1	_	_	PUNCT
aji-160	7	1	_	_	PUNCT
aji-160	8	1	_	_	PUNCT
aji-160	9	1	_	_	PUNCT
aji-160	10	1	_	_	PUNCT
aji-160	11	1	_	_	PUNCT
aji-160	12	1	_	_	PUNCT
aji-160	13	1	_	_	PUNCT
aji-160	14	1	_	_	PUNCT
aji-160	15	1	_	_	PUNCT
aji-160	16	1	_	_	PUNCT
aji-160	17	1	_	_	PUNCT
aji-160	18	1	_	_	PUNCT
aji-160	19	1	_	_	PUNCT
aji-160	20	1	_	_	PUNCT
aji-160	21	1	_	_	PUNCT
aji-160	22	1	_	_	PUNCT
aji-160	23	1	_	_	PUNCT
aji-160	24	1	_	_	PUNCT
aji-160	25	1	_	_	PUNCT
aji-160	26	1	_	_	PUNCT
aji-160	27	1	_	_	PUNCT
aji-160	28	1	_	_	PUNCT
aji-160	29	1	_	_	PUNCT
aji-160	30	1	_	_	PUNCT
aji-160	31	1	_	_	PUNCT
aji-160	32	1	_	_	PUNCT
aji-160	33	1	_	_	PUNCT
aji-160	34	1	_	_	PUNCT
aji-160	35	1	_	_	PUNCT
aji-160	36	1	_	_	PUNCT
aji-160	37	1	_	_	PUNCT
aji-160	38	1	_	_	PUNCT
aji-160	39	1	_	_	PUNCT
aji-160	40	1	_	_	PUNCT
aji-160	41	1	_	_	PUNCT
aji-160	42	1	_	_	PUNCT
aji-160	43	1	_	_	PUNCT
aji-160	44	1	_	_	PUNCT
aji-160	45	1	_	_	PUNCT
aji-160	46	1	_	_	PUNCT
aji-160	47	1	_	_	PUNCT
aji-160	48	1	_	_	PUNCT
aji-160	49	1	_	_	PUNCT
aji-160	50	1	_	_	PUNCT
aji-160	51	1	_	_	PUNCT
aji-160	52	1	_	_	PUNCT
aji-160	53	1	_	_	PUNCT
aji-160	54	1	_	_	PUNCT
aji-160	55	1	_	_	PUNCT
aji-160	56	1	_	_	PUNCT
aji-160	57	1	_	_	PUNCT
aji-160	58	1	_	_	PUNCT
aji-160	59	1	_	_	PUNCT
aji-160	60	1	_	_	PUNCT
aji-160	61	1	_	_	PUNCT
aji-160	62	1	_	_	PUNCT
aji-160	63	1	_	_	PUNCT
aji-160	64	1	_	_	PUNCT
aji-160	65	1	_	_	PUNCT
aji-160	66	1	_	_	PUNCT
aji-160	67	1	_	_	PUNCT
aji-160	68	1	_	_	PUNCT
aji-160	69	1	_	_	PUNCT
aji-160	70	1	_	_	PUNCT
aji-160	71	1	_	_	PUNCT
aji-160	72	1	_	_	PUNCT
aji-160	73	1	_	_	PUNCT
aji-160	74	1	_	_	PUNCT
aji-160	75	1	_	_	PUNCT
aji-160	76	1	_	_	PUNCT
aji-160	77	1	_	_	PUNCT
aji-160	78	1	_	_	PUNCT
aji-160	79	1	_	_	PUNCT
aji-160	80	1	_	_	PUNCT
aji-160	81	1	_	_	PUNCT
aji-160	82	1	_	_	PUNCT
aji-160	83	1	_	_	PUNCT
aji-160	84	1	_	_	PUNCT
aji-160	85	1	_	_	PUNCT
aji-160	86	1	_	_	PUNCT
aji-160	87	1	_	_	PUNCT
aji-160	88	1	_	_	PUNCT
aji-160	89	1	_	_	PUNCT
aji-160	90	1	_	_	PUNCT
aji-160	91	1	_	_	PUNCT
aji-160	92	1	_	_	PUNCT
aji-160	93	1	_	_	PUNCT
aji-160	94	1	_	_	PUNCT
aji-160	95	1	_	_	PUNCT
aji-160	96	1	_	_	PUNCT
aji-160	97	1	_	_	PUNCT
aji-160	98	1	_	_	PUNCT
aji-160	99	1	_	_	PUNCT
aji-160	100	1	_	_	PUNCT
aji-160	101	1	_	_	PUNCT
aji-160	102	1	*	*	PUNCT
aji-160	102	2	corresponding	correspond	VERB
aji-160	102	3	author	author	NOUN
aji-160	102	4	:	:	PUNCT
aji-160	102	5	e	e	NOUN
aji-160	102	6	-	-	NOUN
aji-160	102	7	mail	mail	NOUN
aji-160	102	8	:	:	PUNCT
aji-160	102	9	esmat.shaker@stu.edu.iq	esmat.shaker@stu.edu.iq	NOUN
aji-160	102	10	;	;	PUNCT
aji-160	102	11	cite	cite	VERB
aji-160	102	12	as	as	ADP
aji-160	102	13	:	:	PUNCT
aji-160	102	14	shaker	shaker	NOUN
aji-160	102	15	,	,	PUNCT
aji-160	102	16	esmat	esmat	ADJ
aji-160	102	17	esam	esam	PROPN
aji-160	102	18	.	.	PUNCT
aji-160	103	1	2025	2025	NUM
aji-160	103	2	.	.	PUNCT
aji-160	104	1	“	"	PUNCT
aji-160	104	2	frequency	frequency	NOUN
aji-160	104	3	and	and	CCONJ
aji-160	104	4	patterns	pattern	NOUN
aji-160	104	5	of	of	ADP
aji-160	104	6	cardiac	cardiac	ADJ
aji-160	104	7	involvement	involvement	NOUN
aji-160	104	8	in	in	ADP
aji-160	104	9	systemic	systemic	ADJ
aji-160	104	10	lupus	lupus	PROPN
aji-160	104	11	erythematosus	erythematosus	NOUN
aji-160	104	12	”	"	PUNCT
aji-160	104	13	.	.	PUNCT
aji-160	105	1	asian	asian	ADJ
aji-160	105	2	journal	journal	NOUN
aji-160	105	3	of	of	ADP
aji-160	105	4	immunology	immunology	NOUN
aji-160	105	5	8	8	NUM
aji-160	105	6	(	(	PUNCT
aji-160	105	7	1):60	1):60	NUM
aji-160	105	8	-	-	SYM
aji-160	105	9	69	69	NUM
aji-160	105	10	.	.	PUNCT
aji-160	106	1	https://doi.org/10.9734/aji/2025/v8i1160	https://doi.org/10.9734/aji/2025/v8i1160	PROPN
aji-160	106	2	.	.	PUNCT
aji-160	107	1	asian	asian	ADJ
aji-160	107	2	journal	journal	PROPN
aji-160	107	3	of	of	ADP
aji-160	107	4	immunology	immunology	NOUN
aji-160	107	5	volume	volume	NOUN
aji-160	107	6	8	8	NUM
aji-160	107	7	,	,	PUNCT
aji-160	107	8	issue	issue	NOUN
aji-160	107	9	1	1	NUM
aji-160	107	10	,	,	PUNCT
aji-160	107	11	page	page	NOUN
aji-160	107	12	60	60	NUM
aji-160	107	13	-	-	SYM
aji-160	107	14	69	69	NUM
aji-160	107	15	,	,	PUNCT
aji-160	107	16	2025	2025	NUM
aji-160	107	17	;	;	PUNCT
aji-160	107	18	article	article	NOUN
aji-160	107	19	no.aji.134457	no.aji.134457	PROPN
aji-160	107	20	frequency	frequency	NOUN
aji-160	107	21	and	and	CCONJ
aji-160	107	22	patterns	pattern	NOUN
aji-160	107	23	of	of	ADP
aji-160	107	24	cardiac	cardiac	ADJ
aji-160	107	25	involvement	involvement	NOUN
aji-160	107	26	in	in	ADP
aji-160	107	27	systemic	systemic	ADJ
aji-160	107	28	lupus	lupus	PROPN
aji-160	107	29	erythematosus	erythematosus	PROPN
aji-160	107	30	esmat	esmat	PROPN
aji-160	107	31	esam	esam	PROPN
aji-160	107	32	shaker	shaker	PROPN
aji-160	108	1	a	a	PROPN
aji-160	108	2	*	*	PUNCT
aji-160	108	3	a	a	DET
aji-160	108	4	department	department	NOUN
aji-160	108	5	of	of	ADP
aji-160	108	6	medical	medical	ADJ
aji-160	108	7	laboratories	laboratory	NOUN
aji-160	108	8	at	at	ADP
aji-160	108	9	the	the	DET
aji-160	108	10	technical	technical	PROPN
aji-160	108	11	medical	medical	PROPN
aji-160	108	12	institute	institute	PROPN
aji-160	108	13	in	in	ADP
aji-160	108	14	the	the	DET
aji-160	108	15	southern	southern	PROPN
aji-160	108	16	technical	technical	PROPN
aji-160	108	17	university	university	PROPN
aji-160	108	18	,	,	PUNCT
aji-160	108	19	basra	basra	PROPN
aji-160	108	20	,	,	PUNCT
aji-160	108	21	iraq	iraq	PROPN
aji-160	108	22	.	.	PUNCT
aji-160	109	1	author	author	PROPN
aji-160	109	2	’s	’s	PART
aji-160	109	3	contribution	contribution	NOUN
aji-160	109	4	the	the	DET
aji-160	109	5	sole	sole	ADJ
aji-160	109	6	author	author	NOUN
aji-160	109	7	designed	design	VERB
aji-160	109	8	,	,	PUNCT
aji-160	109	9	analysed	analyse	VERB
aji-160	109	10	,	,	PUNCT
aji-160	109	11	interpreted	interpret	VERB
aji-160	109	12	and	and	CCONJ
aji-160	109	13	prepared	prepare	VERB
aji-160	109	14	the	the	DET
aji-160	109	15	manuscript	manuscript	NOUN
aji-160	109	16	.	.	PUNCT
aji-160	110	1	article	article	NOUN
aji-160	110	2	information	information	PROPN
aji-160	110	3	doi	doi	PROPN
aji-160	110	4	:	:	PUNCT
aji-160	110	5	https://doi.org/10.9734/aji/2025/v8i1160	https://doi.org/10.9734/aji/2025/v8i1160	PROPN
aji-160	110	6	open	open	ADJ
aji-160	110	7	peer	peer	NOUN
aji-160	110	8	review	review	NOUN
aji-160	110	9	history	history	NOUN
aji-160	110	10	:	:	PUNCT
aji-160	110	11	this	this	DET
aji-160	110	12	journal	journal	NOUN
aji-160	110	13	follows	follow	VERB
aji-160	110	14	the	the	DET
aji-160	110	15	advanced	advance	VERB
aji-160	110	16	open	open	ADJ
aji-160	110	17	peer	peer	NOUN
aji-160	110	18	review	review	NOUN
aji-160	110	19	policy	policy	NOUN
aji-160	110	20	.	.	PUNCT
aji-160	111	1	identity	identity	NOUN
aji-160	111	2	of	of	ADP
aji-160	111	3	the	the	DET
aji-160	111	4	reviewers	reviewer	NOUN
aji-160	111	5	,	,	PUNCT
aji-160	111	6	editor(s	editor(s	NOUN
aji-160	111	7	)	)	PUNCT
aji-160	111	8	and	and	CCONJ
aji-160	111	9	additional	additional	ADJ
aji-160	111	10	reviewers	reviewer	NOUN
aji-160	111	11	,	,	PUNCT
aji-160	111	12	peer	peer	NOUN
aji-160	111	13	review	review	NOUN
aji-160	111	14	comments	comment	NOUN
aji-160	111	15	,	,	PUNCT
aji-160	111	16	different	different	ADJ
aji-160	111	17	versions	version	NOUN
aji-160	111	18	of	of	ADP
aji-160	111	19	the	the	DET
aji-160	111	20	manuscript	manuscript	NOUN
aji-160	111	21	,	,	PUNCT
aji-160	111	22	comments	comment	NOUN
aji-160	111	23	of	of	ADP
aji-160	111	24	the	the	DET
aji-160	111	25	editors	editor	NOUN
aji-160	111	26	,	,	PUNCT
aji-160	111	27	etc	etc	X
aji-160	111	28	are	be	AUX
aji-160	111	29	available	available	ADJ
aji-160	111	30	here	here	ADV
aji-160	111	31	:	:	PUNCT
aji-160	111	32	https://pr.sdiarticle5.com/review-history/134457	https://pr.sdiarticle5.com/review-history/134457	NOUN
aji-160	111	33	received	receive	VERB
aji-160	111	34	:	:	PUNCT
aji-160	111	35	13/02/2025	13/02/2025	NUM
aji-160	111	36	published	publish	VERB
aji-160	111	37	:	:	PUNCT
aji-160	111	38	23/04/2025	23/04/2025	NUM
aji-160	111	39	abstract	abstract	NOUN
aji-160	111	40	the	the	DET
aji-160	111	41	aim	aim	NOUN
aji-160	111	42	of	of	ADP
aji-160	111	43	the	the	DET
aji-160	111	44	study	study	NOUN
aji-160	111	45	was	be	AUX
aji-160	111	46	to	to	PART
aji-160	111	47	determine	determine	VERB
aji-160	111	48	the	the	DET
aji-160	111	49	prevalence	prevalence	NOUN
aji-160	111	50	of	of	ADP
aji-160	111	51	myocardial	myocardial	ADJ
aji-160	111	52	and	and	CCONJ
aji-160	111	53	circulatory	circulatory	ADJ
aji-160	111	54	complications	complication	NOUN
aji-160	111	55	among	among	ADP
aji-160	111	56	lupus	lupus	ADJ
aji-160	111	57	patients	patient	NOUN
aji-160	111	58	,	,	PUNCT
aji-160	111	59	such	such	ADJ
aji-160	111	60	as	as	ADP
aji-160	111	61	pericarditis	pericarditis	NOUN
aji-160	111	62	,	,	PUNCT
aji-160	111	63	heart	heart	NOUN
aji-160	111	64	failure	failure	NOUN
aji-160	111	65	,	,	PUNCT
aji-160	111	66	endocarditis	endocarditis	NOUN
aji-160	111	67	,	,	PUNCT
aji-160	111	68	ventricular	ventricular	ADJ
aji-160	111	69	dysfunction	dysfunction	NOUN
aji-160	111	70	,	,	PUNCT
aji-160	111	71	and	and	CCONJ
aji-160	111	72	myocarditis	myocarditis	NOUN
aji-160	111	73	.	.	PUNCT
aji-160	112	1	it	it	PRON
aji-160	112	2	was	be	AUX
aji-160	112	3	also	also	ADV
aji-160	112	4	to	to	PART
aji-160	112	5	assess	assess	VERB
aji-160	112	6	the	the	DET
aji-160	112	7	association	association	NOUN
aji-160	112	8	of	of	ADP
aji-160	112	9	lupus	lupus	NOUN
aji-160	112	10	with	with	ADP
aji-160	112	11	increased	increase	VERB
aji-160	112	12	myocardial	myocardial	ADJ
aji-160	112	13	injury	injury	NOUN
aji-160	112	14	and	and	CCONJ
aji-160	112	15	to	to	PART
aji-160	112	16	evaluate	evaluate	VERB
aji-160	112	17	therapeutic	therapeutic	ADJ
aji-160	112	18	(	(	PUNCT
aji-160	112	19	choriokinin	choriokinin	NOUN
aji-160	112	20	,	,	PUNCT
aji-160	112	21	corticosteroids	corticosteroid	NOUN
aji-160	112	22	,	,	PUNCT
aji-160	112	23	and	and	CCONJ
aji-160	112	24	glucocorticoids	glucocorticoid	NOUN
aji-160	112	25	)	)	PUNCT
aji-160	112	26	interventions	intervention	NOUN
aji-160	112	27	to	to	PART
aji-160	112	28	reduce	reduce	VERB
aji-160	112	29	the	the	DET
aji-160	112	30	complication	complication	NOUN
aji-160	112	31	of	of	ADP
aji-160	112	32	cardiovascular	cardiovascular	ADJ
aji-160	112	33	disease	disease	NOUN
aji-160	112	34	.	.	PUNCT
aji-160	113	1	this	this	DET
aji-160	113	2	study	study	NOUN
aji-160	113	3	focused	focus	VERB
aji-160	113	4	on	on	ADP
aji-160	113	5	the	the	DET
aji-160	113	6	immunological	immunological	ADJ
aji-160	113	7	aspect	aspect	NOUN
aji-160	113	8	of	of	ADP
aji-160	113	9	the	the	DET
aji-160	113	10	effect	effect	NOUN
aji-160	113	11	of	of	ADP
aji-160	113	12	immunosuppressive	immunosuppressive	ADJ
aji-160	113	13	therapy	therapy	NOUN
aji-160	113	14	in	in	ADP
aji-160	113	15	systemic	systemic	ADJ
aji-160	113	16	lupus	lupus	PROPN
aji-160	113	17	erythematous	erythematous	ADJ
aji-160	113	18	(	(	PUNCT
aji-160	113	19	sle	sle	PROPN
aji-160	113	20	)	)	PUNCT
aji-160	113	21	,	,	PUNCT
aji-160	113	22	specifically	specifically	ADV
aji-160	113	23	choriokinin	choriokinin	ADJ
aji-160	113	24	,	,	PUNCT
aji-160	113	25	corticosteroids	corticosteroid	NOUN
aji-160	113	26	,	,	PUNCT
aji-160	113	27	and	and	CCONJ
aji-160	113	28	glucocorticoids	glucocorticoid	NOUN
aji-160	113	29	(	(	PUNCT
aji-160	113	30	gcs	gcs	PROPN
aji-160	113	31	)	)	PUNCT
aji-160	113	32	,	,	PUNCT
aji-160	113	33	on	on	ADP
aji-160	113	34	the	the	DET
aji-160	113	35	exposure	exposure	NOUN
aji-160	113	36	of	of	ADP
aji-160	113	37	cardiovascular	cardiovascular	ADJ
aji-160	113	38	disease	disease	NOUN
aji-160	113	39	.	.	PUNCT
aji-160	114	1	the	the	DET
aji-160	114	2	study	study	NOUN
aji-160	114	3	period	period	NOUN
aji-160	114	4	extended	extend	VERB
aji-160	114	5	from	from	ADP
aji-160	114	6	2022	2022	NUM
aji-160	114	7	to	to	ADP
aji-160	114	8	early	early	ADJ
aji-160	114	9	2024	2024	NUM
aji-160	114	10	and	and	CCONJ
aji-160	114	11	relied	rely	VERB
aji-160	114	12	on	on	ADP
aji-160	114	13	the	the	DET
aji-160	114	14	results	result	NOUN
aji-160	114	15	of	of	ADP
aji-160	114	16	screening	screening	NOUN
aji-160	114	17	of	of	ADP
aji-160	114	18	88	88	NUM
aji-160	114	19	sle	sle	PROPN
aji-160	114	20	patients	patient	NOUN
aji-160	114	21	and	and	CCONJ
aji-160	114	22	a	a	DET
aji-160	114	23	control	control	NOUN
aji-160	114	24	group	group	NOUN
aji-160	114	25	of	of	ADP
aji-160	114	26	85	85	NUM
aji-160	114	27	patients	patient	NOUN
aji-160	114	28	.	.	PUNCT
aji-160	115	1	the	the	DET
aji-160	115	2	causes	cause	NOUN
aji-160	115	3	of	of	ADP
aji-160	115	4	heart	heart	NOUN
aji-160	115	5	damage	damage	NOUN
aji-160	115	6	in	in	ADP
aji-160	115	7	sle	sle	PROPN
aji-160	115	8	patients	patient	NOUN
aji-160	115	9	were	be	AUX
aji-160	115	10	identified	identify	VERB
aji-160	115	11	to	to	PART
aji-160	115	12	assess	assess	VERB
aji-160	115	13	the	the	DET
aji-160	115	14	relationship	relationship	NOUN
aji-160	115	15	with	with	ADP
aji-160	115	16	disease	disease	NOUN
aji-160	115	17	activity	activity	NOUN
aji-160	115	18	,	,	PUNCT
aji-160	115	19	duration	duration	NOUN
aji-160	115	20	,	,	PUNCT
aji-160	115	21	and	and	CCONJ
aji-160	115	22	rheumatic	rheumatic	ADJ
aji-160	115	23	treatment	treatment	NOUN
aji-160	115	24	.	.	PUNCT
aji-160	116	1	previously	previously	ADV
aji-160	116	2	,	,	PUNCT
aji-160	116	3	we	we	PRON
aji-160	116	4	first	first	ADV
aji-160	116	5	determined	determine	VERB
aji-160	116	6	n_terminal	n_terminal	ADJ
aji-160	116	7	prohormone	prohormone	NOUN
aji-160	116	8	of	of	ADP
aji-160	116	9	brain	brain	NOUN
aji-160	116	10	natriuretic	natriuretic	ADJ
aji-160	116	11	peptide	peptide	NOUN
aji-160	116	12	(	(	PUNCT
aji-160	116	13	nt_probnp	nt_probnp	NOUN
aji-160	116	14	)	)	PUNCT
aji-160	116	15	levels	level	NOUN
aji-160	116	16	in	in	ADP
aji-160	116	17	sle	sle	PROPN
aji-160	116	18	patients	patient	NOUN
aji-160	116	19	not	not	PART
aji-160	116	20	receiving	receive	VERB
aji-160	116	21	specific	specific	ADJ
aji-160	116	22	rheumatic	rheumatic	ADJ
aji-160	116	23	original	original	ADJ
aji-160	116	24	research	research	NOUN
aji-160	116	25	article	article	NOUN
aji-160	116	26	https://doi.org/10.9734/aji/2025/v8i1160	https://doi.org/10.9734/aji/2025/v8i1160	PROPN
aji-160	116	27	https://pr.sdiarticle5.com/review-history/134457	https://pr.sdiarticle5.com/review-history/134457	PROPN
aji-160	116	28	shaker	shaker	NOUN
aji-160	116	29	;	;	PUNCT
aji-160	116	30	asian	asian	PROPN
aji-160	116	31	j.	j.	PROPN
aji-160	116	32	immunol	immunol	PROPN
aji-160	116	33	.	.	PROPN
aji-160	116	34	,	,	PUNCT
aji-160	116	35	vol	vol	NOUN
aji-160	116	36	.	.	PROPN
aji-160	116	37	8	8	NUM
aji-160	116	38	,	,	PUNCT
aji-160	116	39	no	no	INTJ
aji-160	116	40	.	.	NOUN
aji-160	116	41	1	1	NUM
aji-160	116	42	,	,	PUNCT
aji-160	116	43	pp	pp	ADJ
aji-160	116	44	.	.	PUNCT
aji-160	117	1	60	60	NUM
aji-160	117	2	-	-	SYM
aji-160	117	3	69	69	NUM
aji-160	117	4	,	,	PUNCT
aji-160	117	5	2025	2025	NUM
aji-160	117	6	;	;	PUNCT
aji-160	117	7	article	article	NOUN
aji-160	117	8	no.aji.134457	no.aji.134457	VERB
aji-160	117	9	61	61	NUM
aji-160	117	10	treatment	treatment	NOUN
aji-160	117	11	and	and	CCONJ
aji-160	117	12	identified	identify	VERB
aji-160	117	13	a	a	DET
aji-160	117	14	relationship	relationship	NOUN
aji-160	117	15	between	between	ADP
aji-160	117	16	biomarker	biomarker	NOUN
aji-160	117	17	and	and	CCONJ
aji-160	117	18	immunological	immunological	ADJ
aji-160	117	19	marker	marker	NOUN
aji-160	117	20	concentrations	concentration	NOUN
aji-160	117	21	of	of	ADP
aji-160	117	22	sle	sle	PROPN
aji-160	117	23	activity	activity	NOUN
aji-160	117	24	(	(	PUNCT
aji-160	117	25	increased	increase	VERB
aji-160	117	26	serum	serum	NOUN
aji-160	117	27	levels	level	NOUN
aji-160	117	28	of	of	ADP
aji-160	117	29	anticardiolipin	anticardiolipin	PROPN
aji-160	117	30	igg	igg	PROPN
aji-160	117	31	,	,	PUNCT
aji-160	117	32	anti_dsdna	anti_dsdna	ADV
aji-160	117	33	,	,	PUNCT
aji-160	117	34	antinuclear	antinuclear	ADJ
aji-160	117	35	antibodies	antibodie	VERB
aji-160	117	36	,	,	PUNCT
aji-160	117	37	and	and	CCONJ
aji-160	117	38	decreased	decrease	VERB
aji-160	117	39	complement	complement	NOUN
aji-160	117	40	c4	c4	NOUN
aji-160	117	41	)	)	PUNCT
aji-160	117	42	and	and	CCONJ
aji-160	117	43	markers	marker	NOUN
aji-160	117	44	reflecting	reflect	VERB
aji-160	117	45	impaired	impaired	ADJ
aji-160	117	46	kidney	kidney	NOUN
aji-160	117	47	function	function	NOUN
aji-160	117	48	(	(	PUNCT
aji-160	117	49	nasonov	nasonov	NOUN
aji-160	117	50	,	,	PUNCT
aji-160	117	51	2010	2010	NUM
aji-160	117	52	,	,	PUNCT
aji-160	117	53	kim	kim	PROPN
aji-160	117	54	,	,	PUNCT
aji-160	117	55	et	et	PROPN
aji-160	117	56	al	al	PROPN
aji-160	117	57	.	.	PROPN
aji-160	117	58	,	,	PUNCT
aji-160	117	59	2017	2017	NUM
aji-160	117	60	)	)	PUNCT
aji-160	117	61	.	.	PUNCT
aji-160	118	1	corticosteroids	corticosteroid	NOUN
aji-160	118	2	are	be	AUX
aji-160	118	3	effective	effective	ADJ
aji-160	118	4	in	in	ADP
aji-160	118	5	preventing	prevent	VERB
aji-160	118	6	the	the	DET
aji-160	118	7	progression	progression	NOUN
aji-160	118	8	of	of	ADP
aji-160	118	9	sle	sle	PROPN
aji-160	118	10	and	and	CCONJ
aji-160	118	11	increasing	increase	VERB
aji-160	118	12	patient	patient	ADJ
aji-160	118	13	survival	survival	NOUN
aji-160	118	14	,	,	PUNCT
aji-160	118	15	while	while	SCONJ
aji-160	118	16	reducing	reduce	VERB
aji-160	118	17	the	the	DET
aji-160	118	18	exposure	exposure	NOUN
aji-160	118	19	of	of	ADP
aji-160	118	20	atherosclerosis	atherosclerosis	NOUN
aji-160	118	21	and	and	CCONJ
aji-160	118	22	thrombosis	thrombosis	NOUN
aji-160	118	23	(	(	PUNCT
aji-160	118	24	nasonov	nasonov	NOUN
aji-160	118	25	,	,	PUNCT
aji-160	118	26	2010	2010	NUM
aji-160	118	27	,	,	PUNCT
aji-160	118	28	tan	tan	PROPN
aji-160	118	29	,	,	PUNCT
aji-160	118	30	et	et	PROPN
aji-160	118	31	al	al	PROPN
aji-160	118	32	.	.	PROPN
aji-160	118	33	,	,	PUNCT
aji-160	118	34	1982	1982	NUM
aji-160	118	35	,	,	PUNCT
aji-160	118	36	hochberg	hochberg	NOUN
aji-160	118	37	,	,	PUNCT
aji-160	118	38	1997	1997	NUM
aji-160	118	39	)	)	PUNCT
aji-160	118	40	and	and	CCONJ
aji-160	118	41	hypercholesterolemia	hypercholesterolemia	NOUN
aji-160	118	42	(	(	PUNCT
aji-160	118	43	kim	kim	PROPN
aji-160	118	44	,	,	PUNCT
aji-160	118	45	et	et	PROPN
aji-160	118	46	al	al	PROPN
aji-160	118	47	.	.	PROPN
aji-160	118	48	,	,	PUNCT
aji-160	118	49	2017	2017	NUM
aji-160	118	50	,	,	PUNCT
aji-160	118	51	petri	petri	ADJ
aji-160	118	52	,	,	PUNCT
aji-160	118	53	et	et	PROPN
aji-160	118	54	al	al	PROPN
aji-160	118	55	.	.	PROPN
aji-160	118	56	,	,	PUNCT
aji-160	118	57	2012	2012	NUM
aji-160	118	58	)	)	PUNCT
aji-160	118	59	,	,	PUNCT
aji-160	118	60	ultimately	ultimately	ADV
aji-160	118	61	reducing	reduce	VERB
aji-160	118	62	a	a	DET
aji-160	118	63	exposure	exposure	NOUN
aji-160	118	64	of	of	ADP
aji-160	118	65	cardiovascular	cardiovascular	ADJ
aji-160	118	66	disease	disease	NOUN
aji-160	118	67	at	at	ADP
aji-160	118	68	sle	sle	PROPN
aji-160	118	69	patients	patient	NOUN
aji-160	118	70	,	,	PUNCT
aji-160	118	71	despite	despite	SCONJ
aji-160	118	72	isolated	isolated	ADJ
aji-160	118	73	reports	report	NOUN
aji-160	118	74	of	of	ADP
aji-160	118	75	cardiac	cardiac	ADJ
aji-160	118	76	toxicity	toxicity	NOUN
aji-160	118	77	(	(	PUNCT
aji-160	118	78	hochberg	hochberg	NOUN
aji-160	118	79	,	,	PUNCT
aji-160	118	80	1997	1997	NUM
aji-160	118	81	)	)	PUNCT
aji-160	118	82	.	.	PUNCT
aji-160	119	1	noticed	notice	VERB
aji-160	119	2	a	a	DET
aji-160	119	3	statistical	statistical	ADJ
aji-160	119	4	difference	difference	NOUN
aji-160	119	5	between	between	ADP
aji-160	119	6	the	the	DET
aji-160	119	7	two	two	NUM
aji-160	119	8	groups	group	NOUN
aji-160	119	9	in	in	ADP
aji-160	119	10	nt_probnp	nt_probnp	NOUN
aji-160	119	11	,	,	PUNCT
aji-160	119	12	as	as	SCONJ
aji-160	119	13	it	it	PRON
aji-160	119	14	was	be	AUX
aji-160	119	15	shown	show	VERB
aji-160	119	16	that	that	SCONJ
aji-160	119	17	the	the	DET
aji-160	119	18	second	second	ADJ
aji-160	119	19	group	group	NOUN
aji-160	119	20	had	have	VERB
aji-160	119	21	a	a	DET
aji-160	119	22	lower	low	ADJ
aji-160	119	23	nt_probnp	nt_probnp	NOUN
aji-160	119	24	result	result	VERB
aji-160	119	25	0.05	0.05	NUM
aji-160	119	26	than	than	ADP
aji-160	119	27	the	the	DET
aji-160	119	28	first	first	ADJ
aji-160	119	29	group	group	NOUN
aji-160	119	30	,	,	PUNCT
aji-160	119	31	and	and	CCONJ
aji-160	119	32	the	the	DET
aji-160	119	33	same	same	ADJ
aji-160	119	34	applies	apply	VERB
aji-160	119	35	to	to	ADP
aji-160	119	36	anti_jo1	anti_jo1	PROPN
aji-160	119	37	,	,	PUNCT
aji-160	119	38	which	which	PRON
aji-160	119	39	gives	give	VERB
aji-160	119	40	us	we	PRON
aji-160	119	41	evidence	evidence	NOUN
aji-160	119	42	beyond	beyond	ADP
aji-160	119	43	doubt	doubt	NOUN
aji-160	119	44	that	that	SCONJ
aji-160	119	45	immunosuppressive	immunosuppressive	ADJ
aji-160	119	46	treatments	treatment	NOUN
aji-160	119	47	work	work	VERB
aji-160	119	48	positively	positively	ADV
aji-160	119	49	in	in	ADP
aji-160	119	50	treating	treat	VERB
aji-160	119	51	heart	heart	NOUN
aji-160	119	52	muscle	muscle	NOUN
aji-160	119	53	diseases	disease	NOUN
aji-160	119	54	resulting	result	VERB
aji-160	119	55	from	from	ADP
aji-160	119	56	lupus	lupus	NOUN
aji-160	119	57	.	.	PUNCT
aji-160	120	1	keywords	keyword	NOUN
aji-160	120	2	:	:	PUNCT
aji-160	120	3	immunosuppressant	immunosuppressant	ADJ
aji-160	120	4	;	;	PUNCT
aji-160	120	5	sle	sle	PROPN
aji-160	120	6	;	;	PUNCT
aji-160	120	7	immunosuppressive	immunosuppressive	ADJ
aji-160	120	8	;	;	PUNCT
aji-160	120	9	myocarditis	myocarditis	ADJ
aji-160	120	10	;	;	PUNCT
aji-160	120	11	bnp	bnp	PROPN
aji-160	120	12	;	;	PUNCT
aji-160	120	13	aca	aca	PROPN
aji-160	120	14	;	;	PUNCT
aji-160	120	15	anti_jo1	anti_jo1	PROPN
aji-160	120	16	.	.	PUNCT
aji-160	121	1	1	1	X
aji-160	121	2	.	.	X
aji-160	121	3	introduction	introduction	NOUN
aji-160	121	4	systemic	systemic	ADJ
aji-160	121	5	lupus	lupus	PROPN
aji-160	121	6	erythematous	erythematous	ADJ
aji-160	121	7	(	(	PUNCT
aji-160	121	8	sle	sle	PROPN
aji-160	121	9	)	)	PUNCT
aji-160	121	10	is	be	AUX
aji-160	121	11	a	a	DET
aji-160	121	12	chronic	chronic	NOUN
aji-160	121	13	,	,	PUNCT
aji-160	121	14	multisystem	multisystem	NOUN
aji-160	121	15	immunological	immunological	ADJ
aji-160	121	16	disorder	disorder	NOUN
aji-160	121	17	of	of	ADP
aji-160	121	18	unknown	unknown	ADJ
aji-160	121	19	causality	causality	NOUN
aji-160	121	20	and	and	CCONJ
aji-160	121	21	genetic	genetic	ADJ
aji-160	121	22	predisposition	predisposition	NOUN
aji-160	121	23	it	it	PRON
aji-160	121	24	presents	present	VERB
aji-160	121	25	with	with	ADP
aji-160	121	26	diverse	diverse	ADJ
aji-160	121	27	clinical	clinical	ADJ
aji-160	121	28	features	feature	NOUN
aji-160	121	29	and	and	CCONJ
aji-160	121	30	follows	follow	VERB
aji-160	121	31	an	an	DET
aji-160	121	32	unpredictable	unpredictable	ADJ
aji-160	121	33	progression	progression	NOUN
aji-160	121	34	(	(	PUNCT
aji-160	121	35	nasonov	nasonov	NOUN
aji-160	121	36	,	,	PUNCT
aji-160	121	37	2010	2010	NUM
aji-160	121	38	)	)	PUNCT
aji-160	121	39	.	.	PUNCT
aji-160	122	1	myocarditis	myocarditis	PROPN
aji-160	122	2	affects	affect	VERB
aji-160	122	3	more	more	ADJ
aji-160	122	4	than	than	ADP
aji-160	122	5	55	55	NUM
aji-160	122	6	%	%	NOUN
aji-160	122	7	of	of	ADP
aji-160	122	8	sle	sle	PROPN
aji-160	122	9	patients	patient	NOUN
aji-160	122	10	and	and	CCONJ
aji-160	122	11	is	be	AUX
aji-160	122	12	a	a	DET
aji-160	122	13	leading	lead	VERB
aji-160	122	14	cause	cause	NOUN
aji-160	122	15	of	of	ADP
aji-160	122	16	fatal	fatal	ADJ
aji-160	122	17	condition	condition	NOUN
aji-160	122	18	.	.	PUNCT
aji-160	123	1	all	all	DET
aji-160	123	2	cardiac	cardiac	ADJ
aji-160	123	3	anatomical	anatomical	ADJ
aji-160	123	4	structures	structure	NOUN
aji-160	123	5	can	can	AUX
aji-160	123	6	be	be	AUX
aji-160	123	7	affected	affect	VERB
aji-160	123	8	by	by	ADP
aji-160	123	9	sle	sle	PROPN
aji-160	123	10	,	,	PUNCT
aji-160	123	11	such	such	ADJ
aji-160	123	12	as	as	ADP
aji-160	123	13	the	the	DET
aji-160	123	14	pericardium	pericardium	NOUN
aji-160	123	15	,	,	PUNCT
aji-160	123	16	endocardium	endocardium	NOUN
aji-160	123	17	,	,	PUNCT
aji-160	123	18	coronary	coronary	ADJ
aji-160	123	19	vessels	vessel	NOUN
aji-160	123	20	,	,	PUNCT
aji-160	123	21	and	and	CCONJ
aji-160	123	22	myocardium	myocardium	ADJ
aji-160	123	23	,	,	PUNCT
aji-160	123	24	with	with	ADP
aji-160	123	25	heart	heart	NOUN
aji-160	123	26	failure	failure	NOUN
aji-160	123	27	(	(	PUNCT
aji-160	123	28	hf	hf	X
aji-160	123	29	)	)	PUNCT
aji-160	123	30	being	be	AUX
aji-160	123	31	the	the	DET
aji-160	123	32	final	final	ADJ
aji-160	123	33	stage	stage	NOUN
aji-160	123	34	of	of	ADP
aji-160	123	35	cardiac	cardiac	ADJ
aji-160	123	36	and	and	CCONJ
aji-160	123	37	circulatory	circulatory	ADJ
aji-160	123	38	disease	disease	NOUN
aji-160	123	39	(	(	PUNCT
aji-160	123	40	kim	kim	PROPN
aji-160	123	41	,	,	PUNCT
aji-160	123	42	et	et	PROPN
aji-160	123	43	al	al	PROPN
aji-160	123	44	.	.	PROPN
aji-160	123	45	,	,	PUNCT
aji-160	123	46	2017	2017	NUM
aji-160	123	47	)	)	PUNCT
aji-160	123	48	.	.	PUNCT
aji-160	124	1	recent	recent	ADJ
aji-160	124	2	studies	study	NOUN
aji-160	124	3	indicate	indicate	VERB
aji-160	124	4	that	that	SCONJ
aji-160	124	5	systemic	systemic	ADJ
aji-160	124	6	lupus	lupus	NOUN
aji-160	124	7	erythematosus	erythematosus	NOUN
aji-160	124	8	(	(	PUNCT
aji-160	124	9	sle	sle	PROPN
aji-160	124	10	)	)	PUNCT
aji-160	124	11	is	be	AUX
aji-160	124	12	a	a	DET
aji-160	124	13	major	major	ADJ
aji-160	124	14	risk	risk	NOUN
aji-160	124	15	factor	factor	NOUN
aji-160	124	16	for	for	ADP
aji-160	124	17	myocarditis	myocarditis	NOUN
aji-160	124	18	and	and	CCONJ
aji-160	124	19	has	have	VERB
aji-160	124	20	a	a	DET
aji-160	124	21	significant	significant	ADJ
aji-160	124	22	impact	impact	NOUN
aji-160	124	23	on	on	ADP
aji-160	124	24	causing	cause	VERB
aji-160	124	25	actual	actual	ADJ
aji-160	124	26	damage	damage	NOUN
aji-160	124	27	to	to	ADP
aji-160	124	28	the	the	DET
aji-160	124	29	myocardic	myocardic	ADJ
aji-160	124	30	,	,	PUNCT
aji-160	124	31	pulmonary	pulmonary	ADJ
aji-160	124	32	valve	valve	NOUN
aji-160	124	33	,	,	PUNCT
aji-160	124	34	and	and	CCONJ
aji-160	124	35	ventricular	ventricular	ADJ
aji-160	124	36	,	,	PUNCT
aji-160	124	37	endocardial	endocardial	ADJ
aji-160	124	38	,	,	PUNCT
aji-160	124	39	and	and	CCONJ
aji-160	124	40	pericardial	pericardial	ADJ
aji-160	124	41	dysfunction	dysfunction	NOUN
aji-160	124	42	,	,	PUNCT
aji-160	124	43	which	which	PRON
aji-160	124	44	requires	require	VERB
aji-160	124	45	continuous	continuous	ADJ
aji-160	124	46	monitoring	monitoring	NOUN
aji-160	124	47	in	in	ADP
aji-160	124	48	the	the	DET
aji-160	124	49	intensive	intensive	ADJ
aji-160	124	50	care	care	NOUN
aji-160	124	51	unit	unit	NOUN
aji-160	124	52	(	(	PUNCT
aji-160	124	53	icu	icu	PROPN
aji-160	124	54	)	)	PUNCT
aji-160	124	55	(	(	PUNCT
aji-160	124	56	tan	tan	PROPN
aji-160	124	57	,	,	PUNCT
aji-160	124	58	et	et	PROPN
aji-160	124	59	al	al	PROPN
aji-160	124	60	.	.	PROPN
aji-160	124	61	,	,	PUNCT
aji-160	124	62	1982	1982	NUM
aji-160	124	63	,	,	PUNCT
aji-160	124	64	cieślik	cieślik	NOUN
aji-160	124	65	&	&	CCONJ
aji-160	124	66	holecki	holecki	NOUN
aji-160	124	67	,	,	PUNCT
aji-160	124	68	2022	2022	NUM
aji-160	124	69	)	)	PUNCT
aji-160	124	70	.	.	PUNCT
aji-160	125	1	alarming	alarming	ADJ
aji-160	125	2	results	result	NOUN
aji-160	125	3	have	have	AUX
aji-160	125	4	been	be	AUX
aji-160	125	5	recorded	record	VERB
aji-160	125	6	for	for	ADP
aji-160	125	7	deaths	death	NOUN
aji-160	125	8	due	due	ADP
aji-160	125	9	to	to	ADP
aji-160	125	10	heart	heart	NOUN
aji-160	125	11	failure	failure	NOUN
aji-160	125	12	in	in	ADP
aji-160	125	13	several	several	ADJ
aji-160	125	14	countries	country	NOUN
aji-160	125	15	around	around	ADP
aji-160	125	16	the	the	DET
aji-160	125	17	world	world	NOUN
aji-160	125	18	.	.	PUNCT
aji-160	126	1	in	in	ADP
aji-160	126	2	the	the	DET
aji-160	126	3	middle	middle	PROPN
aji-160	126	4	east	east	PROPN
aji-160	126	5	,	,	PUNCT
aji-160	126	6	saudi	saudi	PROPN
aji-160	126	7	arabia	arabia	PROPN
aji-160	126	8	occupied	occupy	VERB
aji-160	126	9	an	an	DET
aji-160	126	10	advanced	advanced	ADJ
aji-160	126	11	position	position	NOUN
aji-160	126	12	in	in	ADP
aji-160	126	13	deaths	death	NOUN
aji-160	126	14	,	,	PUNCT
aji-160	126	15	with	with	ADP
aji-160	126	16	36	36	NUM
aji-160	126	17	%	%	NOUN
aji-160	126	18	of	of	ADP
aji-160	126	19	deaths	death	NOUN
aji-160	126	20	due	due	ADP
aji-160	126	21	to	to	ADP
aji-160	126	22	heart	heart	NOUN
aji-160	126	23	muscle	muscle	NOUN
aji-160	126	24	failure	failure	NOUN
aji-160	126	25	due	due	ADP
aji-160	126	26	to	to	ADP
aji-160	126	27	pericarditis	pericarditis	NOUN
aji-160	126	28	,	,	PUNCT
aji-160	126	29	followed	follow	VERB
aji-160	126	30	by	by	ADP
aji-160	126	31	egypt	egypt	PROPN
aji-160	126	32	with	with	ADP
aji-160	126	33	a	a	DET
aji-160	126	34	rate	rate	NOUN
aji-160	126	35	of	of	ADP
aji-160	126	36	21.5	21.5	NUM
aji-160	126	37	%	%	NOUN
aji-160	126	38	of	of	ADP
aji-160	126	39	deaths	death	NOUN
aji-160	126	40	due	due	ADP
aji-160	126	41	to	to	ADP
aji-160	126	42	myocardial	myocardial	ADJ
aji-160	126	43	infarction	infarction	NOUN
aji-160	126	44	,	,	PUNCT
aji-160	126	45	and	and	CCONJ
aji-160	126	46	jordan	jordan	PROPN
aji-160	126	47	with	with	ADP
aji-160	126	48	a	a	DET
aji-160	126	49	rate	rate	NOUN
aji-160	126	50	of	of	ADP
aji-160	126	51	12	12	NUM
aji-160	126	52	%	%	NOUN
aji-160	126	53	due	due	ADP
aji-160	126	54	to	to	ADP
aji-160	126	55	myocardial	myocardial	ADJ
aji-160	126	56	infarction	infarction	NOUN
aji-160	126	57	(	(	PUNCT
aji-160	126	58	mazurek	mazurek	NOUN
aji-160	126	59	,	,	PUNCT
aji-160	126	60	et	et	PROPN
aji-160	126	61	al	al	PROPN
aji-160	126	62	.	.	PROPN
aji-160	126	63	,	,	PUNCT
aji-160	126	64	2022	2022	NUM
aji-160	126	65	)	)	PUNCT
aji-160	126	66	.	.	PUNCT
aji-160	127	1	while	while	SCONJ
aji-160	127	2	the	the	DET
aji-160	127	3	death	death	NOUN
aji-160	127	4	rate	rate	NOUN
aji-160	127	5	due	due	ADP
aji-160	127	6	to	to	ADP
aji-160	127	7	heart	heart	NOUN
aji-160	127	8	failure	failure	NOUN
aji-160	127	9	in	in	ADP
aji-160	127	10	latin	latin	PROPN
aji-160	127	11	america	america	PROPN
aji-160	127	12	was	be	AUX
aji-160	127	13	recorded	record	VERB
aji-160	127	14	in	in	ADP
aji-160	127	15	2023	2023	NUM
aji-160	127	16	alone	alone	ADV
aji-160	127	17	,	,	PUNCT
aji-160	127	18	more	more	ADJ
aji-160	127	19	than	than	ADP
aji-160	127	20	470	470	NUM
aji-160	127	21	deaths	death	NOUN
aji-160	127	22	due	due	ADJ
aji-160	127	23	to	to	ADP
aji-160	127	24	myocardial	myocardial	ADJ
aji-160	127	25	infarction	infarction	NOUN
aji-160	127	26	resulting	result	VERB
aji-160	127	27	from	from	ADP
aji-160	127	28	lupus	lupus	PROPN
aji-160	127	29	,	,	PUNCT
aji-160	127	30	in	in	ADP
aji-160	127	31	mexico	mexico	PROPN
aji-160	127	32	there	there	PRON
aji-160	127	33	are	be	VERB
aji-160	127	34	no	no	DET
aji-160	127	35	official	official	ADJ
aji-160	127	36	statistics	statistic	NOUN
aji-160	127	37	on	on	ADP
aji-160	127	38	these	these	DET
aji-160	127	39	cases	case	NOUN
aji-160	127	40	,	,	PUNCT
aji-160	127	41	but	but	CCONJ
aji-160	127	42	medical	medical	ADJ
aji-160	127	43	investigative	investigative	ADJ
aji-160	127	44	reports	report	NOUN
aji-160	127	45	suggest	suggest	VERB
aji-160	127	46	that	that	SCONJ
aji-160	127	47	the	the	DET
aji-160	127	48	percentage	percentage	NOUN
aji-160	127	49	is	be	AUX
aji-160	127	50	increasing	increase	VERB
aji-160	127	51	due	due	ADJ
aji-160	127	52	to	to	ADP
aji-160	127	53	myocardial	myocardial	ADJ
aji-160	127	54	infarction	infarction	NOUN
aji-160	127	55	(	(	PUNCT
aji-160	127	56	adawi	adawi	PROPN
aji-160	127	57	&	&	CCONJ
aji-160	127	58	blum	blum	PROPN
aji-160	127	59	,	,	PUNCT
aji-160	127	60	2020	2020	NUM
aji-160	127	61	,	,	PUNCT
aji-160	127	62	mazurek	mazurek	NOUN
aji-160	127	63	,	,	PUNCT
aji-160	127	64	et	et	PROPN
aji-160	127	65	al	al	PROPN
aji-160	127	66	.	.	PROPN
aji-160	127	67	,	,	PUNCT
aji-160	127	68	2022	2022	NUM
aji-160	127	69	)	)	PUNCT
aji-160	127	70	.	.	PUNCT
aji-160	128	1	the	the	DET
aji-160	128	2	american	american	PROPN
aji-160	128	3	heart	heart	PROPN
aji-160	128	4	association	association	PROPN
aji-160	128	5	reported	report	VERB
aji-160	128	6	that	that	SCONJ
aji-160	128	7	approximately	approximately	ADV
aji-160	128	8	2	2	NUM
aji-160	128	9	million	million	NUM
aji-160	128	10	patients	patient	NOUN
aji-160	128	11	suffer	suffer	VERB
aji-160	128	12	from	from	ADP
aji-160	128	13	fatal	fatal	ADJ
aji-160	128	14	myocardial	myocardial	ADJ
aji-160	128	15	infarctions	infarction	NOUN
aji-160	128	16	,	,	PUNCT
aji-160	128	17	most	most	ADJ
aji-160	128	18	of	of	ADP
aji-160	128	19	whom	whom	PRON
aji-160	128	20	are	be	AUX
aji-160	128	21	women	woman	NOUN
aji-160	128	22	of	of	ADP
aji-160	128	23	childbearing	childbeare	VERB
aji-160	128	24	age	age	NOUN
aji-160	128	25	.	.	PUNCT
aji-160	129	1	there	there	PRON
aji-160	129	2	are	be	VERB
aji-160	129	3	myocardial	myocardial	ADJ
aji-160	129	4	infarctions	infarction	NOUN
aji-160	129	5	that	that	PRON
aji-160	129	6	have	have	AUX
aji-160	129	7	become	become	VERB
aji-160	129	8	chronic	chronic	ADJ
aji-160	129	9	and	and	CCONJ
aji-160	129	10	life	life	NOUN
aji-160	129	11	-	-	PUNCT
aji-160	129	12	threatening	threatening	ADJ
aji-160	129	13	,	,	PUNCT
aji-160	129	14	and	and	CCONJ
aji-160	129	15	diseases	disease	NOUN
aji-160	129	16	resulting	result	VERB
aji-160	129	17	from	from	ADP
aji-160	129	18	hypertension	hypertension	NOUN
aji-160	129	19	and	and	CCONJ
aji-160	129	20	repeated	repeat	VERB
aji-160	129	21	myocardial	myocardial	ADJ
aji-160	129	22	infarction	infarction	NOUN
aji-160	129	23	(	(	PUNCT
aji-160	129	24	foret	foret	PROPN
aji-160	129	25	,	,	PUNCT
aji-160	129	26	et	et	PROPN
aji-160	129	27	al	al	PROPN
aji-160	129	28	.	.	PROPN
aji-160	129	29	,	,	PUNCT
aji-160	129	30	2022	2022	NUM
aji-160	129	31	,	,	PUNCT
aji-160	129	32	mazurek	mazurek	NOUN
aji-160	129	33	,	,	PUNCT
aji-160	129	34	et	et	PROPN
aji-160	129	35	al	al	PROPN
aji-160	129	36	.	.	PROPN
aji-160	129	37	,	,	PUNCT
aji-160	129	38	2022	2022	NUM
aji-160	129	39	)	)	PUNCT
aji-160	129	40	.	.	PUNCT
aji-160	130	1	the	the	DET
aji-160	130	2	pathogenesis	pathogenesis	NOUN
aji-160	130	3	of	of	ADP
aji-160	130	4	cardiac	cardiac	ADJ
aji-160	130	5	damage	damage	NOUN
aji-160	130	6	in	in	ADP
aji-160	130	7	sle	sle	PROPN
aji-160	130	8	is	be	AUX
aji-160	130	9	thought	think	VERB
aji-160	130	10	to	to	PART
aji-160	130	11	depend	depend	VERB
aji-160	130	12	on	on	ADP
aji-160	130	13	the	the	DET
aji-160	130	14	combined	combine	VERB
aji-160	130	15	or	or	CCONJ
aji-160	130	16	independent	independent	ADJ
aji-160	130	17	effects	effect	NOUN
aji-160	130	18	of	of	ADP
aji-160	130	19	chronic	chronic	ADJ
aji-160	130	20	immunological	immunological	ADJ
aji-160	130	21	disorder	disorder	NOUN
aji-160	130	22	inflammation	inflammation	NOUN
aji-160	130	23	,	,	PUNCT
aji-160	130	24	accelerated	accelerate	VERB
aji-160	130	25	progression	progression	NOUN
aji-160	130	26	of	of	ADP
aji-160	130	27	atherosclerosis	atherosclerosis	NOUN
aji-160	130	28	,	,	PUNCT
aji-160	130	29	and	and	CCONJ
aji-160	130	30	the	the	DET
aji-160	130	31	use	use	NOUN
aji-160	130	32	of	of	ADP
aji-160	130	33	certain	certain	ADJ
aji-160	130	34	ant	ant	ADJ
aji-160	130	35	rheumatic	rheumatic	ADJ
aji-160	130	36	drugs	drug	NOUN
aji-160	130	37	(	(	PUNCT
aji-160	130	38	tan	tan	PROPN
aji-160	130	39	,	,	PUNCT
aji-160	130	40	et	et	PROPN
aji-160	130	41	al	al	PROPN
aji-160	130	42	.	.	PROPN
aji-160	130	43	,	,	PUNCT
aji-160	130	44	1982	1982	NUM
aji-160	130	45	)	)	PUNCT
aji-160	130	46	.	.	PUNCT
aji-160	131	1	according	accord	VERB
aji-160	131	2	to	to	ADP
aji-160	131	3	an	an	DET
aji-160	131	4	epidemiological	epidemiological	ADJ
aji-160	131	5	study	study	NOUN
aji-160	131	6	(	(	PUNCT
aji-160	131	7	n	n	NOUN
aji-160	131	8	=	=	SYM
aji-160	131	9	500	500	NUM
aji-160	131	10	people	people	NOUN
aji-160	131	11	)	)	PUNCT
aji-160	131	12	,	,	PUNCT
aji-160	131	13	in	in	ADP
aji-160	131	14	patients	patient	NOUN
aji-160	131	15	with	with	ADP
aji-160	131	16	systemic	systemic	ADJ
aji-160	131	17	lupus	lupu	NOUN
aji-160	131	18	erythematous	erythematous	ADJ
aji-160	131	19	m	m	VERB
aji-160	131	20	cardiac	cardiac	ADJ
aji-160	131	21	damage	damage	NOUN
aji-160	131	22	was	be	AUX
aji-160	131	23	more	more	ADV
aji-160	131	24	frequently	frequently	ADV
aji-160	131	25	recorded	record	VERB
aji-160	131	26	(	(	PUNCT
aji-160	131	27	gladman	gladman	NOUN
aji-160	131	28	&	&	CCONJ
aji-160	131	29	ibanez	ibanez	PROPN
aji-160	131	30	,	,	PUNCT
aji-160	131	31	2002	2002	NUM
aji-160	131	32	):	):	PUNCT
aji-160	131	33	arrhythmia	arrhythmia	NOUN
aji-160	131	34	and	and	CCONJ
aji-160	131	35	electrical	electrical	ADJ
aji-160	131	36	disturbances	disturbance	NOUN
aji-160	131	37	in	in	ADP
aji-160	131	38	22	22	NUM
aji-160	131	39	%	%	NOUN
aji-160	131	40	and	and	CCONJ
aji-160	131	41	6	6	NUM
aji-160	131	42	%	%	NOUN
aji-160	131	43	,	,	PUNCT
aji-160	131	44	coronary	coronary	ADJ
aji-160	131	45	myocarditis	myocarditis	NOUN
aji-160	131	46	in	in	ADP
aji-160	131	47	13	13	NUM
aji-160	131	48	%	%	NOUN
aji-160	131	49	and	and	CCONJ
aji-160	131	50	4	4	NUM
aji-160	131	51	%	%	NOUN
aji-160	131	52	,	,	PUNCT
aji-160	131	53	major	major	ADJ
aji-160	131	54	valve	valve	NOUN
aji-160	131	55	insufficiency	insufficiency	NOUN
aji-160	131	56	in	in	ADP
aji-160	131	57	11	11	NUM
aji-160	131	58	%	%	NOUN
aji-160	131	59	and	and	CCONJ
aji-160	131	60	2	2	NUM
aji-160	131	61	%	%	NOUN
aji-160	131	62	,	,	PUNCT
aji-160	131	63	myocardial	myocardial	ADJ
aji-160	131	64	infarction	infarction	NOUN
aji-160	131	65	(	(	PUNCT
aji-160	131	66	mi	mi	NOUN
aji-160	131	67	)	)	PUNCT
aji-160	131	68	in	in	ADP
aji-160	131	69	6	6	NUM
aji-160	131	70	%	%	NOUN
aji-160	131	71	and	and	CCONJ
aji-160	131	72	2	2	NUM
aji-160	131	73	%	%	NOUN
aji-160	131	74	,	,	PUNCT
aji-160	131	75	cor	cor	PROPN
aji-160	131	76	pulmonale	pulmonale	PROPN
aji-160	131	77	in	in	ADP
aji-160	131	78	2.2	2.2	NUM
aji-160	131	79	%	%	NOUN
aji-160	131	80	and	and	CCONJ
aji-160	131	81	0.2	0.2	NUM
aji-160	131	82	%	%	NOUN
aji-160	131	83	,	,	PUNCT
aji-160	131	84	heart	heart	NOUN
aji-160	131	85	failure	failure	NOUN
aji-160	131	86	(	(	PUNCT
aji-160	131	87	hf	hf	NOUN
aji-160	131	88	)	)	PUNCT
aji-160	131	89	in	in	ADP
aji-160	131	90	1.0	1.0	NUM
aji-160	131	91	%	%	NOUN
aji-160	131	92	.	.	PUNCT
aji-160	132	1	in	in	ADP
aji-160	132	2	iraq	iraq	PROPN
aji-160	132	3	,	,	PUNCT
aji-160	132	4	there	there	PRON
aji-160	132	5	are	be	VERB
aji-160	132	6	no	no	DET
aji-160	132	7	statistics	statistic	NOUN
aji-160	132	8	that	that	PRON
aji-160	132	9	show	show	VERB
aji-160	132	10	us	we	PRON
aji-160	132	11	the	the	DET
aji-160	132	12	death	death	NOUN
aji-160	132	13	rate	rate	NOUN
aji-160	132	14	resulting	result	VERB
aji-160	132	15	from	from	ADP
aji-160	132	16	systemic	systemic	ADJ
aji-160	132	17	lupus	lupus	PROPN
aji-160	132	18	erythematosus	erythematosus	PROPN
aji-160	132	19	.	.	PUNCT
aji-160	133	1	the	the	DET
aji-160	133	2	last	last	ADJ
aji-160	133	3	statistics	statistic	NOUN
aji-160	133	4	for	for	ADP
aji-160	133	5	iraq	iraq	PROPN
aji-160	133	6	reached	reach	VERB
aji-160	133	7	11	11	NUM
aji-160	133	8	%	%	NOUN
aji-160	133	9	in	in	ADP
aji-160	133	10	1989	1989	NUM
aji-160	133	11	,	,	PUNCT
aji-160	133	12	and	and	CCONJ
aji-160	133	13	baghdad	baghdad	PROPN
aji-160	133	14	,	,	PUNCT
aji-160	133	15	the	the	DET
aji-160	133	16	capital	capital	NOUN
aji-160	133	17	,	,	PUNCT
aji-160	133	18	topped	top	VERB
aji-160	133	19	the	the	DET
aji-160	133	20	list	list	NOUN
aji-160	133	21	.	.	PUNCT
aji-160	134	1	all	all	DET
aji-160	134	2	deaths	death	NOUN
aji-160	134	3	were	be	AUX
aji-160	134	4	among	among	ADP
aji-160	134	5	fertile	fertile	ADJ
aji-160	134	6	women	woman	NOUN
aji-160	134	7	between	between	ADP
aji-160	134	8	the	the	DET
aji-160	134	9	ages	age	NOUN
aji-160	134	10	of	of	ADP
aji-160	134	11	25	25	NUM
aji-160	134	12	45	45	NUM
aji-160	134	13	,	,	PUNCT
aji-160	134	14	and	and	CCONJ
aji-160	134	15	the	the	DET
aji-160	134	16	statistics	statistic	NOUN
aji-160	134	17	indicated	indicate	VERB
aji-160	134	18	myocardial	myocardial	ADJ
aji-160	134	19	infarction	infarction	NOUN
aji-160	134	20	.	.	PUNCT
aji-160	135	1	after	after	ADP
aji-160	135	2	years	year	NOUN
aji-160	135	3	of	of	ADP
aji-160	135	4	war	war	NOUN
aji-160	135	5	,	,	PUNCT
aji-160	135	6	annual	annual	ADJ
aji-160	135	7	statistics	statistic	NOUN
aji-160	135	8	were	be	AUX
aji-160	135	9	absent	absent	ADJ
aji-160	135	10	.	.	PUNCT
aji-160	136	1	in	in	ADP
aji-160	136	2	this	this	DET
aji-160	136	3	research	research	NOUN
aji-160	136	4	,	,	PUNCT
aji-160	136	5	i	i	PRON
aji-160	136	6	focused	focus	VERB
aji-160	136	7	on	on	ADP
aji-160	136	8	studying	study	VERB
aji-160	136	9	the	the	DET
aji-160	136	10	effect	effect	NOUN
aji-160	136	11	of	of	ADP
aji-160	136	12	lupus	lupus	NOUN
aji-160	136	13	on	on	ADP
aji-160	136	14	the	the	DET
aji-160	136	15	heart	heart	NOUN
aji-160	136	16	muscle	muscle	NOUN
aji-160	136	17	for	for	ADP
aji-160	136	18	the	the	DET
aji-160	136	19	year	year	NOUN
aji-160	136	20	2022	2022	NUM
aji-160	136	21	to	to	ADP
aji-160	136	22	the	the	DET
aji-160	136	23	beginning	beginning	NOUN
aji-160	136	24	of	of	ADP
aji-160	136	25	2024	2024	NUM
aji-160	136	26	,	,	PUNCT
aji-160	136	27	in	in	ADP
aji-160	136	28	terms	term	NOUN
aji-160	136	29	of	of	ADP
aji-160	136	30	the	the	DET
aji-160	136	31	effect	effect	NOUN
aji-160	136	32	of	of	ADP
aji-160	136	33	lupus	lupus	NOUN
aji-160	136	34	on	on	ADP
aji-160	136	35	heart	heart	NOUN
aji-160	136	36	function	function	NOUN
aji-160	136	37	within	within	ADP
aji-160	136	38	the	the	DET
aji-160	136	39	available	available	ADJ
aji-160	136	40	medical	medical	ADJ
aji-160	136	41	data	datum	NOUN
aji-160	136	42	and	and	CCONJ
aji-160	136	43	for	for	ADP
aji-160	136	44	the	the	DET
aji-160	136	45	same	same	ADJ
aji-160	136	46	age	age	NOUN
aji-160	136	47	group	group	NOUN
aji-160	136	48	in	in	ADP
aji-160	136	49	1989	1989	NUM
aji-160	136	50	.	.	PUNCT
aji-160	137	1	shaker	shaker	NOUN
aji-160	137	2	;	;	PUNCT
aji-160	137	3	asian	asian	PROPN
aji-160	137	4	j.	j.	PROPN
aji-160	137	5	immunol	immunol	PROPN
aji-160	137	6	.	.	PROPN
aji-160	137	7	,	,	PUNCT
aji-160	137	8	vol	vol	NOUN
aji-160	137	9	.	.	PROPN
aji-160	137	10	8	8	NUM
aji-160	137	11	,	,	PUNCT
aji-160	137	12	no	no	INTJ
aji-160	137	13	.	.	NOUN
aji-160	137	14	1	1	NUM
aji-160	137	15	,	,	PUNCT
aji-160	137	16	pp	pp	ADJ
aji-160	137	17	.	.	PUNCT
aji-160	138	1	60	60	NUM
aji-160	138	2	-	-	SYM
aji-160	138	3	69	69	NUM
aji-160	138	4	,	,	PUNCT
aji-160	138	5	2025	2025	NUM
aji-160	138	6	;	;	PUNCT
aji-160	138	7	article	article	NOUN
aji-160	138	8	no.aji.134457	no.aji.134457	VERB
aji-160	138	9	62	62	NUM
aji-160	138	10	2	2	NUM
aji-160	138	11	.	.	PUNCT
aji-160	138	12	methodology	methodology	NOUN
aji-160	138	13	the	the	DET
aji-160	138	14	study	study	NOUN
aji-160	138	15	included	include	VERB
aji-160	138	16	88	88	NUM
aji-160	138	17	patients	patient	NOUN
aji-160	138	18	,	,	PUNCT
aji-160	138	19	80	80	NUM
aji-160	138	20	(	(	PUNCT
aji-160	138	21	92	92	NUM
aji-160	138	22	%	%	NOUN
aji-160	138	23	)	)	PUNCT
aji-160	138	24	females	female	NOUN
aji-160	138	25	and	and	CCONJ
aji-160	138	26	8	8	NUM
aji-160	138	27	(	(	PUNCT
aji-160	138	28	9.5	9.5	NUM
aji-160	138	29	%	%	NOUN
aji-160	138	30	)	)	PUNCT
aji-160	138	31	males	male	NOUN
aji-160	138	32	,	,	PUNCT
aji-160	138	33	with	with	ADP
aji-160	138	34	a	a	DET
aji-160	138	35	mean	mean	ADJ
aji-160	138	36	age	age	NOUN
aji-160	138	37	of	of	ADP
aji-160	138	38	35	35	NUM
aji-160	138	39	years	year	NOUN
aji-160	138	40	,	,	PUNCT
aji-160	138	41	making	make	VERB
aji-160	138	42	it	it	PRON
aji-160	138	43	an	an	DET
aji-160	138	44	ideal	ideal	ADJ
aji-160	138	45	sample	sample	NOUN
aji-160	138	46	for	for	ADP
aji-160	138	47	the	the	DET
aji-160	138	48	study	study	NOUN
aji-160	138	49	.	.	PUNCT
aji-160	139	1	a	a	DET
aji-160	139	2	control	control	NOUN
aji-160	139	3	group	group	NOUN
aji-160	139	4	of	of	ADP
aji-160	139	5	85	85	NUM
aji-160	139	6	patients	patient	NOUN
aji-160	139	7	was	be	AUX
aji-160	139	8	selected	select	VERB
aji-160	139	9	.	.	PUNCT
aji-160	140	1	we	we	PRON
aji-160	140	2	did	do	AUX
aji-160	140	3	not	not	PART
aji-160	140	4	care	care	VERB
aji-160	140	5	about	about	ADP
aji-160	140	6	gender	gender	NOUN
aji-160	140	7	matching	matching	NOUN
aji-160	140	8	,	,	PUNCT
aji-160	140	9	although	although	SCONJ
aji-160	140	10	the	the	DET
aji-160	140	11	majority	majority	NOUN
aji-160	140	12	of	of	ADP
aji-160	140	13	participants	participant	NOUN
aji-160	140	14	in	in	ADP
aji-160	140	15	the	the	DET
aji-160	140	16	control	control	NOUN
aji-160	140	17	group	group	NOUN
aji-160	140	18	were	be	AUX
aji-160	140	19	female	female	ADJ
aji-160	140	20	and	and	CCONJ
aji-160	140	21	had	have	VERB
aji-160	140	22	similar	similar	ADJ
aji-160	140	23	symptoms	symptom	NOUN
aji-160	140	24	and	and	CCONJ
aji-160	140	25	conditions	condition	NOUN
aji-160	140	26	to	to	ADP
aji-160	140	27	the	the	DET
aji-160	140	28	study	study	NOUN
aji-160	140	29	group	group	NOUN
aji-160	140	30	.	.	PUNCT
aji-160	141	1	the	the	DET
aji-160	141	2	patients	patient	NOUN
aji-160	141	3	were	be	AUX
aji-160	141	4	monitored	monitor	VERB
aji-160	141	5	at	at	ADP
aji-160	141	6	almawaddah	almawaddah	NOUN
aji-160	141	7	private	private	ADJ
aji-160	141	8	hospital	hospital	NOUN
aji-160	141	9	and	and	CCONJ
aji-160	141	10	private	private	ADJ
aji-160	141	11	laboratories	laboratory	NOUN
aji-160	141	12	specializing	specialize	VERB
aji-160	141	13	in	in	ADP
aji-160	141	14	immunodiagnostics	immunodiagnostic	NOUN
aji-160	141	15	from	from	ADP
aji-160	141	16	2022	2022	NUM
aji-160	141	17	to	to	ADP
aji-160	141	18	2024	2024	NUM
aji-160	141	19	.	.	PUNCT
aji-160	142	1	1	1	X
aji-160	142	2	.	.	X
aji-160	142	3	the	the	DET
aji-160	142	4	medical	medical	ADJ
aji-160	142	5	history	history	NOUN
aji-160	142	6	of	of	ADP
aji-160	142	7	each	each	DET
aji-160	142	8	participating	participate	VERB
aji-160	142	9	patient	patient	NOUN
aji-160	142	10	was	be	AUX
aji-160	142	11	analyzed	analyze	VERB
aji-160	142	12	,	,	PUNCT
aji-160	142	13	including	include	VERB
aji-160	142	14	confirmation	confirmation	NOUN
aji-160	142	15	of	of	ADP
aji-160	142	16	lupus	lupus	ADJ
aji-160	142	17	and	and	CCONJ
aji-160	142	18	cardiac	cardiac	ADJ
aji-160	142	19	symptoms	symptom	NOUN
aji-160	142	20	such	such	ADJ
aji-160	142	21	as	as	ADP
aji-160	142	22	impaired	impaired	ADJ
aji-160	142	23	carbohydrate	carbohydrate	NOUN
aji-160	142	24	metabolism	metabolism	NOUN
aji-160	142	25	and	and	CCONJ
aji-160	142	26	cardiac	cardiac	ADJ
aji-160	142	27	and	and	CCONJ
aji-160	142	28	circulatory	circulatory	ADJ
aji-160	142	29	complications	complication	NOUN
aji-160	142	30	in	in	ADP
aji-160	142	31	patients	patient	NOUN
aji-160	142	32	with	with	ADP
aji-160	142	33	rheumatoid	rheumatoid	NOUN
aji-160	142	34	arthritis	arthritis	NOUN
aji-160	142	35	and	and	CCONJ
aji-160	142	36	systemic	systemic	ADJ
aji-160	142	37	lupus	lupus	PROPN
aji-160	142	38	erythematosus	erythematosus	PROPN
aji-160	142	39	.	.	PUNCT
aji-160	143	1	2	2	X
aji-160	143	2	.	.	X
aji-160	143	3	identifying	identify	VERB
aji-160	143	4	the	the	DET
aji-160	143	5	immune	immune	ADJ
aji-160	143	6	damage	damage	NOUN
aji-160	143	7	caused	cause	VERB
aji-160	143	8	by	by	ADP
aji-160	143	9	lupus	lupus	NOUN
aji-160	143	10	other	other	ADJ
aji-160	143	11	than	than	ADP
aji-160	143	12	cardiac	cardiac	ADJ
aji-160	143	13	muscle	muscle	NOUN
aji-160	143	14	,	,	PUNCT
aji-160	143	15	to	to	PART
aji-160	143	16	help	help	VERB
aji-160	143	17	us	we	PRON
aji-160	143	18	understand	understand	VERB
aji-160	143	19	the	the	DET
aji-160	143	20	context	context	NOUN
aji-160	143	21	of	of	ADP
aji-160	143	22	cardiac	cardiac	ADJ
aji-160	143	23	damage	damage	NOUN
aji-160	143	24	,	,	PUNCT
aji-160	143	25	whether	whether	SCONJ
aji-160	143	26	direct	direct	ADJ
aji-160	143	27	or	or	CCONJ
aji-160	143	28	indirect	indirect	ADJ
aji-160	143	29	(	(	PUNCT
aji-160	143	30	table	table	NOUN
aji-160	143	31	1	1	NUM
aji-160	143	32	)	)	PUNCT
aji-160	143	33	.	.	PUNCT
aji-160	144	1	3	3	X
aji-160	144	2	.	.	X
aji-160	145	1	all	all	DET
aji-160	145	2	participants	participant	NOUN
aji-160	145	3	underwent	undergo	VERB
aji-160	145	4	an	an	DET
aji-160	145	5	ecg	ecg	PROPN
aji-160	145	6	and	and	CCONJ
aji-160	145	7	echo	echo	NOUN
aji-160	145	8	-	-	PUNCT
aji-160	145	9	cardiography	cardiography	NOUN
aji-160	145	10	to	to	PART
aji-160	145	11	confirm	confirm	VERB
aji-160	145	12	cardiac	cardiac	ADJ
aji-160	145	13	involvement	involvement	NOUN
aji-160	145	14	or	or	CCONJ
aji-160	145	15	detect	detect	VERB
aji-160	145	16	signs	sign	NOUN
aji-160	145	17	of	of	ADP
aji-160	145	18	myocardial	myocardial	ADJ
aji-160	145	19	ischemia	ischemia	NOUN
aji-160	145	20	(	(	PUNCT
aji-160	145	21	table	table	NOUN
aji-160	145	22	2	2	NUM
aji-160	145	23	)	)	PUNCT
aji-160	145	24	.	.	PUNCT
aji-160	146	1	4	4	X
aji-160	146	2	.	.	X
aji-160	146	3	laboratory	laboratory	NOUN
aji-160	146	4	and	and	CCONJ
aji-160	146	5	immunological	immunological	ADJ
aji-160	146	6	examinations	examination	NOUN
aji-160	146	7	of	of	ADP
aji-160	146	8	the	the	DET
aji-160	146	9	participants	participant	NOUN
aji-160	146	10	were	be	AUX
aji-160	146	11	performed	perform	VERB
aji-160	146	12	to	to	PART
aji-160	146	13	provide	provide	VERB
aji-160	146	14	a	a	DET
aji-160	146	15	clear	clear	ADJ
aji-160	146	16	statistical	statistical	ADJ
aji-160	146	17	picture	picture	NOUN
aji-160	146	18	.	.	PUNCT
aji-160	147	1	note	note	NOUN
aji-160	147	2	/	/	PUNCT
aji-160	147	3	this	this	DET
aji-160	147	4	study	study	NOUN
aji-160	147	5	paid	pay	VERB
aji-160	147	6	special	special	ADJ
aji-160	147	7	attention	attention	NOUN
aji-160	147	8	to	to	ADP
aji-160	147	9	the	the	DET
aji-160	147	10	immunological	immunological	ADJ
aji-160	147	11	aspect	aspect	NOUN
aji-160	147	12	of	of	ADP
aji-160	147	13	the	the	DET
aji-160	147	14	effect	effect	NOUN
aji-160	147	15	of	of	ADP
aji-160	147	16	systemic	systemic	ADJ
aji-160	147	17	lupus	lupus	NOUN
aji-160	147	18	erythematosus	erythematosus	NOUN
aji-160	147	19	on	on	ADP
aji-160	147	20	the	the	DET
aji-160	147	21	cardical	cardical	NOUN
aji-160	147	22	seeking	seeking	NOUN
aji-160	147	23	to	to	PART
aji-160	147	24	understand	understand	VERB
aji-160	147	25	the	the	DET
aji-160	147	26	role	role	NOUN
aji-160	147	27	of	of	ADP
aji-160	147	28	autoimmune	autoimmune	ADJ
aji-160	147	29	diseases	disease	NOUN
aji-160	147	30	(	(	PUNCT
aji-160	147	31	lupus	lupus	NOUN
aji-160	147	32	)	)	PUNCT
aji-160	147	33	on	on	ADP
aji-160	147	34	the	the	DET
aji-160	147	35	cardic	cardic	ADJ
aji-160	147	36	muscle	muscle	NOUN
aji-160	147	37	.	.	PUNCT
aji-160	148	1	table	table	NOUN
aji-160	148	2	1	1	NUM
aji-160	148	3	.	.	PUNCT
aji-160	148	4	key	key	ADJ
aji-160	148	5	immune	immune	ADJ
aji-160	148	6	related	related	ADJ
aji-160	148	7	manifestation	manifestation	NOUN
aji-160	148	8	of	of	ADP
aji-160	148	9	condition	condition	NOUN
aji-160	148	10	.	.	PUNCT
aji-160	149	1	main	main	ADJ
aji-160	149	2	immunological	immunological	ADJ
aji-160	149	3	manifestations	manifestation	NOUN
aji-160	149	4	of	of	ADP
aji-160	149	5	diseases	disease	NOUN
aji-160	149	6	sledai_2k	sledai_2k	NOUN
aji-160	149	7	415	415	NUM
aji-160	149	8	coordinates	coordinate	NOUN
aji-160	149	9	slicc_di	slicc_di	NOUN
aji-160	149	10	(	(	PUNCT
aji-160	149	11	damage	damage	NOUN
aji-160	149	12	index	index	NOUN
aji-160	149	13	)	)	PUNCT
aji-160	149	14	01	01	NUM
aji-160	149	15	coordinates	coordinate	VERB
aji-160	149	16	hematological	hematological	ADJ
aji-160	149	17	disorders	disorder	NOUN
aji-160	149	18	22	22	NUM
aji-160	149	19	%	%	NOUN
aji-160	149	20	nephritis	nephritis	NOUN
aji-160	149	21	31	31	NUM
aji-160	149	22	%	%	NOUN
aji-160	149	23	arthritis	arthritis	NOUN
aji-160	149	24	25	25	NUM
aji-160	149	25	%	%	NOUN
aji-160	149	26	skin	skin	NOUN
aji-160	149	27	lesions	lesion	NOUN
aji-160	149	28	22	22	NUM
aji-160	149	29	%	%	NOUN
aji-160	149	30	sororities	sorority	NOUN
aji-160	149	31	22	22	NUM
aji-160	149	32	%	%	NOUN
aji-160	149	33	antinuclear	antinuclear	ADJ
aji-160	149	34	factor	factor	NOUN
aji-160	149	35	(	(	PUNCT
aji-160	149	36	anf	anf	PROPN
aji-160	149	37	)	)	PUNCT
aji-160	149	38	94	94	NUM
aji-160	149	39	%	%	NOUN
aji-160	149	40	,	,	PUNCT
aji-160	149	41	antibodies	antibodie	VERB
aji-160	149	42	to	to	PART
aji-160	149	43	double	double	ADV
aji-160	149	44	-	-	PUNCT
aji-160	149	45	stranded	strand	VERB
aji-160	149	46	dna	dna	NOUN
aji-160	149	47	(	(	PUNCT
aji-160	149	48	anti_dsdna	anti_dsdna	ADV
aji-160	149	49	)	)	PUNCT
aji-160	149	50	ant	ant	ADJ
aji-160	149	51	phospholipid	phospholipid	NOUN
aji-160	149	52	syndrome	syndrome	NOUN
aji-160	149	53	76	76	NUM
aji-160	149	54	%	%	NOUN
aji-160	149	55	of	of	ADP
aji-160	149	56	patients	patient	NOUN
aji-160	149	57	(	(	PUNCT
aji-160	149	58	positive	positive	ADJ
aji-160	149	59	)	)	PUNCT
aji-160	149	60	sjogren	sjogren	PROPN
aji-160	149	61	's	's	PART
aji-160	149	62	syndrome	syndrome	NOUN
aji-160	149	63	7	7	NUM
aji-160	149	64	%	%	NOUN
aji-160	149	65	(	(	PUNCT
aji-160	149	66	positive	positive	ADJ
aji-160	149	67	)	)	PUNCT
aji-160	149	68	fig	fig	NOUN
aji-160	149	69	.	.	PUNCT
aji-160	150	1	1	1	X
aji-160	150	2	.	.	PUNCT
aji-160	150	3	volumetric	volumetric	ADJ
aji-160	150	4	effect	effect	NOUN
aji-160	150	5	of	of	ADP
aji-160	150	6	immunological	immunological	ADJ
aji-160	150	7	disorder	disorder	NOUN
aji-160	150	8	manifestations	manifestation	NOUN
aji-160	150	9	of	of	ADP
aji-160	150	10	the	the	DET
aji-160	150	11	disease	disease	NOUN
aji-160	150	12	sororities	sorority	NOUN
aji-160	150	13	,	,	PUNCT
aji-160	150	14	18	18	NUM
aji-160	150	15	%	%	NOUN
aji-160	150	16	skin	skin	NOUN
aji-160	150	17	lesions	lesion	NOUN
aji-160	150	18	,	,	PUNCT
aji-160	150	19	18	18	NUM
aji-160	150	20	%	%	NOUN
aji-160	150	21	arthritis	arthritis	NOUN
aji-160	150	22	,	,	PUNCT
aji-160	150	23	21	21	NUM
aji-160	150	24	%	%	NOUN
aji-160	150	25	hematological	hematological	ADJ
aji-160	150	26	disorders	disorder	NOUN
aji-160	150	27	,	,	PUNCT
aji-160	150	28	18.00	18.00	NUM
aji-160	150	29	%	%	NOUN
aji-160	150	30	nephritis	nephritis	NOUN
aji-160	150	31	,	,	PUNCT
aji-160	150	32	25%sororities	25%sororities	NUM
aji-160	150	33	skin	skin	NOUN
aji-160	150	34	lesions	lesion	NOUN
aji-160	150	35	arthritis	arthritis	NOUN
aji-160	150	36	hematological	hematological	ADJ
aji-160	150	37	disorders	disorder	NOUN
aji-160	150	38	nephritis	nephritis	PROPN
aji-160	150	39	shaker	shaker	NOUN
aji-160	150	40	;	;	PUNCT
aji-160	150	41	asian	asian	PROPN
aji-160	150	42	j.	j.	PROPN
aji-160	150	43	immunol	immunol	PROPN
aji-160	150	44	.	.	PROPN
aji-160	150	45	,	,	PUNCT
aji-160	150	46	vol	vol	NOUN
aji-160	150	47	.	.	PROPN
aji-160	150	48	8	8	NUM
aji-160	150	49	,	,	PUNCT
aji-160	150	50	no	no	INTJ
aji-160	150	51	.	.	NOUN
aji-160	150	52	1	1	NUM
aji-160	150	53	,	,	PUNCT
aji-160	150	54	pp	pp	ADJ
aji-160	150	55	.	.	PUNCT
aji-160	151	1	60	60	NUM
aji-160	151	2	-	-	SYM
aji-160	151	3	69	69	NUM
aji-160	151	4	,	,	PUNCT
aji-160	151	5	2025	2025	NUM
aji-160	151	6	;	;	PUNCT
aji-160	151	7	article	article	NOUN
aji-160	151	8	no.aji.134457	no.aji.134457	VERB
aji-160	151	9	63	63	NUM
aji-160	151	10	table	table	NOUN
aji-160	151	11	2	2	NUM
aji-160	151	12	.	.	PUNCT
aji-160	152	1	immunodiagnostic	immunodiagnostic	ADJ
aji-160	152	2	with	with	ADP
aji-160	152	3	systemic	systemic	ADJ
aji-160	152	4	lupus	lupu	NOUN
aji-160	152	5	erythematous	erythematous	ADJ
aji-160	152	6	cautilizing	cautilize	VERB
aji-160	152	7	myocardial	myocardial	ADJ
aji-160	152	8	infection	infection	NOUN
aji-160	152	9	n.	n.	NOUN
aji-160	152	10	sle	sle	PROPN
aji-160	152	11	immunological	immunological	ADJ
aji-160	152	12	disorder	disorder	NOUN
aji-160	152	13	cardiomyopathy	cardiomyopathy	ADJ
aji-160	152	14	by	by	ADP
aji-160	152	15	systemic	systemic	ADJ
aji-160	152	16	lupus	lupus	PROPN
aji-160	152	17	erythematous	erythematous	ADJ
aji-160	152	18	rate	rate	NOUN
aji-160	152	19	values	value	NOUN
aji-160	152	20	16	16	NUM
aji-160	152	21	pericardium	pericardium	NOUN
aji-160	152	22	26	26	NUM
aji-160	152	23	%	%	NOUN
aji-160	152	24	18	18	NUM
aji-160	152	25	adhesive	adhesive	ADJ
aji-160	152	26	pericarditis	pericarditis	NOUN
aji-160	152	27	30	30	NUM
aji-160	152	28	%	%	NOUN
aji-160	152	29	15	15	NUM
aji-160	152	30	exudative	exudative	ADJ
aji-160	152	31	pericarditis	pericarditis	NOUN
aji-160	152	32	10	10	NUM
aji-160	152	33	%	%	NOUN
aji-160	152	34	4	4	NUM
aji-160	152	35	acute	acute	NOUN
aji-160	152	36	myocarditis	myocarditis	ADJ
aji-160	152	37	5	5	NUM
aji-160	152	38	%	%	NOUN
aji-160	152	39	5	5	NUM
aji-160	152	40	ischemic	ischemic	ADJ
aji-160	152	41	myocarditis	myocarditis	ADJ
aji-160	152	42	(	(	PUNCT
aji-160	152	43	ihd	ihd	ADJ
aji-160	152	44	)	)	PUNCT
aji-160	152	45	3	3	NUM
aji-160	152	46	%	%	NOUN
aji-160	152	47	10	10	NUM
aji-160	152	48	heart	heart	NOUN
aji-160	152	49	failure	failure	NOUN
aji-160	152	50	(	(	PUNCT
aji-160	152	51	hf	hf	NOUN
aji-160	152	52	)	)	PUNCT
aji-160	152	53	15	15	NUM
aji-160	152	54	%	%	NOUN
aji-160	152	55	2	2	NUM
aji-160	152	56	myocardial	myocardial	ADJ
aji-160	152	57	infarction	infarction	NOUN
aji-160	152	58	(	(	PUNCT
aji-160	152	59	mi	mi	NOUN
aji-160	152	60	)	)	PUNCT
aji-160	152	61	1	1	NUM
aji-160	152	62	%	%	NOUN
aji-160	152	63	16	16	NUM
aji-160	152	64	cardiac	cardiac	ADJ
aji-160	152	65	arrhythmias	arrhythmia	NOUN
aji-160	152	66	9	9	NUM
aji-160	152	67	%	%	NOUN
aji-160	152	68	2	2	NUM
aji-160	152	69	patients	patient	NOUN
aji-160	152	70	with	with	ADP
aji-160	152	71	sle	sle	PROPN
aji-160	152	72	respectively	respectively	ADV
aji-160	152	73	1	1	NUM
aji-160	152	74	%	%	NOUN
aji-160	152	75	fig	fig	NOUN
aji-160	152	76	.	.	PUNCT
aji-160	153	1	2	2	X
aji-160	153	2	.	.	X
aji-160	153	3	values	value	NOUN
aji-160	153	4	cardiomyopathy	cardiomyopathy	ADJ
aji-160	153	5	by	by	ADP
aji-160	153	6	systemic	systemic	ADJ
aji-160	153	7	lupus	lupus	PROPN
aji-160	153	8	erythematous	erythematous	ADJ
aji-160	153	9	exclusion	exclusion	NOUN
aji-160	153	10	criteria	criterion	NOUN
aji-160	153	11	:	:	PUNCT
aji-160	153	12	this	this	DET
aji-160	153	13	study	study	NOUN
aji-160	153	14	specifically	specifically	ADV
aji-160	153	15	targeted	target	VERB
aji-160	153	16	patients	patient	NOUN
aji-160	153	17	aged	age	VERB
aji-160	153	18	30	30	NUM
aji-160	153	19	±	±	NUM
aji-160	153	20	15	15	NUM
aji-160	153	21	years	year	NOUN
aji-160	153	22	,	,	PUNCT
aji-160	153	23	based	base	VERB
aji-160	153	24	on	on	ADP
aji-160	153	25	the	the	DET
aji-160	153	26	statistical	statistical	ADJ
aji-160	153	27	system	system	NOUN
aji-160	153	28	issued	issue	VERB
aji-160	153	29	by	by	ADP
aji-160	153	30	the	the	DET
aji-160	153	31	iraqi	iraqi	PROPN
aji-160	153	32	ministry	ministry	PROPN
aji-160	153	33	of	of	ADP
aji-160	153	34	health	health	PROPN
aji-160	153	35	before	before	ADP
aji-160	153	36	1989	1989	NUM
aji-160	153	37	regarding	regard	VERB
aji-160	153	38	the	the	DET
aji-160	153	39	rate	rate	NOUN
aji-160	153	40	of	of	ADP
aji-160	153	41	infections	infection	NOUN
aji-160	153	42	and	and	CCONJ
aji-160	153	43	deaths	death	NOUN
aji-160	153	44	from	from	ADP
aji-160	153	45	heart	heart	NOUN
aji-160	153	46	diseases	disease	NOUN
aji-160	153	47	resulting	result	VERB
aji-160	153	48	from	from	ADP
aji-160	153	49	lupus	lupus	NOUN
aji-160	153	50	.	.	PUNCT
aji-160	154	1	the	the	DET
aji-160	154	2	following	follow	VERB
aji-160	154	3	categories	category	NOUN
aji-160	154	4	were	be	AUX
aji-160	154	5	excluded	exclude	VERB
aji-160	154	6	:	:	PUNCT
aji-160	155	1	1	1	X
aji-160	155	2	.	.	X
aji-160	155	3	the	the	DET
aji-160	155	4	following	follow	VERB
aji-160	155	5	categories	category	NOUN
aji-160	155	6	of	of	ADP
aji-160	155	7	people	people	NOUN
aji-160	155	8	under	under	ADP
aji-160	155	9	the	the	DET
aji-160	155	10	legal	legal	ADJ
aji-160	155	11	age	age	NOUN
aji-160	155	12	of	of	ADP
aji-160	155	13	18	18	NUM
aji-160	155	14	were	be	AUX
aji-160	155	15	excluded	exclude	VERB
aji-160	155	16	for	for	ADP
aji-160	155	17	legal	legal	ADJ
aji-160	155	18	considerations	consideration	NOUN
aji-160	155	19	,	,	PUNCT
aji-160	155	20	which	which	PRON
aji-160	155	21	require	require	VERB
aji-160	155	22	the	the	DET
aji-160	155	23	research	research	NOUN
aji-160	155	24	body	body	NOUN
aji-160	155	25	to	to	PART
aji-160	155	26	obtain	obtain	VERB
aji-160	155	27	judicial	judicial	ADJ
aji-160	155	28	approval	approval	NOUN
aji-160	155	29	and	and	CCONJ
aji-160	155	30	be	be	AUX
aji-160	155	31	under	under	ADP
aji-160	155	32	judicial	judicial	ADJ
aji-160	155	33	supervision	supervision	NOUN
aji-160	155	34	2	2	NUM
aji-160	155	35	.	.	PUNCT
aji-160	156	1	those	those	DET
aji-160	156	2	over	over	ADP
aji-160	156	3	45	45	NUM
aji-160	156	4	years	year	NOUN
aji-160	156	5	of	of	ADP
aji-160	156	6	age	age	NOUN
aji-160	156	7	were	be	AUX
aji-160	156	8	excluded	exclude	VERB
aji-160	156	9	,	,	PUNCT
aji-160	156	10	as	as	SCONJ
aji-160	156	11	most	most	ADJ
aji-160	156	12	of	of	ADP
aji-160	156	13	the	the	DET
aji-160	156	14	study	study	NOUN
aji-160	156	15	participants	participant	NOUN
aji-160	156	16	were	be	AUX
aji-160	156	17	women	woman	NOUN
aji-160	156	18	and	and	CCONJ
aji-160	156	19	must	must	AUX
aji-160	156	20	be	be	AUX
aji-160	156	21	fertile	fertile	ADJ
aji-160	156	22	.	.	PUNCT
aji-160	157	1	as	as	SCONJ
aji-160	157	2	is	be	AUX
aji-160	157	3	the	the	DET
aji-160	157	4	practice	practice	NOUN
aji-160	157	5	in	in	ADP
aji-160	157	6	current	current	ADJ
aji-160	157	7	research	research	NOUN
aji-160	157	8	regarding	regard	VERB
aji-160	157	9	lupus	lupus	NOUN
aji-160	157	10	,	,	PUNCT
aji-160	157	11	participants	participant	NOUN
aji-160	157	12	must	must	AUX
aji-160	157	13	be	be	AUX
aji-160	157	14	no	no	ADV
aji-160	157	15	older	old	ADJ
aji-160	157	16	than	than	ADP
aji-160	157	17	45	45	NUM
aji-160	157	18	.	.	NOUN
aji-160	158	1	3	3	X
aji-160	158	2	.	.	X
aji-160	158	3	those	those	PRON
aji-160	158	4	with	with	ADP
aji-160	158	5	comorbidities	comorbiditie	NOUN
aji-160	158	6	such	such	ADJ
aji-160	158	7	as	as	ADP
aji-160	158	8	tumors	tumor	NOUN
aji-160	158	9	,	,	PUNCT
aji-160	158	10	malignancies	malignancy	NOUN
aji-160	158	11	,	,	PUNCT
aji-160	158	12	or	or	CCONJ
aji-160	158	13	infectious	infectious	ADJ
aji-160	158	14	diseases	disease	NOUN
aji-160	158	15	the	the	DET
aji-160	158	16	medical	medical	ADJ
aji-160	158	17	reports	report	NOUN
aji-160	158	18	provided	provide	VERB
aji-160	158	19	by	by	ADP
aji-160	158	20	cardiologists	cardiologist	NOUN
aji-160	158	21	were	be	AUX
aji-160	158	22	reviewed	review	VERB
aji-160	158	23	for	for	ADP
aji-160	158	24	all	all	DET
aji-160	158	25	patients	patient	NOUN
aji-160	158	26	,	,	PUNCT
aji-160	158	27	and	and	CCONJ
aji-160	158	28	they	they	PRON
aji-160	158	29	had	have	VERB
aji-160	158	30	conventional	conventional	ADJ
aji-160	158	31	hazard	hazard	NOUN
aji-160	158	32	factors	factor	NOUN
aji-160	158	33	for	for	ADP
aji-160	158	34	cardiac	cardiac	ADJ
aji-160	158	35	and	and	CCONJ
aji-160	158	36	circulatory	circulatory	ADJ
aji-160	158	37	disease	disease	NOUN
aji-160	158	38	.	.	PUNCT
aji-160	159	1	transthoracic	transthoracic	PROPN
aji-160	159	2	echocardiography	echocardiography	NOUN
aji-160	159	3	was	be	AUX
aji-160	159	4	performed	perform	VERB
aji-160	159	5	.	.	PUNCT
aji-160	160	1	patients	patient	NOUN
aji-160	160	2	were	be	AUX
aji-160	160	3	evaluated	evaluate	VERB
aji-160	160	4	for	for	ADP
aji-160	160	5	left	left	ADJ
aji-160	160	6	ventricular	ventricular	ADJ
aji-160	160	7	diastolic	diastolic	ADJ
aji-160	160	8	and	and	CCONJ
aji-160	160	9	systolic	systolic	ADJ
aji-160	160	10	function	function	NOUN
aji-160	160	11	,	,	PUNCT
aji-160	160	12	ejection	ejection	NOUN
aji-160	160	13	fraction	fraction	NOUN
aji-160	160	14	(	(	PUNCT
aji-160	160	15	ef	ef	PROPN
aji-160	160	16	)	)	PUNCT
aji-160	160	17	,	,	PUNCT
aji-160	160	18	left	leave	VERB
aji-160	160	19	ventricular	ventricular	ADJ
aji-160	160	20	myocardial	myocardial	ADJ
aji-160	160	21	thickness	thickness	NOUN
aji-160	160	22	,	,	PUNCT
aji-160	160	23	chamber	chamber	NOUN
aji-160	160	24	sizes	size	NOUN
aji-160	160	25	,	,	PUNCT
aji-160	160	26	systolic	systolic	ADJ
aji-160	160	27	pulmonary	pulmonary	ADJ
aji-160	160	28	artery	artery	NOUN
aji-160	160	29	and	and	CCONJ
aji-160	160	30	diastolic	diastolic	ADJ
aji-160	160	31	pressure	pressure	NOUN
aji-160	160	32	,	,	PUNCT
aji-160	160	33	pericardial	pericardial	ADJ
aji-160	160	34	status	status	NOUN
aji-160	160	35	,	,	PUNCT
aji-160	160	36	and	and	CCONJ
aji-160	160	37	valves	valve	NOUN
aji-160	160	38	.	.	PUNCT
aji-160	161	1	laboratory	laboratory	NOUN
aji-160	161	2	and	and	CCONJ
aji-160	161	3	statistical	statistical	ADJ
aji-160	161	4	diagnosis	diagnosis	NOUN
aji-160	161	5	:	:	PUNCT
aji-160	161	6	concentration	concentration	NOUN
aji-160	161	7	of	of	ADP
aji-160	161	8	the	the	DET
aji-160	161	9	n	n	CCONJ
aji-160	161	10	-	-	PUNCT
aji-160	161	11	amino	amino	NOUN
aji-160	161	12	terminal	terminal	NOUN
aji-160	161	13	fragment	fragment	NOUN
aji-160	161	14	of	of	ADP
aji-160	161	15	(	(	PUNCT
aji-160	161	16	probrainnatriuretic	probrainnatriuretic	ADJ
aji-160	161	17	–	–	PUNCT
aji-160	161	18	peptide	peptide	NOUN
aji-160	161	19	)	)	PUNCT
aji-160	161	20	(	(	PUNCT
aji-160	161	21	nt_probnp	nt_probnp	NOUN
aji-160	161	22	)	)	PUNCT
aji-160	161	23	in	in	ADP
aji-160	161	24	serum	serum	NOUN
aji-160	161	25	was	be	AUX
aji-160	161	26	determined	determine	VERB
aji-160	161	27	by	by	ADP
aji-160	161	28	electrochemical	electrochemical	ADJ
aji-160	161	29	analysis	analysis	NOUN
aji-160	161	30	(	(	PUNCT
aji-160	161	31	ecl	ecl	NOUN
aji-160	161	32	)	)	PUNCT
aji-160	161	33	on	on	ADP
aji-160	161	34	a	a	DET
aji-160	161	35	cobas	cobas	ADJ
aji-160	161	36	analyzer	analyzer	NOUN
aji-160	161	37	utilizing	utilize	VERB
aji-160	161	38	the	the	DET
aji-160	161	39	elecsys	elecsys	PROPN
aji-160	161	40	probnp	probnp	PROPN
aji-160	161	41	ii	ii	PROPN
aji-160	161	42	test	test	NOUN
aji-160	161	43	system	system	NOUN
aji-160	161	44	.	.	PUNCT
aji-160	162	1	typically	typically	ADV
aji-160	162	2	,	,	PUNCT
aji-160	162	3	myocardial	myocardial	ADJ
aji-160	162	4	infarction	infarction	NOUN
aji-160	162	5	(	(	PUNCT
aji-160	162	6	mi	mi	NOUN
aji-160	162	7	)	)	PUNCT
aji-160	162	8	,	,	PUNCT
aji-160	162	9	1.00	1.00	NUM
aji-160	162	10	%	%	NOUN
aji-160	162	11	heart	heart	NOUN
aji-160	162	12	failure	failure	NOUN
aji-160	162	13	(	(	PUNCT
aji-160	162	14	hf	hf	NOUN
aji-160	162	15	)	)	PUNCT
aji-160	162	16	,	,	PUNCT
aji-160	162	17	20.00	20.00	NUM
aji-160	162	18	%	%	NOUN
aji-160	162	19	ischemic	ischemic	ADJ
aji-160	162	20	heart	heart	NOUN
aji-160	162	21	disease	disease	NOUN
aji-160	162	22	(	(	PUNCT
aji-160	162	23	ihd	ihd	ADJ
aji-160	162	24	)	)	PUNCT
aji-160	162	25	,	,	PUNCT
aji-160	162	26	4.00	4.00	NUM
aji-160	162	27	%	%	NOUN
aji-160	162	28	acute	acute	NOUN
aji-160	162	29	myocarditis	myocarditis	PROPN
aji-160	162	30	,	,	PUNCT
aji-160	162	31	7.00	7.00	NUM
aji-160	162	32	%	%	NOUN
aji-160	162	33	exudative	exudative	ADJ
aji-160	162	34	pericarditis	pericarditis	NOUN
aji-160	162	35	,	,	PUNCT
aji-160	162	36	14	14	NUM
aji-160	162	37	%	%	NOUN
aji-160	162	38	adhesive	adhesive	ADJ
aji-160	162	39	pericarditis	pericarditis	NOUN
aji-160	162	40	,	,	PUNCT
aji-160	162	41	41	41	NUM
aji-160	162	42	%	%	NOUN
aji-160	162	43	cardiac	cardiac	ADJ
aji-160	162	44	arrhythmias	arrhythmia	NOUN
aji-160	162	45	,	,	PUNCT
aji-160	162	46	12	12	NUM
aji-160	162	47	%	%	NOUN
aji-160	162	48	patients	patient	NOUN
aji-160	162	49	with	with	ADP
aji-160	162	50	sle	sle	PROPN
aji-160	162	51	respectively	respectively	ADV
aji-160	162	52	,	,	PUNCT
aji-160	162	53	1	1	NUM
aji-160	162	54	%	%	NOUN
aji-160	162	55	myocardial	myocardial	ADJ
aji-160	162	56	infarction	infarction	NOUN
aji-160	162	57	(	(	PUNCT
aji-160	162	58	mi	mi	NOUN
aji-160	162	59	)	)	PUNCT
aji-160	162	60	heart	heart	NOUN
aji-160	162	61	failure	failure	NOUN
aji-160	162	62	(	(	PUNCT
aji-160	162	63	hf	hf	X
aji-160	162	64	)	)	PUNCT
aji-160	162	65	ischemic	ischemic	ADJ
aji-160	162	66	heart	heart	NOUN
aji-160	162	67	disease	disease	NOUN
aji-160	162	68	(	(	PUNCT
aji-160	162	69	ihd	ihd	ADJ
aji-160	162	70	)	)	PUNCT
aji-160	162	71	acute	acute	NOUN
aji-160	162	72	myocarditis	myocarditis	ADJ
aji-160	162	73	exudative	exudative	ADJ
aji-160	162	74	pericarditis	pericarditis	PROPN
aji-160	162	75	adhesive	adhesive	ADJ
aji-160	162	76	pericarditis	pericarditis	NOUN
aji-160	162	77	cardiac	cardiac	PROPN
aji-160	162	78	arrhythmias	arrhythmia	VERB
aji-160	162	79	patients	patient	NOUN
aji-160	162	80	with	with	ADP
aji-160	162	81	sle	sle	PROPN
aji-160	162	82	respectively	respectively	ADV
aji-160	162	83	shaker	shaker	NOUN
aji-160	162	84	;	;	PUNCT
aji-160	162	85	asian	asian	PROPN
aji-160	162	86	j.	j.	PROPN
aji-160	162	87	immunol	immunol	PROPN
aji-160	162	88	.	.	PROPN
aji-160	162	89	,	,	PUNCT
aji-160	162	90	vol	vol	NOUN
aji-160	162	91	.	.	PROPN
aji-160	162	92	8	8	NUM
aji-160	162	93	,	,	PUNCT
aji-160	162	94	no	no	INTJ
aji-160	162	95	.	.	NOUN
aji-160	162	96	1	1	NUM
aji-160	162	97	,	,	PUNCT
aji-160	162	98	pp	pp	ADJ
aji-160	162	99	.	.	PUNCT
aji-160	163	1	60	60	NUM
aji-160	163	2	-	-	SYM
aji-160	163	3	69	69	NUM
aji-160	163	4	,	,	PUNCT
aji-160	163	5	2025	2025	NUM
aji-160	163	6	;	;	PUNCT
aji-160	163	7	article	article	NOUN
aji-160	163	8	no.aji.134457	no.aji.134457	VERB
aji-160	163	9	64	64	NUM
aji-160	163	10	nt_probnp	nt_probnp	NOUN
aji-160	163	11	levels	level	NOUN
aji-160	163	12	are	be	AUX
aji-160	163	13	≤125	≤125	ADJ
aji-160	163	14	pg	pg	VERB
aji-160	163	15	/	/	SYM
aji-160	163	16	ml	ml	PROPN
aji-160	163	17	,	,	PUNCT
aji-160	163	18	according	accord	VERB
aji-160	163	19	to	to	ADP
aji-160	163	20	procedural	procedural	ADJ
aji-160	163	21	guidelines	guideline	NOUN
aji-160	163	22	(	(	PUNCT
aji-160	163	23	mcmurray	mcmurray	X
aji-160	163	24	,	,	PUNCT
aji-160	163	25	et	et	PROPN
aji-160	163	26	al	al	PROPN
aji-160	163	27	.	.	PROPN
aji-160	163	28	,	,	PUNCT
aji-160	163	29	2012	2012	NUM
aji-160	163	30	)	)	PUNCT
aji-160	163	31	.	.	PUNCT
aji-160	164	1	statistical	statistical	ADJ
aji-160	164	2	analysis	analysis	NOUN
aji-160	164	3	was	be	AUX
aji-160	164	4	performed	perform	VERB
aji-160	164	5	utilizing	utilize	VERB
aji-160	164	6	parametric	parametric	ADJ
aji-160	164	7	and	and	CCONJ
aji-160	164	8	nonparametric	nonparametric	ADJ
aji-160	164	9	statistical	statistical	ADJ
aji-160	164	10	methods	method	NOUN
aji-160	164	11	of	of	ADP
aji-160	164	12	applied	applied	ADJ
aji-160	164	13	statistics	statistic	NOUN
aji-160	164	14	nt_probnp	nt_probnp	VERB
aji-160	164	15	in	in	ADP
aji-160	164	16	the	the	DET
aji-160	164	17	two	two	NUM
aji-160	164	18	groups	group	NOUN
aji-160	164	19	is	be	AUX
aji-160	164	20	equal	equal	ADJ
aji-160	164	21	to	to	ADP
aji-160	164	22	12	12	NUM
aji-160	164	23	.	.	PUNCT
aji-160	165	1	variables	variable	NOUN
aji-160	165	2	were	be	AUX
aji-160	165	3	presented	present	VERB
aji-160	165	4	as	as	ADP
aji-160	165	5	medians	median	NOUN
aji-160	165	6	(	(	PUNCT
aji-160	165	7	me	i	PRON
aji-160	165	8	)	)	PUNCT
aji-160	165	9	,	,	PUNCT
aji-160	165	10	with	with	ADP
aji-160	165	11	the	the	DET
aji-160	165	12	upper	upper	ADJ
aji-160	165	13	and	and	CCONJ
aji-160	165	14	lower	low	ADJ
aji-160	165	15	quartiles	quartile	NOUN
aji-160	165	16	indicated	indicate	VERB
aji-160	165	17	in	in	ADP
aji-160	165	18	parentheses	parenthesis	NOUN
aji-160	165	19	(	(	PUNCT
aji-160	165	20	25th	25th	NOUN
aji-160	165	21	percentile	percentile	ADJ
aji-160	165	22	;	;	PUNCT
aji-160	165	23	75th	75th	ADJ
aji-160	165	24	percentile	percentile	NOUN
aji-160	165	25	)	)	PUNCT
aji-160	165	26	.	.	PUNCT
aji-160	166	1	the	the	DET
aji-160	166	2	reliability	reliability	NOUN
aji-160	166	3	of	of	ADP
aji-160	166	4	variations	variation	NOUN
aji-160	166	5	between	between	ADP
aji-160	166	6	the	the	DET
aji-160	166	7	two	two	NUM
aji-160	166	8	groups	group	NOUN
aji-160	166	9	was	be	AUX
aji-160	166	10	assessed	assess	VERB
aji-160	166	11	utilizing	utilize	VERB
aji-160	166	12	the	the	DET
aji-160	166	13	(	(	PUNCT
aji-160	166	14	spss	spss	PROPN
aji-160	166	15	software	software	NOUN
aji-160	166	16	)	)	PUNCT
aji-160	166	17	criterion	criterion	NOUN
aji-160	166	18	.	.	PUNCT
aji-160	167	1	qualitative	qualitative	ADJ
aji-160	167	2	indicators	indicator	NOUN
aji-160	167	3	were	be	AUX
aji-160	167	4	compared	compare	VERB
aji-160	167	5	in	in	ADP
aji-160	167	6	two	two	NUM
aji-160	167	7	unrelated	unrelated	ADJ
aji-160	167	8	groups	group	NOUN
aji-160	167	9	in	in	ADP
aji-160	167	10	association	association	NOUN
aji-160	167	11	table	table	NOUN
aji-160	167	12	utilizing	utilize	VERB
aji-160	167	13	the	the	DET
aji-160	167	14	χ2	χ2	PROPN
aji-160	167	15	test	test	NOUN
aji-160	167	16	.	.	PUNCT
aji-160	168	1	the	the	DET
aji-160	168	2	significance	significance	NOUN
aji-160	168	3	level	level	NOUN
aji-160	168	4	was	be	AUX
aji-160	168	5	p	p	X
aji-160	168	6	<	<	X
aji-160	168	7	0.05	0.05	NUM
aji-160	168	8	(	(	PUNCT
aji-160	168	9	rebrova	rebrova	ADJ
aji-160	168	10	,	,	PUNCT
aji-160	168	11	2002	2002	NUM
aji-160	168	12	)	)	PUNCT
aji-160	168	13	.	.	PUNCT
aji-160	169	1	procedures	procedure	NOUN
aji-160	169	2	:	:	PUNCT
aji-160	169	3	median	median	ADJ
aji-160	169	4	duration	duration	NOUN
aji-160	169	5	of	of	ADP
aji-160	169	6	sle	sle	PROPN
aji-160	169	7	was	be	AUX
aji-160	169	8	two	two	NUM
aji-160	169	9	years	year	NOUN
aji-160	169	10	,	,	PUNCT
aji-160	169	11	with	with	ADP
aji-160	169	12	moderate	moderate	ADJ
aji-160	169	13	disease	disease	NOUN
aji-160	169	14	activity	activity	NOUN
aji-160	169	15	(	(	PUNCT
aji-160	169	16	sledai_2k	sledai_2k	NOUN
aji-160	169	17	)	)	PUNCT
aji-160	169	18	9	9	NUM
aji-160	169	19	coordinates	coordinate	NOUN
aji-160	169	20	(	(	PUNCT
aji-160	169	21	hochberg	hochberg	NOUN
aji-160	169	22	,	,	PUNCT
aji-160	169	23	1997	1997	NUM
aji-160	169	24	)	)	PUNCT
aji-160	169	25	,	,	PUNCT
aji-160	169	26	and	and	CCONJ
aji-160	169	27	the	the	DET
aji-160	169	28	slicc_di	slicc_di	NOUN
aji-160	169	29	damage	damage	NOUN
aji-160	169	30	index	index	NOUN
aji-160	169	31	was	be	AUX
aji-160	169	32	2	2	NUM
aji-160	169	33	coordinates	coordinate	NOUN
aji-160	169	34	(	(	PUNCT
aji-160	169	35	kim	kim	PROPN
aji-160	169	36	,	,	PUNCT
aji-160	169	37	et	et	PROPN
aji-160	169	38	al	al	PROPN
aji-160	169	39	.	.	PROPN
aji-160	169	40	,	,	PUNCT
aji-160	169	41	2017	2017	NUM
aji-160	169	42	)	)	PUNCT
aji-160	169	43	.	.	PUNCT
aji-160	170	1	the	the	DET
aji-160	170	2	main	main	ADJ
aji-160	170	3	clinical	clinical	ADJ
aji-160	170	4	manifestations	manifestation	NOUN
aji-160	170	5	of	of	ADP
aji-160	170	6	the	the	DET
aji-160	170	7	disease	disease	NOUN
aji-160	170	8	embraced	embrace	VERB
aji-160	170	9	hematological	hematological	ADJ
aji-160	170	10	disorders	disorder	NOUN
aji-160	170	11	(	(	PUNCT
aji-160	170	12	49	49	NUM
aji-160	170	13	%	%	NOUN
aji-160	170	14	)	)	PUNCT
aji-160	170	15	,	,	PUNCT
aji-160	170	16	nephritis	nephritis	NOUN
aji-160	170	17	(	(	PUNCT
aji-160	170	18	45	45	NUM
aji-160	170	19	%	%	NOUN
aji-160	170	20	)	)	PUNCT
aji-160	170	21	,	,	PUNCT
aji-160	170	22	arthritis	arthritis	NOUN
aji-160	170	23	(	(	PUNCT
aji-160	170	24	37	37	NUM
aji-160	170	25	%	%	NOUN
aji-160	170	26	)	)	PUNCT
aji-160	170	27	,	,	PUNCT
aji-160	170	28	skin	skin	NOUN
aji-160	170	29	lesions	lesion	NOUN
aji-160	170	30	(	(	PUNCT
aji-160	170	31	34	34	NUM
aji-160	170	32	%	%	NOUN
aji-160	170	33	)	)	PUNCT
aji-160	170	34	,	,	PUNCT
aji-160	170	35	and	and	CCONJ
aji-160	170	36	synovitis	synovitis	PROPN
aji-160	170	37	(	(	PUNCT
aji-160	170	38	33	33	NUM
aji-160	170	39	%	%	NOUN
aji-160	170	40	)	)	PUNCT
aji-160	170	41	.	.	PUNCT
aji-160	171	1	eighty	eighty	NUM
aji-160	171	2	-	-	PUNCT
aji-160	171	3	six	six	NUM
aji-160	171	4	patients	patient	NOUN
aji-160	171	5	(	(	PUNCT
aji-160	171	6	98	98	NUM
aji-160	171	7	%	%	NOUN
aji-160	171	8	)	)	PUNCT
aji-160	171	9	had	have	VERB
aji-160	171	10	immune	immune	ADJ
aji-160	171	11	disorders	disorder	NOUN
aji-160	171	12	:	:	PUNCT
aji-160	171	13	elevated	elevated	ADJ
aji-160	171	14	levels	level	NOUN
aji-160	171	15	of	of	ADP
aji-160	171	16	antinuclear	antinuclear	ADJ
aji-160	171	17	factor	factor	NOUN
aji-160	171	18	(	(	PUNCT
aji-160	171	19	anf	anf	VERB
aji-160	171	20	)	)	PUNCT
aji-160	171	21	were	be	AUX
aji-160	171	22	recognition	recognition	NOUN
aji-160	171	23	in	in	ADP
aji-160	171	24	95	95	NUM
aji-160	171	25	%	%	NOUN
aji-160	171	26	,	,	PUNCT
aji-160	171	27	and	and	CCONJ
aji-160	171	28	anti_dsdna	anti_dsdna	ADV
aji-160	171	29	antibodies	antibody	NOUN
aji-160	171	30	were	be	AUX
aji-160	171	31	recognition	recognition	NOUN
aji-160	171	32	at	at	ADP
aji-160	171	33	78	78	NUM
aji-160	171	34	%	%	NOUN
aji-160	171	35	of	of	ADP
aji-160	171	36	sle	sle	PROPN
aji-160	171	37	patients	patient	NOUN
aji-160	171	38	.	.	PUNCT
aji-160	172	1	associated	associate	VERB
aji-160	172	2	antiphospholipid	antiphospholipid	NOUN
aji-160	172	3	syndrome	syndrome	NOUN
aji-160	172	4	(	(	PUNCT
aji-160	172	5	allergic	allergic	ADJ
aji-160	172	6	fungal	fungal	ADJ
aji-160	172	7	sinusitis	sinusitis	NOUN
aji-160	172	8	(	(	PUNCT
aji-160	172	9	afs	afs	NOUN
aji-160	172	10	)	)	PUNCT
aji-160	172	11	and	and	CCONJ
aji-160	172	12	sjögren	sjögren	PROPN
aji-160	172	13	's	's	PART
aji-160	172	14	syndrome	syndrome	NOUN
aji-160	172	15	were	be	AUX
aji-160	172	16	identified	identify	VERB
aji-160	172	17	in	in	ADP
aji-160	172	18	9	9	NUM
aji-160	172	19	(	(	PUNCT
aji-160	172	20	9	9	NUM
aji-160	172	21	%	%	NOUN
aji-160	172	22	)	)	PUNCT
aji-160	172	23	and	and	CCONJ
aji-160	172	24	10	10	NUM
aji-160	172	25	(	(	PUNCT
aji-160	172	26	11	11	NUM
aji-160	172	27	%	%	NOUN
aji-160	172	28	)	)	PUNCT
aji-160	172	29	patients	patient	NOUN
aji-160	172	30	,	,	PUNCT
aji-160	172	31	respectively	respectively	ADV
aji-160	172	32	(	(	PUNCT
aji-160	172	33	miyakis	miyakis	PROPN
aji-160	172	34	,	,	PUNCT
aji-160	172	35	et	et	PROPN
aji-160	172	36	al	al	PROPN
aji-160	172	37	.	.	PROPN
aji-160	172	38	,	,	PUNCT
aji-160	172	39	2006	2006	NUM
aji-160	172	40	)	)	PUNCT
aji-160	172	41	.	.	PUNCT
aji-160	173	1	valvular	valvular	ADJ
aji-160	173	2	regurgitation	regurgitation	NOUN
aji-160	173	3	with	with	ADP
aji-160	173	4	varying	vary	VERB
aji-160	173	5	degrees	degree	NOUN
aji-160	173	6	of	of	ADP
aji-160	173	7	regurgitation	regurgitation	NOUN
aji-160	173	8	(	(	PUNCT
aji-160	173	9	not	not	PART
aji-160	173	10	requiring	require	VERB
aji-160	173	11	surgical	surgical	ADJ
aji-160	173	12	treatment	treatment	NOUN
aji-160	173	13	)	)	PUNCT
aji-160	173	14	was	be	AUX
aji-160	173	15	the	the	DET
aji-160	173	16	most	most	ADV
aji-160	173	17	frequently	frequently	ADV
aji-160	173	18	observed	observe	VERB
aji-160	173	19	cardiac	cardiac	ADJ
aji-160	173	20	abnormality	abnormality	NOUN
aji-160	173	21	in	in	ADP
aji-160	173	22	systemic	systemic	ADJ
aji-160	173	23	lupus	lupu	NOUN
aji-160	173	24	erythematous	erythematous	ADJ
aji-160	173	25	(	(	PUNCT
aji-160	173	26	sle	sle	PROPN
aji-160	173	27	)	)	PUNCT
aji-160	173	28	,	,	PUNCT
aji-160	173	29	identified	identify	VERB
aji-160	173	30	in	in	ADP
aji-160	173	31	79	79	NUM
aji-160	173	32	patients	patient	NOUN
aji-160	173	33	(	(	PUNCT
aji-160	173	34	90	90	NUM
aji-160	173	35	%	%	NOUN
aji-160	173	36	):	):	PUNCT
aji-160	173	37	78	78	NUM
aji-160	173	38	patients	patient	NOUN
aji-160	173	39	(	(	PUNCT
aji-160	173	40	89	89	NUM
aji-160	173	41	%	%	NOUN
aji-160	173	42	)	)	PUNCT
aji-160	173	43	with	with	ADP
aji-160	173	44	tricuspid	tricuspid	NOUN
aji-160	173	45	regurgitation	regurgitation	NOUN
aji-160	173	46	,	,	PUNCT
aji-160	173	47	72	72	NUM
aji-160	173	48	patients	patient	NOUN
aji-160	173	49	(	(	PUNCT
aji-160	173	50	82	82	NUM
aji-160	173	51	%	%	NOUN
aji-160	173	52	)	)	PUNCT
aji-160	173	53	with	with	ADP
aji-160	173	54	mitral	mitral	ADJ
aji-160	173	55	regurgitation	regurgitation	NOUN
aji-160	173	56	,	,	PUNCT
aji-160	173	57	57	57	NUM
aji-160	173	58	patients	patient	NOUN
aji-160	173	59	(	(	PUNCT
aji-160	173	60	7	7	NUM
aji-160	173	61	%	%	NOUN
aji-160	173	62	)	)	PUNCT
aji-160	173	63	with	with	ADP
aji-160	173	64	pulmonary	pulmonary	ADJ
aji-160	173	65	artery	artery	NOUN
aji-160	173	66	regurgitation	regurgitation	NOUN
aji-160	173	67	,	,	PUNCT
aji-160	173	68	and	and	CCONJ
aji-160	173	69	15	15	NUM
aji-160	173	70	patients	patient	NOUN
aji-160	173	71	(	(	PUNCT
aji-160	173	72	14	14	NUM
aji-160	173	73	%	%	NOUN
aji-160	173	74	)	)	PUNCT
aji-160	173	75	with	with	ADP
aji-160	173	76	aortic	aortic	ADJ
aji-160	173	77	regurgitation	regurgitation	NOUN
aji-160	173	78	.	.	PUNCT
aji-160	174	1	endocarditis	endocarditis	NOUN
aji-160	174	2	was	be	AUX
aji-160	174	3	identified	identify	VERB
aji-160	174	4	in	in	ADP
aji-160	174	5	26	26	NUM
aji-160	174	6	patients	patient	NOUN
aji-160	174	7	(	(	PUNCT
aji-160	174	8	30	30	NUM
aji-160	174	9	%	%	NOUN
aji-160	174	10	)	)	PUNCT
aji-160	174	11	,	,	PUNCT
aji-160	174	12	and	and	CCONJ
aji-160	174	13	mitral	mitral	ADJ
aji-160	174	14	or	or	CCONJ
aji-160	174	15	tricuspid	tricuspid	NOUN
aji-160	174	16	valve	valve	NOUN
aji-160	174	17	prolapse	prolapse	NOUN
aji-160	174	18	in	in	ADP
aji-160	174	19	30	30	NUM
aji-160	174	20	patients	patient	NOUN
aji-160	174	21	(	(	PUNCT
aji-160	174	22	34	34	NUM
aji-160	174	23	%	%	NOUN
aji-160	174	24	)	)	PUNCT
aji-160	174	25	.	.	PUNCT
aji-160	175	1	the	the	DET
aji-160	175	2	rarest	rare	ADJ
aji-160	175	3	was	be	AUX
aji-160	175	4	mitral	mitral	ADJ
aji-160	175	5	,	,	PUNCT
aji-160	175	6	tricuspid	tricuspid	NOUN
aji-160	175	7	,	,	PUNCT
aji-160	175	8	and	and	CCONJ
aji-160	175	9	aortic	aortic	ADJ
aji-160	175	10	stenosis	stenosis	NOUN
aji-160	175	11	,	,	PUNCT
aji-160	175	12	identified	identify	VERB
aji-160	175	13	in	in	ADP
aji-160	175	14	one	one	NUM
aji-160	175	15	patient	patient	NOUN
aji-160	175	16	(	(	PUNCT
aji-160	175	17	1	1	NUM
aji-160	175	18	%	%	NOUN
aji-160	175	19	)	)	PUNCT
aji-160	175	20	.	.	PUNCT
aji-160	176	1	the	the	DET
aji-160	176	2	median	median	ADJ
aji-160	176	3	concentration	concentration	NOUN
aji-160	176	4	of	of	ADP
aji-160	176	5	nt_probnp	nt_probnp	PROPN
aji-160	176	6	was	be	AUX
aji-160	176	7	92	92	NUM
aji-160	176	8	(	(	PUNCT
aji-160	176	9	27–332	27–332	NUM
aji-160	176	10	)	)	PUNCT
aji-160	176	11	pictograms	pictogram	NOUN
aji-160	176	12	per	per	ADP
aji-160	176	13	milliliter	milliliter	NOUN
aji-160	176	14	,	,	PUNCT
aji-160	176	15	an	an	DET
aji-160	176	16	elevated	elevated	ADJ
aji-160	176	17	level	level	NOUN
aji-160	176	18	of	of	ADP
aji-160	176	19	nt_probnp	nt_probnp	X
aji-160	176	20	(	(	PUNCT
aji-160	176	21	>	>	X
aji-160	176	22	125	125	NUM
aji-160	176	23	pictograms	pictogram	NOUN
aji-160	176	24	per	per	ADP
aji-160	176	25	milliliter	milliliter	NOUN
aji-160	176	26	)	)	PUNCT
aji-160	176	27	was	be	AUX
aji-160	176	28	identified	identify	VERB
aji-160	176	29	in	in	ADP
aji-160	176	30	29	29	NUM
aji-160	176	31	patients	patient	NOUN
aji-160	176	32	(	(	PUNCT
aji-160	176	33	32	32	NUM
aji-160	176	34	%	%	NOUN
aji-160	176	35	)	)	PUNCT
aji-160	176	36	.	.	PUNCT
aji-160	177	1	the	the	DET
aji-160	177	2	possible	possible	ADJ
aji-160	177	3	association	association	NOUN
aji-160	177	4	of	of	ADP
aji-160	177	5	cardiac	cardiac	ADJ
aji-160	177	6	disorders	disorder	NOUN
aji-160	177	7	with	with	ADP
aji-160	177	8	therapy	therapy	NOUN
aji-160	177	9	used	use	VERB
aji-160	177	10	in	in	ADP
aji-160	177	11	sle	sle	PROPN
aji-160	177	12	,	,	PUNCT
aji-160	177	13	patients	patient	NOUN
aji-160	177	14	had	have	AUX
aji-160	177	15	divided	divide	VERB
aji-160	177	16	into	into	ADP
aji-160	177	17	two	two	NUM
aji-160	177	18	groups	group	NOUN
aji-160	177	19	.	.	PUNCT
aji-160	178	1	•	•	NUM
aji-160	178	2	group	group	NOUN
aji-160	178	3	1	1	NUM
aji-160	178	4	:	:	PUNCT
aji-160	178	5	embraced	embrace	VERB
aji-160	178	6	43	43	NUM
aji-160	178	7	patients	patient	NOUN
aji-160	178	8	(	(	PUNCT
aji-160	178	9	40	40	NUM
aji-160	178	10	women	woman	NOUN
aji-160	178	11	3	3	NUM
aji-160	178	12	men	man	NOUN
aji-160	178	13	)	)	PUNCT
aji-160	178	14	with	with	ADP
aji-160	178	15	a	a	DET
aji-160	178	16	median	median	ADJ
aji-160	178	17	age	age	NOUN
aji-160	178	18	of	of	ADP
aji-160	178	19	30	30	NUM
aji-160	178	20	±	±	NUM
aji-160	178	21	15	15	NUM
aji-160	178	22	years	year	NOUN
aji-160	178	23	who	who	PRON
aji-160	178	24	,	,	PUNCT
aji-160	178	25	at	at	ADP
aji-160	178	26	time	time	NOUN
aji-160	178	27	of	of	ADP
aji-160	178	28	examination	examination	NOUN
aji-160	178	29	,	,	PUNCT
aji-160	178	30	had	have	AUX
aji-160	178	31	not	not	PART
aji-160	178	32	received	receive	VERB
aji-160	178	33	glucocorticoids	glucocorticoid	NOUN
aji-160	178	34	(	(	PUNCT
aji-160	178	35	gc	gc	PROPN
aji-160	178	36	)	)	PUNCT
aji-160	178	37	,	,	PUNCT
aji-160	178	38	immunosuppressant	immunosuppressant	ADJ
aji-160	178	39	•	•	NUM
aji-160	178	40	group	group	NOUN
aji-160	178	41	2	2	NUM
aji-160	178	42	:	:	PUNCT
aji-160	178	43	embraced	embrace	VERB
aji-160	178	44	45	45	NUM
aji-160	178	45	patients	patient	NOUN
aji-160	178	46	(	(	PUNCT
aji-160	178	47	40	40	NUM
aji-160	178	48	women	woman	NOUN
aji-160	178	49	5	5	NUM
aji-160	178	50	men	man	NOUN
aji-160	178	51	)	)	PUNCT
aji-160	178	52	,	,	PUNCT
aji-160	178	53	the	the	DET
aji-160	178	54	median	median	ADJ
aji-160	178	55	age	age	NOUN
aji-160	178	56	was	be	AUX
aji-160	178	57	30	30	NUM
aji-160	178	58	±	±	NUM
aji-160	178	59	15	15	NUM
aji-160	178	60	years	year	NOUN
aji-160	178	61	patients	patient	NOUN
aji-160	178	62	took	take	VERB
aji-160	178	63	a	a	DET
aji-160	178	64	variety	variety	NOUN
aji-160	178	65	of	of	ADP
aji-160	178	66	combinations	combination	NOUN
aji-160	178	67	of	of	ADP
aji-160	178	68	these	these	DET
aji-160	178	69	drugs	drug	NOUN
aji-160	178	70	.	.	PUNCT
aji-160	179	1	choroquine	choroquine	PROPN
aji-160	179	2	,	,	PUNCT
aji-160	179	3	corticosteroids	corticosteroid	NOUN
aji-160	179	4	at	at	ADP
aji-160	179	5	a	a	DET
aji-160	179	6	dose	dose	NOUN
aji-160	179	7	of	of	ADP
aji-160	179	8	150	150	NUM
aji-160	179	9	mg	mg	NUM
aji-160	179	10	/	/	SYM
aji-160	179	11	day	day	NOUN
aji-160	179	12	.	.	PUNCT
aji-160	180	1	among	among	ADP
aji-160	180	2	them	they	PRON
aji-160	180	3	were	be	AUX
aji-160	180	4	both	both	PRON
aji-160	180	5	newly	newly	ADV
aji-160	180	6	ill	ill	ADJ
aji-160	180	7	and	and	CCONJ
aji-160	180	8	longterm	longterm	ADJ
aji-160	180	9	patients	patient	NOUN
aji-160	180	10	with	with	ADP
aji-160	180	11	sle	sle	PROPN
aji-160	180	12	,	,	PUNCT
aji-160	180	13	but	but	CCONJ
aji-160	180	14	who	who	PRON
aji-160	180	15	canceled	cancel	VERB
aji-160	180	16	previously	previously	ADV
aji-160	180	17	prescribed	prescribe	VERB
aji-160	180	18	therapy	therapy	NOUN
aji-160	180	19	.	.	PUNCT
aji-160	181	1	ha	ha	INTJ
aji-160	181	2	was	be	AUX
aji-160	181	3	received	receive	VERB
aji-160	181	4	by	by	ADP
aji-160	181	5	44	44	NUM
aji-160	181	6	(	(	PUNCT
aji-160	181	7	98	98	NUM
aji-160	181	8	%	%	NOUN
aji-160	181	9	)	)	PUNCT
aji-160	181	10	of	of	ADP
aji-160	181	11	them	they	PRON
aji-160	181	12	,	,	PUNCT
aji-160	181	13	the	the	DET
aji-160	181	14	median	median	PROPN
aji-160	181	15	dose	dose	NOUN
aji-160	181	16	was	be	AUX
aji-160	181	17	20	20	NUM
aji-160	181	18	mg	mg	NUM
aji-160	181	19	/day	/day	PROPN
aji-160	181	20	when	when	SCONJ
aji-160	181	21	calculated	calculate	VERB
aji-160	181	22	for	for	ADP
aji-160	181	23	prednisone	prednisone	NOUN
aji-160	181	24	.	.	PUNCT
aji-160	182	1	during	during	ADP
aji-160	182	2	the	the	DET
aji-160	182	3	entire	entire	ADJ
aji-160	182	4	period	period	NOUN
aji-160	182	5	of	of	ADP
aji-160	182	6	the	the	DET
aji-160	182	7	disease	disease	NOUN
aji-160	182	8	,	,	PUNCT
aji-160	182	9	cyclophosphamide	cyclophosphamide	PROPN
aji-160	182	10	was	be	AUX
aji-160	182	11	used	use	VERB
aji-160	182	12	in	in	ADP
aji-160	182	13	23	23	NUM
aji-160	182	14	(	(	PUNCT
aji-160	182	15	48	48	NUM
aji-160	182	16	%	%	NOUN
aji-160	182	17	)	)	PUNCT
aji-160	182	18	patients	patient	NOUN
aji-160	182	19	,	,	PUNCT
aji-160	182	20	azathioprine	azathioprine	VERB
aji-160	182	21	in	in	ADP
aji-160	182	22	17	17	NUM
aji-160	182	23	(	(	PUNCT
aji-160	182	24	38	38	NUM
aji-160	182	25	%	%	NOUN
aji-160	182	26	)	)	PUNCT
aji-160	182	27	,	,	PUNCT
aji-160	182	28	mycophenolate	mycophenolate	PROPN
aji-160	182	29	mofetil	mofetil	NOUN
aji-160	182	30	in	in	ADP
aji-160	182	31	16	16	NUM
aji-160	182	32	(	(	PUNCT
aji-160	182	33	36	36	NUM
aji-160	182	34	%	%	NOUN
aji-160	182	35	)	)	PUNCT
aji-160	182	36	,	,	PUNCT
aji-160	182	37	methotrexate	methotrexate	VERB
aji-160	182	38	in	in	ADP
aji-160	182	39	9	9	NUM
aji-160	182	40	(	(	PUNCT
aji-160	182	41	19	19	NUM
aji-160	182	42	%	%	NOUN
aji-160	182	43	)	)	PUNCT
aji-160	182	44	,	,	PUNCT
aji-160	182	45	choroquine	choroquine	NOUN
aji-160	182	46	,	,	PUNCT
aji-160	182	47	corticosteroids	corticosteroid	NOUN
aji-160	182	48	in	in	ADP
aji-160	182	49	43	43	NUM
aji-160	182	50	(	(	PUNCT
aji-160	182	51	96	96	NUM
aji-160	182	52	%	%	NOUN
aji-160	182	53	)	)	PUNCT
aji-160	182	54	.	.	PUNCT
aji-160	183	1	3	3	X
aji-160	183	2	.	.	X
aji-160	183	3	results	result	NOUN
aji-160	183	4	immunological	immunological	ADJ
aji-160	183	5	immunology	immunology	NOUN
aji-160	183	6	and	and	CCONJ
aji-160	183	7	laboratory	laboratory	NOUN
aji-160	183	8	characteristics	characteristic	NOUN
aji-160	183	9	of	of	ADP
aji-160	183	10	patients	patient	NOUN
aji-160	183	11	of	of	ADP
aji-160	183	12	both	both	DET
aji-160	183	13	groups	group	NOUN
aji-160	183	14	are	be	AUX
aji-160	183	15	presented	present	VERB
aji-160	183	16	in	in	ADP
aji-160	183	17	table	table	NOUN
aji-160	183	18	2	2	NUM
aji-160	183	19	.	.	PUNCT
aji-160	184	1	the	the	DET
aji-160	184	2	groups	group	NOUN
aji-160	184	3	were	be	AUX
aji-160	184	4	comparable	comparable	ADJ
aji-160	184	5	in	in	ADP
aji-160	184	6	age	age	NOUN
aji-160	184	7	and	and	CCONJ
aji-160	184	8	gender	gender	NOUN
aji-160	184	9	,	,	PUNCT
aji-160	184	10	women	woman	NOUN
aji-160	184	11	predominated	predominate	VERB
aji-160	184	12	(	(	PUNCT
aji-160	184	13	93	93	NUM
aji-160	184	14	%	%	NOUN
aji-160	184	15	90	90	NUM
aji-160	184	16	%	%	NOUN
aji-160	184	17	)	)	PUNCT
aji-160	184	18	.	.	PUNCT
aji-160	185	1	patients	patient	NOUN
aji-160	185	2	of	of	ADP
aji-160	185	3	the	the	DET
aji-160	185	4	2nd	2nd	ADJ
aji-160	185	5	group	group	NOUN
aji-160	185	6	had	have	VERB
aji-160	185	7	a	a	DET
aji-160	185	8	longer	long	ADJ
aji-160	185	9	duration	duration	NOUN
aji-160	185	10	of	of	ADP
aji-160	185	11	illness	illness	NOUN
aji-160	185	12	than	than	ADP
aji-160	185	13	participants	participant	NOUN
aji-160	185	14	of	of	ADP
aji-160	185	15	the	the	DET
aji-160	185	16	1st	1st	ADJ
aji-160	185	17	group	group	NOUN
aji-160	185	18	p	p	X
aji-160	185	19	<	<	X
aji-160	185	20	0.00001	0.00001	NUM
aji-160	185	21	)	)	PUNCT
aji-160	185	22	,	,	PUNCT
aji-160	185	23	less	less	ADJ
aji-160	185	24	activity	activity	NOUN
aji-160	185	25	(	(	PUNCT
aji-160	185	26	sledai_2k	sledai_2k	NOUN
aji-160	185	27	and	and	CCONJ
aji-160	185	28	12	12	NUM
aji-160	185	29	coordinates	coordinate	NOUN
aji-160	185	30	,	,	PUNCT
aji-160	185	31	p	p	X
aji-160	185	32	<	<	X
aji-160	185	33	0.001	0.001	NUM
aji-160	185	34	)	)	PUNCT
aji-160	185	35	,	,	PUNCT
aji-160	185	36	a	a	DET
aji-160	185	37	higher	high	ADJ
aji-160	185	38	damage	damage	NOUN
aji-160	185	39	index	index	NOUN
aji-160	185	40	(	(	PUNCT
aji-160	185	41	slicc_di	slicc_di	NOUN
aji-160	185	42	1	1	NUM
aji-160	185	43	0	0	NUM
aji-160	185	44	coordinates	coordinate	NOUN
aji-160	185	45	,	,	PUNCT
aji-160	185	46	p	p	X
aji-160	185	47	<	<	X
aji-160	185	48	0.001	0.001	NUM
aji-160	185	49	)	)	PUNCT
aji-160	185	50	,	,	PUNCT
aji-160	185	51	they	they	PRON
aji-160	185	52	exhibited	exhibit	VERB
aji-160	185	53	a	a	DET
aji-160	185	54	lower	low	ADJ
aji-160	185	55	incidence	incidence	NOUN
aji-160	185	56	of	of	ADP
aji-160	185	57	skin	skin	NOUN
aji-160	185	58	lesions	lesion	NOUN
aji-160	185	59	(	(	PUNCT
aji-160	185	60	11	11	NUM
aji-160	185	61	%	%	NOUN
aji-160	185	62	and	and	CCONJ
aji-160	185	63	57	57	NUM
aji-160	185	64	%	%	NOUN
aji-160	185	65	,	,	PUNCT
aji-160	185	66	p	p	X
aji-160	185	67	<	<	X
aji-160	185	68	0.0001	0.0001	NUM
aji-160	185	69	)	)	PUNCT
aji-160	185	70	,	,	PUNCT
aji-160	185	71	joints	joint	NOUN
aji-160	185	72	(	(	PUNCT
aji-160	185	73	22	22	NUM
aji-160	185	74	%	%	NOUN
aji-160	185	75	52	52	NUM
aji-160	185	76	%	%	NOUN
aji-160	185	77	,	,	PUNCT
aji-160	185	78	p	p	X
aji-160	185	79	<	<	X
aji-160	185	80	0.05	0.05	NUM
aji-160	185	81	)	)	PUNCT
aji-160	185	82	and	and	CCONJ
aji-160	185	83	hematological	hematological	ADJ
aji-160	185	84	disorders	disorder	NOUN
aji-160	185	85	(	(	PUNCT
aji-160	185	86	24	24	NUM
aji-160	185	87	%	%	NOUN
aji-160	185	88	and	and	CCONJ
aji-160	185	89	73.8	73.8	NUM
aji-160	185	90	%	%	NOUN
aji-160	185	91	,	,	PUNCT
aji-160	185	92	p	p	X
aji-160	185	93	<	<	X
aji-160	185	94	0.0001	0.0001	NUM
aji-160	185	95	)	)	PUNCT
aji-160	185	96	.	.	PUNCT
aji-160	186	1	the	the	DET
aji-160	186	2	main	main	ADJ
aji-160	186	3	immunology	immunology	NOUN
aji-160	186	4	examination	examination	NOUN
aji-160	186	5	manifestations	manifestation	NOUN
aji-160	186	6	of	of	ADP
aji-160	186	7	sle	sle	PROPN
aji-160	186	8	in	in	ADP
aji-160	186	9	group	group	NOUN
aji-160	186	10	1	1	NUM
aji-160	186	11	patients	patient	NOUN
aji-160	186	12	have	have	VERB
aji-160	186	13	hematological	hematological	ADJ
aji-160	186	14	disorders	disorder	NOUN
aji-160	186	15	(	(	PUNCT
aji-160	186	16	74	74	NUM
aji-160	186	17	%	%	NOUN
aji-160	186	18	)	)	PUNCT
aji-160	186	19	,	,	PUNCT
aji-160	186	20	skin	skin	NOUN
aji-160	186	21	lesions	lesion	NOUN
aji-160	186	22	(	(	PUNCT
aji-160	186	23	57	57	NUM
aji-160	186	24	%	%	NOUN
aji-160	186	25	)	)	PUNCT
aji-160	186	26	,	,	PUNCT
aji-160	186	27	kidneys	kidney	NOUN
aji-160	186	28	(	(	PUNCT
aji-160	186	29	55	55	NUM
aji-160	186	30	%	%	NOUN
aji-160	186	31	)	)	PUNCT
aji-160	186	32	and	and	CCONJ
aji-160	186	33	joints	joint	NOUN
aji-160	186	34	(	(	PUNCT
aji-160	186	35	52	52	NUM
aji-160	186	36	%	%	NOUN
aji-160	186	37	)	)	PUNCT
aji-160	186	38	,	,	PUNCT
aji-160	186	39	all	all	PRON
aji-160	186	40	also	also	ADV
aji-160	186	41	revealed	reveal	VERB
aji-160	186	42	immunological	immunological	ADJ
aji-160	186	43	disorders	disorder	NOUN
aji-160	186	44	an	an	DET
aji-160	186	45	increase	increase	NOUN
aji-160	186	46	the	the	DET
aji-160	186	47	level	level	NOUN
aji-160	186	48	of	of	ADP
aji-160	186	49	antinuclear	antinuclear	ADJ
aji-160	186	50	factor	factor	NOUN
aji-160	186	51	(	(	PUNCT
aji-160	186	52	anf	anf	NOUN
aji-160	186	53	)	)	PUNCT
aji-160	186	54	in	in	ADP
aji-160	186	55	100	100	NUM
aji-160	186	56	%	%	NOUN
aji-160	186	57	,	,	PUNCT
aji-160	186	58	anti	anti	X
aji-160	186	59	dsdna	dsdna	NOUN
aji-160	186	60	in	in	ADP
aji-160	186	61	80	80	NUM
aji-160	186	62	%	%	NOUN
aji-160	186	63	patients	patient	NOUN
aji-160	186	64	.	.	PUNCT
aji-160	187	1	•	•	NUM
aji-160	187	2	group	group	NOUN
aji-160	187	3	1	1	NUM
aji-160	187	4	:	:	PUNCT
aji-160	187	5	nephritis	nephritis	NOUN
aji-160	187	6	(	(	PUNCT
aji-160	187	7	36	36	NUM
aji-160	187	8	%	%	NOUN
aji-160	187	9	)	)	PUNCT
aji-160	187	10	,	,	PUNCT
aji-160	187	11	sororities	sorority	NOUN
aji-160	187	12	(	(	PUNCT
aji-160	187	13	29	29	NUM
aji-160	187	14	%	%	NOUN
aji-160	187	15	)	)	PUNCT
aji-160	187	16	,	,	PUNCT
aji-160	187	17	hematological	hematological	ADJ
aji-160	187	18	disorders	disorder	NOUN
aji-160	187	19	(	(	PUNCT
aji-160	187	20	24	24	NUM
aji-160	187	21	%	%	NOUN
aji-160	187	22	)	)	PUNCT
aji-160	187	23	and	and	CCONJ
aji-160	187	24	arthritis	arthritis	NOUN
aji-160	187	25	(	(	PUNCT
aji-160	187	26	22.2	22.2	NUM
aji-160	187	27	%	%	NOUN
aji-160	187	28	)	)	PUNCT
aji-160	187	29	.	.	PUNCT
aji-160	188	1	•	•	NUM
aji-160	188	2	group	group	NOUN
aji-160	188	3	2	2	NUM
aji-160	188	4	:	:	PUNCT
aji-160	188	5	immunological	immunological	ADJ
aji-160	188	6	disorders	disorder	NOUN
aji-160	188	7	have	have	AUX
aji-160	188	8	identified	identify	VERB
aji-160	188	9	in	in	ADP
aji-160	188	10	96	96	NUM
aji-160	188	11	%	%	NOUN
aji-160	188	12	of	of	ADP
aji-160	188	13	patients	patient	NOUN
aji-160	188	14	.	.	PUNCT
aji-160	189	1	no	no	DET
aji-160	189	2	relevant	relevant	ADJ
aji-160	189	3	variations	variation	NOUN
aji-160	189	4	were	be	AUX
aji-160	189	5	identified	identify	VERB
aji-160	189	6	in	in	ADP
aji-160	189	7	the	the	DET
aji-160	189	8	concomitant	concomitant	PROPN
aji-160	189	9	sjogren	sjogren	PROPN
aji-160	189	10	's	's	PART
aji-160	189	11	syndrome	syndrome	NOUN
aji-160	189	12	and	and	CCONJ
aji-160	189	13	allergic	allergic	ADJ
aji-160	189	14	fungal	fungal	ADJ
aji-160	189	15	sinusitis	sinusitis	NOUN
aji-160	189	16	(	(	PUNCT
aji-160	189	17	afs	afs	NOUN
aji-160	189	18	)	)	PUNCT
aji-160	189	19	.	.	PUNCT
aji-160	190	1	this	this	PRON
aji-160	190	2	,	,	PUNCT
aji-160	190	3	division	division	NOUN
aji-160	190	4	of	of	ADP
aji-160	190	5	patients	patient	NOUN
aji-160	190	6	with	with	ADP
aji-160	190	7	sle	sle	PROPN
aji-160	190	8	into	into	ADP
aji-160	190	9	groups	group	NOUN
aji-160	190	10	upon	upon	SCONJ
aji-160	190	11	taking	take	VERB
aji-160	190	12	ant	ant	ADJ
aji-160	190	13	rheumatic	rheumatic	ADJ
aji-160	190	14	therapy	therapy	NOUN
aji-160	190	15	shaker	shaker	NOUN
aji-160	190	16	;	;	PUNCT
aji-160	190	17	asian	asian	PROPN
aji-160	190	18	j.	j.	PROPN
aji-160	190	19	immunol	immunol	PROPN
aji-160	190	20	.	.	PROPN
aji-160	190	21	,	,	PUNCT
aji-160	190	22	vol	vol	NOUN
aji-160	190	23	.	.	PROPN
aji-160	190	24	8	8	NUM
aji-160	190	25	,	,	PUNCT
aji-160	190	26	no	no	INTJ
aji-160	190	27	.	.	NOUN
aji-160	190	28	1	1	NUM
aji-160	190	29	,	,	PUNCT
aji-160	190	30	pp	pp	ADJ
aji-160	190	31	.	.	PUNCT
aji-160	191	1	60	60	NUM
aji-160	191	2	-	-	SYM
aji-160	191	3	69	69	NUM
aji-160	191	4	,	,	PUNCT
aji-160	191	5	2025	2025	NUM
aji-160	191	6	;	;	PUNCT
aji-160	191	7	article	article	NOUN
aji-160	191	8	no.aji.134457	no.aji.134457	VERB
aji-160	191	9	65	65	NUM
aji-160	191	10	(	(	PUNCT
aji-160	191	11	immunosuppressant	immunosuppressant	NOUN
aji-160	191	12	,	,	PUNCT
aji-160	191	13	gibp	gibp	PROPN
aji-160	191	14	)	)	PUNCT
aji-160	191	15	allowed	allow	VERB
aji-160	191	16	us	we	PRON
aji-160	191	17	to	to	PART
aji-160	191	18	assess	assess	VERB
aji-160	191	19	its	its	PRON
aji-160	191	20	relationship	relationship	NOUN
aji-160	191	21	with	with	ADP
aji-160	191	22	the	the	DET
aji-160	191	23	activity	activity	NOUN
aji-160	191	24	and	and	CCONJ
aji-160	191	25	duration	duration	NOUN
aji-160	191	26	of	of	ADP
aji-160	191	27	sle	sle	PROPN
aji-160	191	28	,	,	PUNCT
aji-160	191	29	since	since	SCONJ
aji-160	191	30	the	the	DET
aji-160	191	31	groups	group	NOUN
aji-160	191	32	differed	differ	VERB
aji-160	191	33	relevantly	relevantly	ADV
aji-160	191	34	in	in	ADP
aji-160	191	35	these	these	DET
aji-160	191	36	indicators	indicator	NOUN
aji-160	191	37	.	.	PUNCT
aji-160	192	1	value	value	NOUN
aji-160	192	2	level	level	NOUN
aji-160	192	3	of	of	ADP
aji-160	192	4	nt_probnp	nt_probnp	NOUN
aji-160	192	5	in	in	ADP
aji-160	192	6	untreated	untreated	ADJ
aji-160	192	7	patients	patient	NOUN
aji-160	192	8	was	be	AUX
aji-160	192	9	elevated	elevate	VERB
aji-160	192	10	than	than	ADP
aji-160	192	11	in	in	ADP
aji-160	192	12	group	group	NOUN
aji-160	192	13	2nt	2nt	NOUN
aji-160	192	14	(	(	PUNCT
aji-160	192	15	151	151	NUM
aji-160	192	16	33	33	NUM
aji-160	192	17	pictograms	pictogram	NOUN
aji-160	192	18	per	per	ADP
aji-160	192	19	milliliter	milliliter	NOUN
aji-160	192	20	,	,	PUNCT
aji-160	192	21	respectively	respectively	ADV
aji-160	192	22	,	,	PUNCT
aji-160	192	23	p	p	X
aji-160	192	24	<	<	X
aji-160	192	25	0.01	0.01	NUM
aji-160	192	26	)	)	PUNCT
aji-160	192	27	,	,	PUNCT
aji-160	192	28	while	while	SCONJ
aji-160	192	29	exceeding	exceed	VERB
aji-160	192	30	normal	normal	ADJ
aji-160	192	31	values	value	NOUN
aji-160	192	32	.	.	PUNCT
aji-160	193	1	note	note	NOUN
aji-160	193	2	/	/	PUNCT
aji-160	193	3	that	that	SCONJ
aji-160	193	4	the	the	DET
aji-160	193	5	mean	mean	ADJ
aji-160	193	6	value	value	NOUN
aji-160	193	7	of	of	ADP
aji-160	193	8	and	and	CCONJ
aji-160	193	9	the	the	DET
aji-160	193	10	mean	mean	ADJ
aji-160	193	11	value	value	NOUN
aji-160	193	12	of	of	ADP
aji-160	193	13	the	the	DET
aji-160	193	14	control	control	NOUN
aji-160	193	15	group	group	NOUN
aji-160	193	16	is	be	AUX
aji-160	193	17	equal	equal	ADJ
aji-160	193	18	to	to	ADP
aji-160	193	19	4	4	NUM
aji-160	193	20	,	,	PUNCT
aji-160	193	21	noting	note	VERB
aji-160	193	22	that	that	SCONJ
aji-160	193	23	p.	p.	NOUN
aji-160	193	24	value	value	NOUN
aji-160	193	25	nt_probnp	nt_probnp	X
aji-160	193	26	equal	equal	ADJ
aji-160	193	27	0.05	0.05	NUM
aji-160	193	28	mean	mean	NOUN
aji-160	193	29	value	value	NOUN
aji-160	193	30	lupus	lupus	NOUN
aji-160	193	31	value	value	NOUN
aji-160	193	32	is	be	AUX
aji-160	193	33	equal	equal	ADJ
aji-160	193	34	19.37	19.37	NUM
aji-160	193	35	.	.	PUNCT
aji-160	193	36	table	table	NOUN
aji-160	193	37	3	3	NUM
aji-160	193	38	.	.	PUNCT
aji-160	193	39	comparison	comparison	NOUN
aji-160	193	40	immunological	immunological	ADJ
aji-160	193	41	and	and	CCONJ
aji-160	193	42	laboratory	laboratory	NOUN
aji-160	193	43	characteristics	characteristic	NOUN
aji-160	193	44	of	of	ADP
aji-160	193	45	patients	patient	NOUN
aji-160	193	46	of	of	ADP
aji-160	193	47	both	both	DET
aji-160	193	48	groups	group	NOUN
aji-160	193	49	are	be	AUX
aji-160	193	50	presented	present	VERB
aji-160	193	51	characters	character	NOUN
aji-160	193	52	sle	sle	PROPN
aji-160	193	53	(	(	PUNCT
aji-160	193	54	n	n	NOUN
aji-160	193	55	=	=	SYM
aji-160	193	56	88	88	NUM
aji-160	193	57	)	)	PUNCT
aji-160	193	58	control	control	NOUN
aji-160	193	59	(	(	PUNCT
aji-160	193	60	n=85	n=85	PROPN
aji-160	193	61	)	)	PUNCT
aji-160	193	62	p.	p.	NOUN
aji-160	193	63	value	value	NOUN
aji-160	193	64	notes	note	VERB
aji-160	193	65	nt_probnp	nt_probnp	X
aji-160	193	66	(	(	PUNCT
aji-160	193	67	mean	mean	VERB
aji-160	193	68	)	)	PUNCT
aji-160	193	69	19.37	19.37	NUM
aji-160	193	70	4	4	NUM
aji-160	193	71	0.05	0.05	NUM
aji-160	193	72	based	base	VERB
aji-160	193	73	on	on	ADP
aji-160	193	74	the	the	DET
aji-160	193	75	assumption	assumption	NOUN
aji-160	193	76	that	that	SCONJ
aji-160	193	77	the	the	DET
aji-160	193	78	overall	overall	ADJ
aji-160	193	79	mean	mean	NOUN
aji-160	193	80	for	for	ADP
aji-160	193	81	both	both	DET
aji-160	193	82	groups	group	NOUN
aji-160	193	83	is	be	AUX
aji-160	193	84	equal	equal	ADJ
aji-160	193	85	to	to	ADP
aji-160	193	86	12	12	NUM
aji-160	193	87	,	,	PUNCT
aji-160	193	88	the	the	DET
aji-160	193	89	probability	probability	NOUN
aji-160	193	90	value	value	NOUN
aji-160	193	91	indicates	indicate	VERB
aji-160	193	92	the	the	DET
aji-160	193	93	difference	difference	NOUN
aji-160	193	94	in	in	ADP
aji-160	193	95	statistical	statistical	ADJ
aji-160	193	96	significance	significance	NOUN
aji-160	193	97	age	age	NOUN
aji-160	193	98	(	(	PUNCT
aji-160	193	99	mean	mean	PROPN
aji-160	193	100	±	±	NUM
aji-160	193	101	sd	sd	NOUN
aji-160	193	102	)	)	PUNCT
aji-160	193	103	30	30	NUM
aji-160	193	104	±	±	NUM
aji-160	193	105	15	15	NUM
aji-160	193	106	30	30	NUM
aji-160	193	107	±	±	NUM
aji-160	193	108	14	14	NUM
aji-160	193	109	<	<	NOUN
aji-160	193	110	0.001	0.001	NUM
aji-160	193	111	there	there	PRON
aji-160	193	112	is	be	VERB
aji-160	193	113	a	a	DET
aji-160	193	114	difference	difference	NOUN
aji-160	193	115	in	in	ADP
aji-160	193	116	the	the	DET
aji-160	193	117	statistical	statistical	ADJ
aji-160	193	118	results	result	NOUN
aji-160	193	119	regarding	regard	VERB
aji-160	193	120	the	the	DET
aji-160	193	121	distribution	distribution	NOUN
aji-160	193	122	of	of	ADP
aji-160	193	123	ages	age	NOUN
aji-160	193	124	gender	gender	NOUN
aji-160	193	125	(	(	PUNCT
aji-160	193	126	male	male	NOUN
aji-160	193	127	)	)	PUNCT
aji-160	193	128	3	3	NUM
aji-160	193	129	(	(	PUNCT
aji-160	193	130	10	10	NUM
aji-160	193	131	%	%	NOUN
aji-160	193	132	)	)	PUNCT
aji-160	193	133	5	5	NUM
aji-160	193	134	(	(	PUNCT
aji-160	193	135	4	4	NUM
aji-160	193	136	%	%	NOUN
aji-160	193	137	)	)	PUNCT
aji-160	193	138	<	<	X
aji-160	193	139	0.0001	0.0001	NUM
aji-160	193	140	the	the	DET
aji-160	193	141	statistical	statistical	ADJ
aji-160	193	142	difference	difference	NOUN
aji-160	193	143	in	in	ADP
aji-160	193	144	results	result	NOUN
aji-160	193	145	is	be	AUX
aji-160	193	146	very	very	ADV
aji-160	193	147	high	high	ADJ
aji-160	193	148	between	between	ADP
aji-160	193	149	the	the	DET
aji-160	193	150	two	two	NUM
aji-160	193	151	genders	gender	NOUN
aji-160	193	152	gender	gender	NOUN
aji-160	193	153	(	(	PUNCT
aji-160	193	154	female	female	NOUN
aji-160	193	155	)	)	PUNCT
aji-160	193	156	40	40	NUM
aji-160	193	157	(	(	PUNCT
aji-160	193	158	90	90	NUM
aji-160	193	159	%	%	NOUN
aji-160	193	160	)	)	PUNCT
aji-160	193	161	40	40	NUM
aji-160	193	162	(	(	PUNCT
aji-160	193	163	96	96	NUM
aji-160	193	164	%	%	NOUN
aji-160	193	165	)	)	PUNCT
aji-160	194	1	<	<	X
aji-160	194	2	0.0001	0.0001	NUM
aji-160	194	3	the	the	DET
aji-160	194	4	statistical	statistical	ADJ
aji-160	194	5	difference	difference	NOUN
aji-160	194	6	in	in	ADP
aji-160	194	7	results	result	NOUN
aji-160	194	8	is	be	AUX
aji-160	194	9	very	very	ADV
aji-160	194	10	high	high	ADJ
aji-160	194	11	between	between	ADP
aji-160	194	12	the	the	DET
aji-160	194	13	two	two	NUM
aji-160	194	14	genders	gender	NOUN
aji-160	194	15	total	total	ADJ
aji-160	194	16	sample	sample	NOUN
aji-160	194	17	size	size	NOUN
aji-160	194	18	88	88	NUM
aji-160	194	19	85	85	NUM
aji-160	194	20	n.	n.	NOUN
aji-160	194	21	of	of	ADP
aji-160	194	22	individuals	individual	NOUN
aji-160	194	23	with	with	ADP
aji-160	194	24	determined	determined	ADJ
aji-160	194	25	gender	gender	NOUN
aji-160	194	26	43	43	NUM
aji-160	194	27	45	45	NUM
aji-160	194	28	anti_ena	anti_ena	NUM
aji-160	194	29	(	(	PUNCT
aji-160	194	30	extractable	extractable	ADJ
aji-160	194	31	nuclear	nuclear	ADJ
aji-160	194	32	antibodies	antibody	NOUN
aji-160	194	33	):	):	PUNCT
aji-160	194	34	antibody	antibody	NOUN
aji-160	194	35	ranges	range	VERB
aji-160	194	36	intermediate	intermediate	ADJ
aji-160	194	37	to	to	ADP
aji-160	194	38	sle	sle	PROPN
aji-160	194	39	sufferers	sufferer	NOUN
aji-160	194	40	and	and	CCONJ
aji-160	194	41	manipulate	manipulate	VERB
aji-160	194	42	organization	organization	NOUN
aji-160	194	43	is	be	AUX
aji-160	194	44	supplied	supply	VERB
aji-160	194	45	in	in	ADP
aji-160	194	46	table	table	NOUN
aji-160	194	47	5	5	NUM
aji-160	194	48	.	.	PUNCT
aji-160	195	1	the	the	DET
aji-160	195	2	evaluation	evaluation	NOUN
aji-160	195	3	outcomes	outcome	NOUN
aji-160	195	4	reveal	reveal	VERB
aji-160	195	5	there	there	ADV
aji-160	195	6	have	have	VERB
aji-160	195	7	n’t	n’t	ADJ
aji-160	195	8	extensive	extensive	ADJ
aji-160	195	9	variations	variation	NOUN
aji-160	195	10	(	(	PUNCT
aji-160	195	11	p	p	X
aji-160	195	12	>	>	X
aji-160	195	13	0.015	0.015	NUM
aji-160	195	14	)	)	PUNCT
aji-160	195	15	within	within	ADP
aji-160	195	16	the	the	DET
aji-160	195	17	detection	detection	NOUN
aji-160	195	18	results	result	NOUN
aji-160	195	19	of	of	ADP
aji-160	195	20	anti_jo1	anti_jo1	NOUN
aji-160	195	21	and	and	CCONJ
aji-160	195	22	anti_scl70	anti_scl70	NOUN
aji-160	195	23	antibody	antibody	NOUN
aji-160	195	24	<	<	X
aji-160	195	25	0.001	0.001	NUM
aji-160	195	26	intermediate	intermediate	ADJ
aji-160	195	27	to	to	ADP
aji-160	195	28	sle	sle	PROPN
aji-160	195	29	patients	patient	NOUN
aji-160	195	30	and	and	CCONJ
aji-160	195	31	manage	manage	VERB
aji-160	195	32	institution	institution	NOUN
aji-160	195	33	.	.	PUNCT
aji-160	196	1	but	but	CCONJ
aji-160	196	2	,	,	PUNCT
aji-160	196	3	the	the	DET
aji-160	196	4	sle	sle	PROPN
aji-160	196	5	patient	patient	ADJ
aji-160	196	6	institution	institution	NOUN
aji-160	196	7	exhibited	exhibit	VERB
aji-160	196	8	relevantly	relevantly	ADV
aji-160	196	9	raised	raise	VERB
aji-160	196	10	of	of	ADP
aji-160	196	11	antirnp	antirnp	PROPN
aji-160	196	12	levels	level	NOUN
aji-160	196	13	<	<	NOUN
aji-160	196	14	0.001	0.001	NUM
aji-160	196	15	,	,	PUNCT
aji-160	196	16	anti_sm	anti_sm	NOUN
aji-160	196	17	<	<	X
aji-160	196	18	0.001	0.001	NUM
aji-160	196	19	,	,	PUNCT
aji-160	196	20	anti	anti	ADJ
aji-160	196	21	ssa	ssa	NOUN
aji-160	196	22	,	,	PUNCT
aji-160	196	23	and	and	CCONJ
aji-160	196	24	anti	anti	PROPN
aji-160	196	25	ssb	ssb	PROPN
aji-160	196	26	compared	compare	VERB
aji-160	196	27	with	with	ADP
aji-160	196	28	group	group	NOUN
aji-160	196	29	of	of	ADP
aji-160	196	30	control	control	NOUN
aji-160	196	31	,	,	PUNCT
aji-160	196	32	with	with	ADP
aji-160	196	33	all	all	DET
aji-160	196	34	variations	variation	NOUN
aji-160	196	35	being	be	AUX
aji-160	196	36	statistically	statistically	ADV
aji-160	196	37	relevant	relevant	ADJ
aji-160	196	38	(	(	PUNCT
aji-160	196	39	p	p	X
aji-160	196	40	<	<	X
aji-160	196	41	0.01	0.01	NUM
aji-160	196	42	)	)	PUNCT
aji-160	196	43	.	.	PUNCT
aji-160	197	1	these	these	DET
aji-160	197	2	results	result	NOUN
aji-160	197	3	in	in	ADP
aji-160	197	4	the	the	DET
aji-160	197	5	bottom	bottom	NOUN
aji-160	197	6	.	.	PUNCT
aji-160	198	1	table	table	NOUN
aji-160	198	2	4	4	NUM
aji-160	198	3	.	.	PUNCT
aji-160	198	4	comparison	comparison	NOUN
aji-160	198	5	levels	level	NOUN
aji-160	198	6	anti_ena	anti_ena	AUX
aji-160	198	7	antibody	antibody	NOUN
aji-160	198	8	sle	sle	NOUN
aji-160	198	9	(	(	PUNCT
aji-160	198	10	n	n	NOUN
aji-160	198	11	=	=	SYM
aji-160	198	12	88	88	NUM
aji-160	198	13	)	)	PUNCT
aji-160	198	14	control	control	NOUN
aji-160	198	15	(	(	PUNCT
aji-160	198	16	n	n	NOUN
aji-160	198	17	=	=	SYM
aji-160	198	18	85	85	NUM
aji-160	198	19	)	)	PUNCT
aji-160	199	1	p.	p.	NOUN
aji-160	199	2	values	value	NOUN
aji-160	199	3	anti_jo1	anti_jo1	ADP
aji-160	199	4	negative	negative	ADJ
aji-160	199	5	6(7	6(7	NUM
aji-160	199	6	%	%	NOUN
aji-160	199	7	)	)	PUNCT
aji-160	200	1	78(92	78(92	NUM
aji-160	200	2	%	%	NOUN
aji-160	200	3	)	)	PUNCT
aji-160	201	1	<	<	X
aji-160	201	2	0.001	0.001	NUM
aji-160	201	3	positive	positive	ADJ
aji-160	201	4	82(93	82(93	NUM
aji-160	201	5	%	%	NOUN
aji-160	201	6	)	)	PUNCT
aji-160	202	1	7(8	7(8	NUM
aji-160	202	2	%	%	NOUN
aji-160	202	3	)	)	PUNCT
aji-160	202	4	anti	anti	PROPN
aji-160	202	5	-	-	NOUN
aji-160	202	6	rnp	rnp	NOUN
aji-160	202	7	<	<	X
aji-160	202	8	0.001	0.001	NUM
aji-160	202	9	negative	negative	ADJ
aji-160	202	10	13(15	13(15	NUM
aji-160	202	11	%	%	NOUN
aji-160	202	12	)	)	PUNCT
aji-160	203	1	72(85	72(85	NUM
aji-160	203	2	%	%	NOUN
aji-160	203	3	)	)	PUNCT
aji-160	203	4	positive	positive	ADJ
aji-160	203	5	75(85	75(85	NUM
aji-160	203	6	%	%	NOUN
aji-160	203	7	)	)	PUNCT
aji-160	203	8	13(15	13(15	NUM
aji-160	203	9	%	%	NOUN
aji-160	203	10	)	)	PUNCT
aji-160	203	11	anti_scl70	anti_scl70	NOUN
aji-160	203	12	0.15	0.15	NUM
aji-160	203	13	negative	negative	ADJ
aji-160	203	14	77(88	77(88	NUM
aji-160	203	15	%	%	NOUN
aji-160	203	16	)	)	PUNCT
aji-160	203	17	81(95	81(95	NUM
aji-160	203	18	%	%	NOUN
aji-160	203	19	)	)	PUNCT
aji-160	203	20	positive	positive	ADJ
aji-160	203	21	11(12	11(12	NOUN
aji-160	203	22	%	%	NOUN
aji-160	203	23	)	)	PUNCT
aji-160	203	24	4(5	4(5	NUM
aji-160	203	25	%	%	NOUN
aji-160	203	26	)	)	PUNCT
aji-160	203	27	anti_sm	anti_sm	NOUN
aji-160	203	28	<	<	X
aji-160	203	29	0.001	0.001	NUM
aji-160	203	30	negative	negative	ADJ
aji-160	203	31	66(75	66(75	NUM
aji-160	203	32	%	%	NOUN
aji-160	203	33	)	)	PUNCT
aji-160	203	34	83(98	83(98	NOUN
aji-160	203	35	%	%	NOUN
aji-160	203	36	)	)	PUNCT
aji-160	203	37	positive	positive	ADJ
aji-160	203	38	22(25	22(25	NUM
aji-160	203	39	%	%	NOUN
aji-160	203	40	)	)	PUNCT
aji-160	203	41	2(2	2(2	NUM
aji-160	203	42	%	%	NOUN
aji-160	203	43	)	)	PUNCT
aji-160	203	44	anti_ssa	anti_ssa	PROPN
aji-160	203	45	<	<	X
aji-160	203	46	0.001	0.001	NUM
aji-160	203	47	negative	negative	ADJ
aji-160	203	48	35(40	35(40	NUM
aji-160	203	49	%	%	NOUN
aji-160	203	50	)	)	PUNCT
aji-160	204	1	68(80	68(80	NOUN
aji-160	204	2	%	%	NOUN
aji-160	204	3	)	)	PUNCT
aji-160	204	4	positive	positive	ADJ
aji-160	204	5	53(60	53(60	NUM
aji-160	204	6	%	%	NOUN
aji-160	204	7	)	)	PUNCT
aji-160	204	8	17(20	17(20	NUM
aji-160	204	9	%	%	NOUN
aji-160	204	10	)	)	PUNCT
aji-160	204	11	anti_ssb	anti_ssb	NOUN
aji-160	204	12	0.005	0.005	NUM
aji-160	204	13	negative	negative	ADJ
aji-160	204	14	72(82	72(82	NUM
aji-160	204	15	%	%	NOUN
aji-160	204	16	)	)	PUNCT
aji-160	205	1	77(90	77(90	NUM
aji-160	205	2	%	%	NOUN
aji-160	205	3	)	)	PUNCT
aji-160	205	4	positive	positive	ADJ
aji-160	205	5	16(18	16(18	NOUN
aji-160	205	6	%	%	NOUN
aji-160	205	7	)	)	PUNCT
aji-160	205	8	8(10	8(10	NUM
aji-160	205	9	%	%	NOUN
aji-160	205	10	)	)	PUNCT
aji-160	205	11	shaker	shaker	NOUN
aji-160	205	12	;	;	PUNCT
aji-160	205	13	asian	asian	PROPN
aji-160	205	14	j.	j.	PROPN
aji-160	205	15	immunol	immunol	PROPN
aji-160	205	16	.	.	PROPN
aji-160	205	17	,	,	PUNCT
aji-160	205	18	vol	vol	NOUN
aji-160	205	19	.	.	PROPN
aji-160	205	20	8	8	NUM
aji-160	205	21	,	,	PUNCT
aji-160	205	22	no	no	INTJ
aji-160	205	23	.	.	NOUN
aji-160	205	24	1	1	NUM
aji-160	205	25	,	,	PUNCT
aji-160	205	26	pp	pp	ADJ
aji-160	205	27	.	.	PUNCT
aji-160	206	1	60	60	NUM
aji-160	206	2	-	-	SYM
aji-160	206	3	69	69	NUM
aji-160	206	4	,	,	PUNCT
aji-160	206	5	2025	2025	NUM
aji-160	206	6	;	;	PUNCT
aji-160	206	7	article	article	NOUN
aji-160	206	8	no.aji.134457	no.aji.134457	VERB
aji-160	206	9	66	66	NUM
aji-160	206	10	analysis	analysis	NOUN
aji-160	206	11	of	of	ADP
aji-160	206	12	associate	associate	ADJ
aji-160	206	13	chartered	charter	VERB
aji-160	206	14	accountant	accountant	NOUN
aji-160	206	15	(	(	PUNCT
aji-160	206	16	aca	aca	NOUN
aji-160	206	17	)	)	PUNCT
aji-160	206	18	levels	level	NOUN
aji-160	206	19	:	:	PUNCT
aji-160	207	1	results	result	NOUN
aji-160	207	2	comparing	compare	VERB
aji-160	207	3	aca	aca	PROPN
aji-160	207	4	levels	level	NOUN
aji-160	207	5	in	in	ADP
aji-160	207	6	patients	patient	NOUN
aji-160	207	7	with	with	ADP
aji-160	207	8	sle	sle	PROPN
aji-160	207	9	to	to	ADP
aji-160	207	10	those	those	PRON
aji-160	207	11	in	in	ADP
aji-160	207	12	the	the	DET
aji-160	207	13	control	control	NOUN
aji-160	207	14	group	group	NOUN
aji-160	207	15	are	be	AUX
aji-160	207	16	outlined	outline	VERB
aji-160	207	17	in	in	ADP
aji-160	207	18	table	table	NOUN
aji-160	207	19	6	6	NUM
aji-160	207	20	.	.	PUNCT
aji-160	208	1	the	the	DET
aji-160	208	2	analysis	analysis	NOUN
aji-160	208	3	revealed	reveal	VERB
aji-160	208	4	that	that	SCONJ
aji-160	208	5	positive	positive	ADJ
aji-160	208	6	rate	rate	NOUN
aji-160	208	7	of	of	ADP
aji-160	208	8	aca	aca	PROPN
aji-160	208	9	antibodies	antibody	NOUN
aji-160	208	10	had	have	AUX
aji-160	208	11	increased	increase	VERB
aji-160	208	12	over	over	ADP
aji-160	208	13	time	time	NOUN
aji-160	208	14	,	,	PUNCT
aji-160	208	15	aca	aca	PROPN
aji-160	208	16	(	(	PUNCT
aji-160	208	17	iga	iga	PROPN
aji-160	208	18	,	,	PUNCT
aji-160	208	19	igg	igg	PROPN
aji-160	208	20	,	,	PUNCT
aji-160	208	21	igm	igm	PROPN
aji-160	208	22	)	)	PUNCT
aji-160	208	23	,	,	PUNCT
aji-160	208	24	are	be	AUX
aji-160	208	25	elevated	elevate	VERB
aji-160	208	26	in	in	ADP
aji-160	208	27	sle	sle	PROPN
aji-160	208	28	group	group	NOUN
aji-160	208	29	compared	compare	VERB
aji-160	208	30	to	to	ADP
aji-160	208	31	the	the	DET
aji-160	208	32	control	control	NOUN
aji-160	208	33	group	group	NOUN
aji-160	208	34	,	,	PUNCT
aji-160	208	35	with	with	ADP
aji-160	208	36	these	these	DET
aji-160	208	37	variations	variation	NOUN
aji-160	208	38	achieving	achieve	VERB
aji-160	208	39	statistically	statistically	ADV
aji-160	208	40	relevant	relevant	ADJ
aji-160	208	41	(	(	PUNCT
aji-160	208	42	p	p	X
aji-160	208	43	<	<	X
aji-160	208	44	0.05	0.05	NUM
aji-160	208	45	)	)	PUNCT
aji-160	208	46	as	as	SCONJ
aji-160	208	47	shown	show	VERB
aji-160	208	48	in	in	ADP
aji-160	208	49	table	table	NOUN
aji-160	208	50	6	6	NUM
aji-160	208	51	.	.	NOUN
aji-160	208	52	•	•	NUM
aji-160	209	1	p25	p25	NOUN
aji-160	209	2	represents	represent	VERB
aji-160	209	3	the	the	DET
aji-160	209	4	first	first	ADJ
aji-160	209	5	quartile	quartile	NOUN
aji-160	209	6	of	of	ADP
aji-160	209	7	the	the	DET
aji-160	209	8	25	25	NUM
aji-160	209	9	%	%	NOUN
aji-160	209	10	percentile	percentile	ADJ
aji-160	209	11	.	.	PUNCT
aji-160	210	1	•	•	NUM
aji-160	210	2	p75	p75	NOUN
aji-160	210	3	represents	represent	VERB
aji-160	210	4	the	the	DET
aji-160	210	5	middle	middle	ADJ
aji-160	210	6	quartile	quartile	NOUN
aji-160	210	7	of	of	ADP
aji-160	210	8	the	the	DET
aji-160	210	9	75	75	NUM
aji-160	210	10	%	%	NOUN
aji-160	210	11	percentile	percentile	ADJ
aji-160	210	12	.	.	PUNCT
aji-160	211	1	•	•	NUM
aji-160	211	2	interquartile	interquartile	NOUN
aji-160	211	3	range	range	NOUN
aji-160	211	4	(	(	PUNCT
aji-160	211	5	iqr	iqr	NOUN
aji-160	211	6	)	)	PUNCT
aji-160	211	7	measure	measure	NOUN
aji-160	211	8	of	of	ADP
aji-160	211	9	spread	spread	NOUN
aji-160	211	10	and	and	CCONJ
aji-160	211	11	dispersion	dispersion	NOUN
aji-160	211	12	shows	show	VERB
aji-160	211	13	the	the	DET
aji-160	211	14	least	least	ADJ
aji-160	211	15	effect	effect	NOUN
aji-160	211	16	of	of	ADP
aji-160	211	17	infection	infection	NOUN
aji-160	211	18	and	and	CCONJ
aji-160	211	19	the	the	DET
aji-160	211	20	result	result	NOUN
aji-160	211	21	is	be	AUX
aji-160	211	22	the	the	DET
aji-160	211	23	first	first	ADJ
aji-160	211	24	quartile	quartile	NOUN
aji-160	211	25	the	the	DET
aji-160	211	26	middle	middle	ADJ
aji-160	211	27	quartile	quartile	NOUN
aji-160	211	28	.	.	PUNCT
aji-160	212	1	table	table	NOUN
aji-160	212	2	5	5	NUM
aji-160	212	3	.	.	PUNCT
aji-160	212	4	comparison	comparison	NOUN
aji-160	212	5	of	of	ADP
aji-160	212	6	aca	aca	PROPN
aji-160	212	7	detection	detection	NOUN
aji-160	212	8	results	result	NOUN
aji-160	212	9	between	between	ADP
aji-160	212	10	sle	sle	PROPN
aji-160	212	11	group	group	NOUN
aji-160	212	12	and	and	CCONJ
aji-160	212	13	the	the	DET
aji-160	212	14	control	control	NOUN
aji-160	212	15	group	group	NOUN
aji-160	212	16	aca	aca	PROPN
aji-160	212	17	(	(	PUNCT
aji-160	212	18	n	n	PROPN
aji-160	212	19	(	(	PUNCT
aji-160	212	20	%	%	INTJ
aji-160	212	21	)	)	PUNCT
aji-160	212	22	sle	sle	NOUN
aji-160	212	23	(	(	PUNCT
aji-160	212	24	n	n	NOUN
aji-160	212	25	=	=	SYM
aji-160	212	26	88	88	NUM
aji-160	212	27	)	)	PUNCT
aji-160	212	28	control	control	NOUN
aji-160	212	29	(	(	PUNCT
aji-160	212	30	n	n	NOUN
aji-160	212	31	=	=	SYM
aji-160	212	32	85	85	NUM
aji-160	212	33	)	)	PUNCT
aji-160	213	1	p.	p.	NOUN
aji-160	213	2	values	value	NOUN
aji-160	213	3	negative	negative	ADJ
aji-160	213	4	59(67	59(67	NUM
aji-160	213	5	%	%	NOUN
aji-160	213	6	)	)	PUNCT
aji-160	214	1	53(62	53(62	NUM
aji-160	214	2	%	%	NOUN
aji-160	214	3	)	)	PUNCT
aji-160	215	1	<	<	X
aji-160	215	2	0.001	0.001	NUM
aji-160	215	3	positive	positive	ADJ
aji-160	215	4	29	29	NUM
aji-160	215	5	(	(	PUNCT
aji-160	215	6	33	33	NUM
aji-160	215	7	%	%	NOUN
aji-160	215	8	)	)	PUNCT
aji-160	215	9	32(38	32(38	NUM
aji-160	215	10	%	%	NOUN
aji-160	215	11	)	)	PUNCT
aji-160	215	12	antibody	antibody	NOUN
aji-160	215	13	median	median	ADJ
aji-160	215	14	iqr	iqr	PROPN
aji-160	216	1	=	=	SYM
aji-160	216	2	p75p25	p75p25	NOUN
aji-160	216	3	p.	p.	NOUN
aji-160	216	4	values	value	NOUN
aji-160	217	1	aca	aca	PROPN
aji-160	217	2	iga	iga	PROPN
aji-160	217	3	(	(	PUNCT
aji-160	217	4	p75	p75	ADJ
aji-160	217	5	-	-	PUNCT
aji-160	217	6	p25	p25	NOUN
aji-160	217	7	)	)	PUNCT
aji-160	217	8	5	5	NUM
aji-160	217	9	(	(	PUNCT
aji-160	217	10	7.67	7.67	NUM
aji-160	217	11	-	-	SYM
aji-160	217	12	2.32	2.32	NUM
aji-160	217	13	)	)	PUNCT
aji-160	217	14	5.35	5.35	NUM
aji-160	217	15	0.017	0.017	NUM
aji-160	217	16	aca	aca	PROPN
aji-160	217	17	igg	igg	PROPN
aji-160	217	18	(	(	PUNCT
aji-160	217	19	p75	p75	ADJ
aji-160	217	20	-	-	PUNCT
aji-160	217	21	p25	p25	NOUN
aji-160	217	22	)	)	PUNCT
aji-160	217	23	6	6	NUM
aji-160	217	24	(	(	PUNCT
aji-160	217	25	8.75	8.75	NUM
aji-160	217	26	-	-	SYM
aji-160	217	27	2.63	2.63	NUM
aji-160	217	28	)	)	PUNCT
aji-160	217	29	6.12	6.12	NUM
aji-160	217	30	0.001	0.001	NUM
aji-160	217	31	aca	aca	PROPN
aji-160	217	32	igm	igm	PROPN
aji-160	217	33	(	(	PUNCT
aji-160	217	34	p75	p75	ADJ
aji-160	217	35	-	-	PUNCT
aji-160	217	36	p25	p25	NOUN
aji-160	217	37	)	)	PUNCT
aji-160	217	38	9	9	NUM
aji-160	217	39	(	(	PUNCT
aji-160	217	40	13.51	13.51	NUM
aji-160	217	41	-	-	SYM
aji-160	217	42	4.82	4.82	NUM
aji-160	217	43	)	)	PUNCT
aji-160	217	44	8.69	8.69	NUM
aji-160	217	45	0.004	0.004	NUM
aji-160	217	46	table	table	NOUN
aji-160	217	47	6	6	NUM
aji-160	217	48	.	.	PUNCT
aji-160	217	49	comparison	comparison	NOUN
aji-160	217	50	of	of	ADP
aji-160	217	51	b2_gpi	b2_gpi	NOUN
aji-160	217	52	autoantibodies	autoantibody	NOUN
aji-160	217	53	detection	detection	NOUN
aji-160	217	54	results	result	NOUN
aji-160	217	55	between	between	ADP
aji-160	217	56	sle	sle	PROPN
aji-160	217	57	group	group	PROPN
aji-160	217	58	and	and	CCONJ
aji-160	217	59	control	control	PROPN
aji-160	217	60	group	group	NOUN
aji-160	217	61	antibody	antibody	NOUN
aji-160	217	62	sle	sle	NOUN
aji-160	217	63	(	(	PUNCT
aji-160	217	64	n	n	NOUN
aji-160	217	65	=	=	SYM
aji-160	217	66	88	88	NUM
aji-160	217	67	)	)	PUNCT
aji-160	217	68	control	control	NOUN
aji-160	217	69	(	(	PUNCT
aji-160	217	70	n	n	NOUN
aji-160	217	71	=	=	SYM
aji-160	217	72	85	85	NUM
aji-160	217	73	)	)	PUNCT
aji-160	217	74	p.	p.	NOUN
aji-160	217	75	value	value	NOUN
aji-160	217	76	b2_gpi	b2_gpi	NOUN
aji-160	217	77	autoantibodies	autoantibody	NOUN
aji-160	218	1	25(28	25(28	NOUN
aji-160	218	2	%	%	NOUN
aji-160	218	3	)	)	PUNCT
aji-160	219	1	14(17	14(17	NUM
aji-160	219	2	%	%	NOUN
aji-160	219	3	)	)	PUNCT
aji-160	220	1	<	<	X
aji-160	220	2	0.001	0.001	NUM
aji-160	220	3	iga	iga	PROPN
aji-160	220	4	(	(	PUNCT
aji-160	220	5	median	median	PROPN
aji-160	220	6	)	)	PUNCT
aji-160	220	7	8(12.94	8(12.94	PROPN
aji-160	220	8	-	-	SYM
aji-160	220	9	4.08	4.08	NUM
aji-160	220	10	)	)	PUNCT
aji-160	220	11	6(8.36	6(8.36	NUM
aji-160	220	12	-	-	SYM
aji-160	220	13	2.77	2.77	NUM
aji-160	220	14	)	)	PUNCT
aji-160	220	15	<	<	X
aji-160	220	16	0.001	0.001	NUM
aji-160	220	17	igg	igg	PROPN
aji-160	220	18	(	(	PUNCT
aji-160	220	19	median	median	PROPN
aji-160	220	20	)	)	PUNCT
aji-160	220	21	6(8.36	6(8.36	NUM
aji-160	220	22	-	-	SYM
aji-160	220	23	2.8	2.8	NUM
aji-160	220	24	)	)	PUNCT
aji-160	220	25	5(7.84	5(7.84	NUM
aji-160	220	26	-	-	SYM
aji-160	220	27	2.53	2.53	NUM
aji-160	220	28	)	)	PUNCT
aji-160	220	29	<	<	X
aji-160	220	30	0.001	0.001	NUM
aji-160	220	31	igm	igm	NOUN
aji-160	220	32	(	(	PUNCT
aji-160	220	33	median	median	PROPN
aji-160	220	34	)	)	PUNCT
aji-160	220	35	6(8.35	6(8.35	NUM
aji-160	220	36	-	-	SYM
aji-160	220	37	3	3	NUM
aji-160	220	38	)	)	PUNCT
aji-160	220	39	5(7.84	5(7.84	NUM
aji-160	220	40	-	-	SYM
aji-160	220	41	2.53	2.53	NUM
aji-160	220	42	)	)	PUNCT
aji-160	220	43	<	<	NOUN
aji-160	220	44	0.001	0.001	NUM
aji-160	220	45	table	table	NOUN
aji-160	220	46	7	7	NUM
aji-160	220	47	.	.	PUNCT
aji-160	220	48	operational	operational	ADJ
aji-160	220	49	definition	definition	NOUN
aji-160	220	50	immunological	immunological	ADJ
aji-160	220	51	test	test	NOUN
aji-160	220	52	examination	examination	NOUN
aji-160	220	53	(	(	PUNCT
aji-160	220	54	manufacturer	manufacturer	NOUN
aji-160	220	55	)	)	PUNCT
aji-160	220	56	aim	aim	NOUN
aji-160	220	57	sllicc_di	sllicc_di	PROPN
aji-160	220	58	n	n	CCONJ
aji-160	220	59	/	/	SYM
aji-160	220	60	n	n	NOUN
aji-160	220	61	the	the	DET
aji-160	220	62	aim	aim	NOUN
aji-160	220	63	of	of	ADP
aji-160	220	64	the	the	DET
aji-160	220	65	examination	examination	NOUN
aji-160	220	66	is	be	AUX
aji-160	220	67	to	to	PART
aji-160	220	68	assess	assess	VERB
aji-160	220	69	the	the	DET
aji-160	220	70	amount	amount	NOUN
aji-160	220	71	of	of	ADP
aji-160	220	72	accumulated	accumulate	VERB
aji-160	220	73	damage	damage	NOUN
aji-160	220	74	to	to	ADP
aji-160	220	75	the	the	DET
aji-160	220	76	organs	organ	NOUN
aji-160	220	77	resulting	result	VERB
aji-160	220	78	from	from	ADP
aji-160	220	79	lupus	lupus	PROPN
aji-160	220	80	anti_dsdna	anti_dsdna	ADP
aji-160	220	81	elisa	elisa	NOUN
aji-160	220	82	test	test	NOUN
aji-160	220	83	(	(	PUNCT
aji-160	220	84	thermo	thermo	NOUN
aji-160	220	85	fisher	fisher	PROPN
aji-160	220	86	scientific	scientific	PROPN
aji-160	220	87	)	)	PUNCT
aji-160	220	88	it	it	PRON
aji-160	220	89	aims	aim	VERB
aji-160	220	90	to	to	PART
aji-160	220	91	detect	detect	VERB
aji-160	220	92	autoantibodies	autoantibody	NOUN
aji-160	220	93	,	,	PUNCT
aji-160	220	94	which	which	PRON
aji-160	220	95	are	be	AUX
aji-160	220	96	responsible	responsible	ADJ
aji-160	220	97	for	for	ADP
aji-160	220	98	attacking	attack	VERB
aji-160	220	99	the	the	DET
aji-160	220	100	body	body	NOUN
aji-160	220	101	's	's	PART
aji-160	220	102	tissues	tissue	NOUN
aji-160	220	103	.	.	PUNCT
aji-160	221	1	nt_probnp	nt_probnp	PROPN
aji-160	221	2	cobas	cobas	PROPN
aji-160	221	3	(	(	PUNCT
aji-160	221	4	beckman	beckman	PROPN
aji-160	221	5	coulter	coulter	PROPN
aji-160	221	6	)	)	PUNCT
aji-160	221	7	the	the	DET
aji-160	221	8	purpose	purpose	NOUN
aji-160	221	9	of	of	ADP
aji-160	221	10	screening	screening	NOUN
aji-160	221	11	is	be	AUX
aji-160	221	12	to	to	PART
aji-160	221	13	diagnose	diagnose	VERB
aji-160	221	14	a	a	DET
aji-160	221	15	heart	heart	NOUN
aji-160	221	16	condition	condition	NOUN
aji-160	221	17	by	by	ADP
aji-160	221	18	detecting	detect	VERB
aji-160	221	19	the	the	DET
aji-160	221	20	level	level	NOUN
aji-160	221	21	of	of	ADP
aji-160	221	22	peripheral	peripheral	ADJ
aji-160	221	23	brain	brain	NOUN
aji-160	221	24	peptide	peptide	NOUN
aji-160	221	25	aca	aca	PROPN
aji-160	221	26	elisa	elisa	PROPN
aji-160	221	27	test	test	PROPN
aji-160	221	28	(	(	PUNCT
aji-160	221	29	euroimmun	euroimmun	PROPN
aji-160	221	30	)	)	PUNCT
aji-160	221	31	the	the	DET
aji-160	221	32	aim	aim	NOUN
aji-160	221	33	is	be	AUX
aji-160	221	34	to	to	PART
aji-160	221	35	detect	detect	VERB
aji-160	221	36	anticentromere	anticentromere	ADV
aji-160	221	37	antibodies	antibody	NOUN
aji-160	221	38	responsible	responsible	ADJ
aji-160	221	39	for	for	ADP
aji-160	221	40	attacking	attack	VERB
aji-160	221	41	healthy	healthy	ADJ
aji-160	221	42	tissues	tissue	NOUN
aji-160	221	43	in	in	ADP
aji-160	221	44	an	an	DET
aji-160	221	45	immunological	immunological	ADJ
aji-160	221	46	disorder	disorder	NOUN
aji-160	221	47	disease	disease	NOUN
aji-160	221	48	.	.	PUNCT
aji-160	222	1	anti_ena	anti_ena	AUX
aji-160	222	2	elisa	elisa	VERB
aji-160	222	3	test	test	NOUN
aji-160	222	4	(	(	PUNCT
aji-160	222	5	inova	inova	PROPN
aji-160	222	6	)	)	PUNCT
aji-160	222	7	it	it	PRON
aji-160	222	8	aims	aim	VERB
aji-160	222	9	to	to	PART
aji-160	222	10	detect	detect	VERB
aji-160	222	11	antibodies	antibody	NOUN
aji-160	222	12	to	to	ADP
aji-160	222	13	nuclear	nuclear	ADJ
aji-160	222	14	antigens	antigen	NOUN
aji-160	222	15	and	and	CCONJ
aji-160	222	16	is	be	AUX
aji-160	222	17	used	use	VERB
aji-160	222	18	to	to	PART
aji-160	222	19	detect	detect	VERB
aji-160	222	20	sjögren	sjögren	NOUN
aji-160	222	21	's	's	PART
aji-160	222	22	syndrome	syndrome	NOUN
aji-160	222	23	and	and	CCONJ
aji-160	222	24	polymyositis	polymyositis	PROPN
aji-160	222	25	.	.	PUNCT
aji-160	223	1	sledai_2k	sledai_2k	NOUN
aji-160	223	2	n	n	CCONJ
aji-160	223	3	/	/	SYM
aji-160	223	4	n	n	CCONJ
aji-160	223	5	the	the	DET
aji-160	223	6	index	index	NOUN
aji-160	223	7	is	be	AUX
aji-160	223	8	used	use	VERB
aji-160	223	9	to	to	PART
aji-160	223	10	evaluate	evaluate	VERB
aji-160	223	11	lupus	lupus	NOUN
aji-160	223	12	disease	disease	NOUN
aji-160	223	13	and	and	CCONJ
aji-160	223	14	helps	help	VERB
aji-160	223	15	doctors	doctor	NOUN
aji-160	223	16	assess	assess	VERB
aji-160	223	17	the	the	DET
aji-160	223	18	patient	patient	NOUN
aji-160	223	19	's	's	PART
aji-160	223	20	response	response	NOUN
aji-160	223	21	to	to	ADP
aji-160	223	22	treatment	treatment	NOUN
aji-160	223	23	.	.	PUNCT
aji-160	224	1	anti_jo_1	anti_jo_1	NOUN
aji-160	224	2	antibody	antibody	VERB
aji-160	224	3	elisa	elisa	PROPN
aji-160	224	4	test	test	NOUN
aji-160	224	5	(	(	PUNCT
aji-160	224	6	inova	inova	PROPN
aji-160	224	7	)	)	PUNCT
aji-160	224	8	type	type	NOUN
aji-160	224	9	of	of	ADP
aji-160	224	10	anti	anti	X
aji-160	224	11	_	_	PROPN
aji-160	224	12	ena	ena	PROPN
aji-160	224	13	test	test	NOUN
aji-160	224	14	anti_rnp	anti_rnp	PROPN
aji-160	224	15	antibody	antibody	NOUN
aji-160	224	16	elisa	elisa	PROPN
aji-160	224	17	test	test	PROPN
aji-160	224	18	(	(	PUNCT
aji-160	224	19	inova	inova	PROPN
aji-160	224	20	)	)	PUNCT
aji-160	224	21	type	type	NOUN
aji-160	224	22	of	of	ADP
aji-160	224	23	anti	anti	X
aji-160	224	24	_	_	PROPN
aji-160	224	25	ena	ena	NOUN
aji-160	224	26	test	test	NOUN
aji-160	224	27	anti_sci70	anti_sci70	PUNCT
aji-160	224	28	antibody	antibody	VERB
aji-160	224	29	topoisomerase	topoisomerase	NOUN
aji-160	224	30	test	test	NOUN
aji-160	224	31	the	the	DET
aji-160	224	32	aim	aim	NOUN
aji-160	224	33	of	of	ADP
aji-160	224	34	detecting	detect	VERB
aji-160	224	35	sci70	sci70	PROPN
aji-160	224	36	antibodies	antibodie	VERB
aji-160	224	37	in	in	ADP
aji-160	224	38	the	the	DET
aji-160	224	39	blood	blood	NOUN
aji-160	224	40	is	be	AUX
aji-160	224	41	to	to	PART
aji-160	224	42	diagnose	diagnose	VERB
aji-160	224	43	systemic	systemic	ADJ
aji-160	224	44	scleroderma	scleroderma	NOUN
aji-160	224	45	.	.	PUNCT
aji-160	225	1	anti_sm	anti_sm	NOUN
aji-160	225	2	_	_	DET
aji-160	225	3	antibody	antibody	NOUN
aji-160	225	4	elisa	elisa	NOUN
aji-160	225	5	test	test	NOUN
aji-160	225	6	(	(	PUNCT
aji-160	225	7	inova	inova	PROPN
aji-160	225	8	)	)	PUNCT
aji-160	225	9	type	type	NOUN
aji-160	225	10	of	of	ADP
aji-160	225	11	anti	anti	X
aji-160	225	12	_	_	PROPN
aji-160	225	13	ena	ena	NOUN
aji-160	225	14	test	test	NOUN
aji-160	225	15	anti_ssa	anti_ssa	VERB
aji-160	225	16	antibody	antibody	NOUN
aji-160	225	17	elisa	elisa	NOUN
aji-160	225	18	test	test	NOUN
aji-160	225	19	(	(	PUNCT
aji-160	225	20	inova	inova	PROPN
aji-160	225	21	)	)	PUNCT
aji-160	225	22	type	type	NOUN
aji-160	225	23	of	of	ADP
aji-160	225	24	anti	anti	X
aji-160	225	25	_	_	PROPN
aji-160	225	26	ena	ena	PROPN
aji-160	225	27	test	test	PROPN
aji-160	225	28	anti_ssb	anti_ssb	PROPN
aji-160	225	29	antibody	antibody	NOUN
aji-160	225	30	elisa	elisa	NOUN
aji-160	225	31	test	test	NOUN
aji-160	225	32	(	(	PUNCT
aji-160	225	33	inova	inova	PROPN
aji-160	225	34	)	)	PUNCT
aji-160	225	35	type	type	NOUN
aji-160	225	36	of	of	ADP
aji-160	225	37	anti	anti	X
aji-160	225	38	_	_	PROPN
aji-160	225	39	ena	ena	NOUN
aji-160	225	40	test	test	NOUN
aji-160	225	41	b2_gpi	b2_gpi	NOUN
aji-160	225	42	autoantibodies	autoantibody	NOUN
aji-160	225	43	elisa	elisa	VERB
aji-160	225	44	test	test	NOUN
aji-160	225	45	(	(	PUNCT
aji-160	225	46	euroimmun	euroimmun	PROPN
aji-160	225	47	)	)	PUNCT
aji-160	225	48	the	the	DET
aji-160	225	49	aim	aim	NOUN
aji-160	225	50	of	of	ADP
aji-160	225	51	detecting	detect	VERB
aji-160	225	52	antiphospholipid	antiphospholipid	NOUN
aji-160	225	53	syndrome	syndrome	NOUN
aji-160	225	54	is	be	AUX
aji-160	225	55	to	to	PART
aji-160	225	56	detect	detect	VERB
aji-160	225	57	antibodies	antibody	NOUN
aji-160	225	58	to	to	ADP
aji-160	225	59	beta-2	beta-2	NUM
aji-160	225	60	protein	protein	NOUN
aji-160	225	61	.	.	PUNCT
aji-160	226	1	shaker	shaker	NOUN
aji-160	226	2	;	;	PUNCT
aji-160	226	3	asian	asian	PROPN
aji-160	226	4	j.	j.	PROPN
aji-160	226	5	immunol	immunol	PROPN
aji-160	226	6	.	.	PROPN
aji-160	226	7	,	,	PUNCT
aji-160	226	8	vol	vol	NOUN
aji-160	226	9	.	.	PROPN
aji-160	226	10	8	8	NUM
aji-160	226	11	,	,	PUNCT
aji-160	226	12	no	no	INTJ
aji-160	226	13	.	.	NOUN
aji-160	226	14	1	1	NUM
aji-160	226	15	,	,	PUNCT
aji-160	226	16	pp	pp	ADJ
aji-160	226	17	.	.	PUNCT
aji-160	227	1	60	60	NUM
aji-160	227	2	-	-	SYM
aji-160	227	3	69	69	NUM
aji-160	227	4	,	,	PUNCT
aji-160	227	5	2025	2025	NUM
aji-160	227	6	;	;	PUNCT
aji-160	227	7	article	article	NOUN
aji-160	227	8	no.aji.134457	no.aji.134457	VERB
aji-160	227	9	67	67	NUM
aji-160	227	10	b2_gpi	b2_gpi	NOUN
aji-160	227	11	autoantibodies	autoantibody	NOUN
aji-160	227	12	levels	level	NOUN
aji-160	227	13	:	:	PUNCT
aji-160	227	14	when	when	SCONJ
aji-160	227	15	detecting	detect	VERB
aji-160	227	16	antibodies	antibodie	VERB
aji-160	227	17	b2_gpi	b2_gpi	NOUN
aji-160	227	18	autoantibodies	autoantibody	NOUN
aji-160	227	19	and	and	CCONJ
aji-160	227	20	comparing	compare	VERB
aji-160	227	21	the	the	DET
aji-160	227	22	results	result	NOUN
aji-160	227	23	with	with	ADP
aji-160	227	24	the	the	DET
aji-160	227	25	lupus	lupus	ADJ
aji-160	227	26	disease	disease	NOUN
aji-160	227	27	and	and	CCONJ
aji-160	227	28	control	control	NOUN
aji-160	227	29	group	group	NOUN
aji-160	227	30	,	,	PUNCT
aji-160	227	31	it	it	PRON
aji-160	227	32	was	be	AUX
aji-160	227	33	identified	identify	VERB
aji-160	227	34	that	that	SCONJ
aji-160	227	35	positive	positive	ADJ
aji-160	227	36	results	result	NOUN
aji-160	227	37	for	for	ADP
aji-160	227	38	antibodies	antibody	NOUN
aji-160	227	39	b2_gpi	b2_gpi	NOUN
aji-160	227	40	autoantibodies	autoantibody	NOUN
aji-160	227	41	were	be	AUX
aji-160	227	42	higher	high	ADJ
aji-160	227	43	in	in	ADP
aji-160	227	44	lupus	lupus	ADJ
aji-160	227	45	patients	patient	NOUN
aji-160	227	46	compared	compare	VERB
aji-160	227	47	to	to	ADP
aji-160	227	48	the	the	DET
aji-160	227	49	control	control	NOUN
aji-160	227	50	group	group	NOUN
aji-160	227	51	as	as	SCONJ
aji-160	227	52	shown	show	VERB
aji-160	227	53	in	in	ADP
aji-160	227	54	table	table	NOUN
aji-160	227	55	7	7	NUM
aji-160	227	56	.	.	NOUN
aji-160	227	57	4	4	NUM
aji-160	227	58	.	.	NOUN
aji-160	227	59	results	result	NOUN
aji-160	227	60	and	and	CCONJ
aji-160	227	61	discussion	discussion	VERB
aji-160	227	62	the	the	DET
aji-160	227	63	influence	influence	NOUN
aji-160	227	64	of	of	ADP
aji-160	227	65	immunological	immunological	ADJ
aji-160	227	66	disorder	disorder	NOUN
aji-160	227	67	inflammation	inflammation	NOUN
aji-160	227	68	in	in	ADP
aji-160	227	69	the	the	DET
aji-160	227	70	endocardium	endocardium	NOUN
aji-160	227	71	,	,	PUNCT
aji-160	227	72	valves	valve	NOUN
aji-160	227	73	,	,	PUNCT
aji-160	227	74	aortic	aortic	ADJ
aji-160	227	75	dissection	dissection	NOUN
aji-160	227	76	and	and	CCONJ
aji-160	227	77	hypertension	hypertension	NOUN
aji-160	227	78	and	and	CCONJ
aji-160	227	79	ha	ha	INTJ
aji-160	227	80	therapy	therapy	NOUN
aji-160	227	81	are	be	AUX
aji-160	227	82	discussed	discuss	VERB
aji-160	227	83	as	as	ADP
aji-160	227	84	possible	possible	ADJ
aji-160	227	85	causes	cause	NOUN
aji-160	227	86	of	of	ADP
aji-160	227	87	these	these	DET
aji-160	227	88	changes	change	NOUN
aji-160	227	89	.	.	PUNCT
aji-160	228	1	the	the	DET
aji-160	228	2	use	use	NOUN
aji-160	228	3	of	of	ADP
aji-160	228	4	ha	ha	INTJ
aji-160	228	5	can	can	AUX
aji-160	228	6	lead	lead	VERB
aji-160	228	7	to	to	ADP
aji-160	228	8	rapid	rapid	ADJ
aji-160	228	9	"	"	PUNCT
aji-160	228	10	healing	healing	NOUN
aji-160	228	11	"	"	PUNCT
aji-160	228	12	of	of	ADP
aji-160	228	13	inflammation	inflammation	NOUN
aji-160	228	14	of	of	ADP
aji-160	228	15	a	a	DET
aji-160	228	16	valve	valve	NOUN
aji-160	228	17	especially	especially	ADV
aji-160	228	18	of	of	ADP
aji-160	228	19	the	the	DET
aji-160	228	20	heart	heart	NOUN
aji-160	228	21	(	(	PUNCT
aji-160	228	22	valvulitis	valvulitis	PROPN
aji-160	228	23	)	)	PUNCT
aji-160	228	24	(	(	PUNCT
aji-160	228	25	gladman	gladman	NOUN
aji-160	228	26	&	&	CCONJ
aji-160	228	27	ibanez	ibanez	PROPN
aji-160	228	28	,	,	PUNCT
aji-160	228	29	2002	2002	NUM
aji-160	228	30	)	)	PUNCT
aji-160	228	31	.	.	PUNCT
aji-160	229	1	despite	despite	SCONJ
aji-160	229	2	the	the	DET
aji-160	229	3	fact	fact	NOUN
aji-160	229	4	that	that	SCONJ
aji-160	229	5	bacterial	bacterial	ADJ
aji-160	229	6	or	or	CCONJ
aji-160	229	7	nonbacterial	nonbacterial	ADJ
aji-160	229	8	thrombotic	thrombotic	ADJ
aji-160	229	9	endocarditis	endocarditis	NOUN
aji-160	229	10	is	be	AUX
aji-160	229	11	a	a	DET
aji-160	229	12	characteristic	characteristic	ADJ
aji-160	229	13	classic	classic	ADJ
aji-160	229	14	valve	valve	NOUN
aji-160	229	15	lesion	lesion	NOUN
aji-160	229	16	in	in	ADP
aji-160	229	17	sle	sle	PROPN
aji-160	229	18	(	(	PUNCT
aji-160	229	19	adawi	adawi	PROPN
aji-160	229	20	&	&	CCONJ
aji-160	229	21	blum	blum	PROPN
aji-160	229	22	,	,	PUNCT
aji-160	229	23	2020	2020	NUM
aji-160	229	24	)	)	PUNCT
aji-160	229	25	,	,	PUNCT
aji-160	229	26	most	most	ADJ
aji-160	229	27	researchers	researcher	NOUN
aji-160	229	28	agree	agree	VERB
aji-160	229	29	that	that	SCONJ
aji-160	229	30	the	the	DET
aji-160	229	31	most	most	ADV
aji-160	229	32	common	common	ADJ
aji-160	229	33	change	change	NOUN
aji-160	229	34	in	in	ADP
aji-160	229	35	heart	heart	NOUN
aji-160	229	36	valves	valve	NOUN
aji-160	229	37	is	be	AUX
aji-160	229	38	insufficiency	insufficiency	NOUN
aji-160	229	39	with	with	ADP
aji-160	229	40	varying	vary	VERB
aji-160	229	41	degrees	degree	NOUN
aji-160	229	42	of	of	ADP
aji-160	229	43	regurgitation	regurgitation	NOUN
aji-160	229	44	(	(	PUNCT
aji-160	229	45	mazurek	mazurek	NOUN
aji-160	229	46	,	,	PUNCT
aji-160	229	47	et	et	PROPN
aji-160	229	48	al	al	PROPN
aji-160	229	49	.	.	PROPN
aji-160	229	50	,	,	PUNCT
aji-160	229	51	2022	2022	NUM
aji-160	229	52	)	)	PUNCT
aji-160	229	53	.	.	PUNCT
aji-160	230	1	some	some	PRON
aji-160	230	2	indicate	indicate	VERB
aji-160	230	3	a	a	DET
aji-160	230	4	high	high	ADJ
aji-160	230	5	incidence	incidence	NOUN
aji-160	230	6	of	of	ADP
aji-160	230	7	aortic	aortic	ADJ
aji-160	230	8	valve	valve	NOUN
aji-160	230	9	insufficiency	insufficiency	NOUN
aji-160	230	10	,	,	PUNCT
aji-160	230	11	others	other	NOUN
aji-160	230	12	indicate	indicate	VERB
aji-160	230	13	mitral	mitral	ADJ
aji-160	230	14	valve	valve	NOUN
aji-160	230	15	insufficiency	insufficiency	NOUN
aji-160	230	16	(	(	PUNCT
aji-160	230	17	kim	kim	PROPN
aji-160	230	18	,	,	PUNCT
aji-160	230	19	et	et	PROPN
aji-160	230	20	al	al	PROPN
aji-160	230	21	.	.	PROPN
aji-160	230	22	,	,	PUNCT
aji-160	230	23	2017	2017	NUM
aji-160	230	24	)	)	PUNCT
aji-160	230	25	.	.	PUNCT
aji-160	231	1	in	in	ADP
aji-160	231	2	my	my	PRON
aji-160	231	3	study	study	NOUN
aji-160	231	4	,	,	PUNCT
aji-160	231	5	tricuspid	tricuspid	NOUN
aji-160	231	6	and	and	CCONJ
aji-160	231	7	mitral	mitral	ADJ
aji-160	231	8	valve	valve	NOUN
aji-160	231	9	insufficiency	insufficiency	NOUN
aji-160	231	10	was	be	AUX
aji-160	231	11	more	more	ADV
aji-160	231	12	common	common	ADJ
aji-160	231	13	,	,	PUNCT
aji-160	231	14	and	and	CCONJ
aji-160	231	15	aortic	aortic	ADJ
aji-160	231	16	valve	valve	NOUN
aji-160	231	17	insufficiency	insufficiency	NOUN
aji-160	231	18	was	be	AUX
aji-160	231	19	less	less	ADV
aji-160	231	20	common	common	ADJ
aji-160	231	21	;	;	PUNCT
aji-160	231	22	the	the	DET
aji-160	231	23	changes	change	NOUN
aji-160	231	24	were	be	AUX
aji-160	231	25	not	not	PART
aji-160	231	26	clinically	clinically	ADV
aji-160	231	27	relevant	relevant	ADJ
aji-160	231	28	and	and	CCONJ
aji-160	231	29	did	do	AUX
aji-160	231	30	not	not	PART
aji-160	231	31	require	require	VERB
aji-160	231	32	surgical	surgical	ADJ
aji-160	231	33	correction	correction	NOUN
aji-160	231	34	.	.	PUNCT
aji-160	232	1	an	an	DET
aji-160	232	2	increase	increase	NOUN
aji-160	232	3	in	in	ADP
aji-160	232	4	the	the	DET
aji-160	232	5	level	level	NOUN
aji-160	232	6	of	of	ADP
aji-160	232	7	natriuretic	natriuretic	ADJ
aji-160	232	8	peptide	peptide	NOUN
aji-160	232	9	(	(	PUNCT
aji-160	232	10	bnp	bnp	PROPN
aji-160	232	11	)	)	PUNCT
aji-160	232	12	is	be	AUX
aji-160	232	13	not	not	PART
aji-160	232	14	specific	specific	ADJ
aji-160	232	15	for	for	ADP
aji-160	232	16	myocarditis	myocarditis	PROPN
aji-160	232	17	,	,	PUNCT
aji-160	232	18	based	base	VERB
aji-160	232	19	on	on	ADP
aji-160	232	20	the	the	DET
aji-160	232	21	dynamics	dynamic	NOUN
aji-160	232	22	of	of	ADP
aji-160	232	23	the	the	DET
aji-160	232	24	nt_probnp	nt_probnp	NOUN
aji-160	232	25	level	level	NOUN
aji-160	232	26	,	,	PUNCT
aji-160	232	27	the	the	DET
aji-160	232	28	effectiveness	effectiveness	NOUN
aji-160	232	29	of	of	ADP
aji-160	232	30	treatment	treatment	NOUN
aji-160	232	31	is	be	AUX
aji-160	232	32	evaluated	evaluate	VERB
aji-160	232	33	and	and	CCONJ
aji-160	232	34	a	a	DET
aji-160	232	35	prognosis	prognosis	NOUN
aji-160	232	36	is	be	AUX
aji-160	232	37	made	make	VERB
aji-160	232	38	.	.	PUNCT
aji-160	233	1	while	while	SCONJ
aji-160	233	2	maintaining	maintain	VERB
aji-160	233	3	its	its	PRON
aji-160	233	4	high	high	ADJ
aji-160	233	5	concentration	concentration	NOUN
aji-160	233	6	,	,	PUNCT
aji-160	233	7	it	it	PRON
aji-160	233	8	can	can	AUX
aji-160	233	9	be	be	AUX
aji-160	233	10	assumed	assume	VERB
aji-160	233	11	that	that	SCONJ
aji-160	233	12	there	there	PRON
aji-160	233	13	is	be	VERB
aji-160	233	14	active	active	ADJ
aji-160	233	15	inflammation	inflammation	NOUN
aji-160	233	16	,	,	PUNCT
aji-160	233	17	its	its	PRON
aji-160	233	18	carbonization	carbonization	NOUN
aji-160	233	19	.	.	PUNCT
aji-160	234	1	therefore	therefore	ADV
aji-160	234	2	,	,	PUNCT
aji-160	234	3	according	accord	VERB
aji-160	234	4	to	to	ADP
aji-160	234	5	the	the	DET
aji-160	234	6	recommendations	recommendation	NOUN
aji-160	234	7	immunologic	immunologic	ADJ
aji-160	234	8	and	and	CCONJ
aji-160	234	9	cardiologists	cardiologist	NOUN
aji-160	234	10	,	,	PUNCT
aji-160	234	11	all	all	DET
aji-160	234	12	patients	patient	NOUN
aji-160	234	13	with	with	ADP
aji-160	234	14	clinical	clinical	ADJ
aji-160	234	15	suspicion	suspicion	NOUN
aji-160	234	16	of	of	ADP
aji-160	234	17	myocarditis	myocarditis	NOUN
aji-160	234	18	should	should	AUX
aji-160	234	19	conduct	conduct	VERB
aji-160	234	20	a	a	DET
aji-160	234	21	study	study	NOUN
aji-160	234	22	of	of	ADP
aji-160	234	23	the	the	DET
aji-160	234	24	initial	initial	ADJ
aji-160	234	25	level	level	NOUN
aji-160	234	26	of	of	ADP
aji-160	234	27	nt_probnp	nt_probnp	NOUN
aji-160	234	28	and	and	CCONJ
aji-160	234	29	its	its	PRON
aji-160	234	30	dynamics	dynamic	NOUN
aji-160	234	31	(	(	PUNCT
aji-160	234	32	hochberg	hochberg	NOUN
aji-160	234	33	,	,	PUNCT
aji-160	234	34	1997	1997	NUM
aji-160	234	35	)	)	PUNCT
aji-160	234	36	.	.	PUNCT
aji-160	235	1	they	they	PRON
aji-160	235	2	do	do	AUX
aji-160	235	3	not	not	PART
aji-160	235	4	have	have	VERB
aji-160	235	5	any	any	DET
aji-160	235	6	special	special	ADJ
aji-160	235	7	features	feature	NOUN
aji-160	235	8	,	,	PUNCT
aji-160	235	9	and	and	CCONJ
aji-160	235	10	associations	association	NOUN
aji-160	235	11	with	with	ADP
aji-160	235	12	sle	sle	NOUN
aji-160	235	13	-	-	PUNCT
aji-160	235	14	specific	specific	ADJ
aji-160	235	15	autoantibodies	autoantibody	NOUN
aji-160	235	16	and	and	CCONJ
aji-160	235	17	therapy	therapy	NOUN
aji-160	235	18	have	have	AUX
aji-160	235	19	also	also	ADV
aji-160	235	20	not	not	PART
aji-160	235	21	been	be	AUX
aji-160	235	22	identified	identify	VERB
aji-160	235	23	.	.	PUNCT
aji-160	236	1	in	in	ADP
aji-160	236	2	the	the	DET
aji-160	236	3	present	present	ADJ
aji-160	236	4	study	study	NOUN
aji-160	236	5	,	,	PUNCT
aji-160	236	6	rhythm	rhythm	NOUN
aji-160	236	7	disturbances	disturbance	NOUN
aji-160	236	8	were	be	AUX
aji-160	236	9	recognition	recognition	NOUN
aji-160	236	10	in	in	ADP
aji-160	236	11	18	18	NUM
aji-160	236	12	%	%	NOUN
aji-160	236	13	of	of	ADP
aji-160	236	14	patients	patient	NOUN
aji-160	236	15	.	.	PUNCT
aji-160	237	1	the	the	DET
aji-160	237	2	number	number	NOUN
aji-160	237	3	of	of	ADP
aji-160	237	4	atherosclerotic	atherosclerotic	ADJ
aji-160	237	5	plaques	plaque	NOUN
aji-160	237	6	in	in	ADP
aji-160	237	7	the	the	DET
aji-160	237	8	coronary	coronary	ADJ
aji-160	237	9	and	and	CCONJ
aji-160	237	10	femoral	femoral	ADJ
aji-160	237	11	arteries	artery	NOUN
aji-160	237	12	is	be	AUX
aji-160	237	13	twice	twice	ADV
aji-160	237	14	as	as	ADV
aji-160	237	15	high	high	ADJ
aji-160	237	16	in	in	ADP
aji-160	237	17	patients	patient	NOUN
aji-160	237	18	with	with	ADP
aji-160	237	19	disease	disease	NOUN
aji-160	237	20	as	as	ADP
aji-160	237	21	in	in	ADP
aji-160	237	22	people	people	NOUN
aji-160	237	23	suffering	suffer	VERB
aji-160	237	24	from	from	ADP
aji-160	237	25	rheumatoid	rheumatoid	NOUN
aji-160	237	26	arthritis	arthritis	NOUN
aji-160	237	27	and	and	CCONJ
aji-160	237	28	dm	dm	NUM
aji-160	237	29	diseases	disease	NOUN
aji-160	237	30	with	with	ADP
aji-160	237	31	high	high	ADJ
aji-160	237	32	cardiovascular	cardiovascular	ADJ
aji-160	237	33	hazard	hazard	NOUN
aji-160	237	34	(	(	PUNCT
aji-160	237	35	petri	petri	ADJ
aji-160	237	36	,	,	PUNCT
aji-160	237	37	et	et	PROPN
aji-160	237	38	al	al	PROPN
aji-160	237	39	.	.	PROPN
aji-160	237	40	,	,	PUNCT
aji-160	237	41	2012	2012	NUM
aji-160	237	42	)	)	PUNCT
aji-160	237	43	.	.	PUNCT
aji-160	238	1	in	in	ADP
aji-160	238	2	my	my	PRON
aji-160	238	3	study	study	NOUN
aji-160	238	4	,	,	PUNCT
aji-160	238	5	i	i	PRON
aji-160	238	6	did	do	AUX
aji-160	238	7	not	not	PART
aji-160	238	8	observe	observe	VERB
aji-160	238	9	a	a	DET
aji-160	238	10	statistical	statistical	ADJ
aji-160	238	11	difference	difference	NOUN
aji-160	238	12	in	in	ADP
aji-160	238	13	the	the	DET
aji-160	238	14	incidence	incidence	NOUN
aji-160	238	15	of	of	ADP
aji-160	238	16	various	various	ADJ
aji-160	238	17	myocarditiss	myocarditiss	ADJ
aji-160	238	18	and	and	CCONJ
aji-160	238	19	heart	heart	NOUN
aji-160	238	20	failure	failure	NOUN
aji-160	238	21	between	between	ADP
aji-160	238	22	those	those	PRON
aji-160	238	23	who	who	PRON
aji-160	238	24	received	receive	VERB
aji-160	238	25	immunosuppressant	immunosuppressant	ADJ
aji-160	238	26	and	and	CCONJ
aji-160	238	27	high	high	ADJ
aji-160	238	28	blood	blood	NOUN
aji-160	238	29	pressure	pressure	NOUN
aji-160	238	30	treatments	treatment	NOUN
aji-160	238	31	and	and	CCONJ
aji-160	238	32	those	those	PRON
aji-160	238	33	who	who	PRON
aji-160	238	34	did	do	AUX
aji-160	238	35	not	not	PART
aji-160	238	36	receive	receive	VERB
aji-160	238	37	them	they	PRON
aji-160	238	38	,	,	PUNCT
aji-160	238	39	but	but	CCONJ
aji-160	238	40	the	the	DET
aji-160	238	41	difference	difference	NOUN
aji-160	238	42	was	be	AUX
aji-160	238	43	clear	clear	ADJ
aji-160	238	44	in	in	ADP
aji-160	238	45	those	those	PRON
aji-160	238	46	who	who	PRON
aji-160	238	47	developed	develop	VERB
aji-160	238	48	lupus	lupus	NOUN
aji-160	238	49	.	.	PUNCT
aji-160	239	1	98	98	NUM
aji-160	239	2	%	%	NOUN
aji-160	239	3	of	of	ADP
aji-160	239	4	cases	case	NOUN
aji-160	239	5	,	,	PUNCT
aji-160	239	6	ha	ha	INTJ
aji-160	239	7	was	be	AUX
aji-160	239	8	used	use	VERB
aji-160	239	9	,	,	PUNCT
aji-160	239	10	hypertension	hypertension	NOUN
aji-160	239	11	,	,	PUNCT
aji-160	239	12	an	an	DET
aji-160	239	13	increase	increase	NOUN
aji-160	239	14	in	in	ADP
aji-160	239	15	total	total	ADJ
aji-160	239	16	cholesterol	cholesterol	NOUN
aji-160	239	17	and	and	CCONJ
aji-160	239	18	bmi	bmi	NOUN
aji-160	239	19	values	value	NOUN
aji-160	239	20	were	be	AUX
aji-160	239	21	more	more	ADV
aji-160	239	22	often	often	ADV
aji-160	239	23	observed	observe	VERB
aji-160	239	24	,	,	PUNCT
aji-160	239	25	which	which	PRON
aji-160	239	26	confirms	confirm	VERB
aji-160	239	27	the	the	DET
aji-160	239	28	opinion	opinion	NOUN
aji-160	239	29	about	about	ADP
aji-160	239	30	the	the	DET
aji-160	239	31	effect	effect	NOUN
aji-160	239	32	of	of	ADP
aji-160	239	33	ha	ha	INTJ
aji-160	239	34	on	on	ADP
aji-160	239	35	the	the	DET
aji-160	239	36	frequency	frequency	NOUN
aji-160	239	37	of	of	ADP
aji-160	239	38	tfr	tfr	PROPN
aji-160	239	39	.	.	PUNCT
aji-160	240	1	currently	currently	ADV
aji-160	240	2	,	,	PUNCT
aji-160	240	3	the	the	DET
aji-160	240	4	determination	determination	NOUN
aji-160	240	5	of	of	ADP
aji-160	240	6	the	the	DET
aji-160	240	7	concentration	concentration	NOUN
aji-160	240	8	of	of	ADP
aji-160	240	9	nt_probnp	nt_probnp	NOUN
aji-160	240	10	is	be	AUX
aji-160	240	11	used	use	VERB
aji-160	240	12	for	for	ADP
aji-160	240	13	the	the	DET
aji-160	240	14	screening	screening	NOUN
aji-160	240	15	of	of	ADP
aji-160	240	16	heart	heart	NOUN
aji-160	240	17	failure	failure	NOUN
aji-160	240	18	(	(	PUNCT
aji-160	240	19	hf	hf	NOUN
aji-160	240	20	)	)	PUNCT
aji-160	240	21	,	,	PUNCT
aji-160	240	22	assessment	assessment	NOUN
aji-160	240	23	of	of	ADP
aji-160	240	24	its	its	PRON
aji-160	240	25	severity	severity	NOUN
aji-160	240	26	and	and	CCONJ
aji-160	240	27	prognosis	prognosis	NOUN
aji-160	240	28	,	,	PUNCT
aji-160	240	29	as	as	ADV
aji-160	240	30	well	well	ADV
aji-160	240	31	as	as	ADP
aji-160	240	32	monitoring	monitor	VERB
aji-160	240	33	the	the	DET
aji-160	240	34	effectiveness	effectiveness	NOUN
aji-160	240	35	of	of	ADP
aji-160	240	36	therapy	therapy	NOUN
aji-160	240	37	.	.	PUNCT
aji-160	241	1	in	in	ADP
aji-160	241	2	addition	addition	NOUN
aji-160	241	3	,	,	PUNCT
aji-160	241	4	a	a	DET
aji-160	241	5	high	high	ADJ
aji-160	241	6	level	level	NOUN
aji-160	241	7	of	of	ADP
aji-160	241	8	nt_probnp	nt_probnp	NOUN
aji-160	241	9	is	be	AUX
aji-160	241	10	an	an	DET
aji-160	241	11	independent	independent	ADJ
aji-160	241	12	hazard	hazard	NOUN
aji-160	241	13	factor	factor	NOUN
aji-160	241	14	not	not	PART
aji-160	241	15	only	only	ADV
aji-160	241	16	for	for	ADP
aji-160	241	17	heart	heart	NOUN
aji-160	241	18	failure	failure	NOUN
aji-160	241	19	(	(	PUNCT
aji-160	241	20	hf	hf	NOUN
aji-160	241	21	)	)	PUNCT
aji-160	241	22	.	.	PUNCT
aji-160	242	1	there	there	PRON
aji-160	242	2	are	be	VERB
aji-160	242	3	isolated	isolated	ADJ
aji-160	242	4	studies	study	NOUN
aji-160	242	5	on	on	ADP
aji-160	242	6	the	the	DET
aji-160	242	7	concentration	concentration	NOUN
aji-160	242	8	of	of	ADP
aji-160	242	9	bnp	bnp	PROPN
aji-160	242	10	nt_probnp	nt_probnp	X
aji-160	242	11	in	in	ADP
aji-160	242	12	immunological	immunological	ADJ
aji-160	242	13	disorder	disorder	NOUN
aji-160	242	14	inflammatory	inflammatory	ADJ
aji-160	242	15	diseases	disease	NOUN
aji-160	242	16	.	.	PUNCT
aji-160	243	1	in	in	ADP
aji-160	243	2	sle	sle	PROPN
aji-160	243	3	,	,	PUNCT
aji-160	243	4	the	the	DET
aji-160	243	5	level	level	NOUN
aji-160	243	6	of	of	ADP
aji-160	243	7	this	this	DET
aji-160	243	8	biomarker	biomarker	NOUN
aji-160	243	9	was	be	AUX
aji-160	243	10	determined	determine	VERB
aji-160	243	11	only	only	ADV
aji-160	243	12	in	in	ADP
aji-160	243	13	patients	patient	NOUN
aji-160	243	14	receiving	receive	VERB
aji-160	243	15	pathogenesis	pathogenesis	NOUN
aji-160	243	16	therapy	therapy	NOUN
aji-160	243	17	(	(	PUNCT
aji-160	243	18	tan	tan	PROPN
aji-160	243	19	,	,	PUNCT
aji-160	243	20	et	et	PROPN
aji-160	243	21	al	al	PROPN
aji-160	243	22	.	.	PROPN
aji-160	243	23	,	,	PUNCT
aji-160	243	24	1982	1982	NUM
aji-160	243	25	,	,	PUNCT
aji-160	243	26	gladman	gladman	NOUN
aji-160	243	27	&	&	CCONJ
aji-160	243	28	ibanez	ibanez	PROPN
aji-160	243	29	,	,	PUNCT
aji-160	243	30	2002	2002	NUM
aji-160	243	31	)	)	PUNCT
aji-160	243	32	.	.	PUNCT
aji-160	244	1	the	the	DET
aji-160	244	2	concentration	concentration	NOUN
aji-160	244	3	of	of	ADP
aji-160	244	4	bnp	bnp	PROPN
aji-160	244	5	nt_probnp	nt_probnp	X
aji-160	244	6	in	in	ADP
aji-160	244	7	patients	patient	NOUN
aji-160	244	8	with	with	ADP
aji-160	244	9	sle	sle	PROPN
aji-160	244	10	was	be	AUX
aji-160	244	11	higher	high	ADJ
aji-160	244	12	than	than	ADP
aji-160	244	13	in	in	ADP
aji-160	244	14	the	the	DET
aji-160	244	15	control	control	NOUN
aji-160	244	16	group	group	NOUN
aji-160	244	17	,	,	PUNCT
aji-160	244	18	this	this	DET
aji-160	244	19	increase	increase	NOUN
aji-160	244	20	was	be	AUX
aji-160	244	21	primarily	primarily	ADV
aji-160	244	22	associated	associate	VERB
aji-160	244	23	with	with	ADP
aji-160	244	24	myocardial	myocardial	ADJ
aji-160	244	25	dysfunction	dysfunction	NOUN
aji-160	244	26	,	,	PUNCT
aji-160	244	27	but	but	CCONJ
aji-160	244	28	was	be	AUX
aji-160	244	29	not	not	PART
aji-160	244	30	associated	associate	VERB
aji-160	244	31	with	with	ADP
aji-160	244	32	vascular	vascular	ADJ
aji-160	244	33	damage	damage	NOUN
aji-160	244	34	,	,	PUNCT
aji-160	244	35	including	include	VERB
aji-160	244	36	atherosclerotic	atherosclerotic	ADJ
aji-160	244	37	,	,	PUNCT
aji-160	244	38	inflammatory	inflammatory	ADJ
aji-160	244	39	markers	marker	NOUN
aji-160	244	40	,	,	PUNCT
aji-160	244	41	and	and	CCONJ
aji-160	244	42	sle	sle	PROPN
aji-160	244	43	activity	activity	NOUN
aji-160	244	44	.	.	PUNCT
aji-160	245	1	5	5	X
aji-160	245	2	.	.	X
aji-160	245	3	conclusion	conclusion	NOUN
aji-160	245	4	despite	despite	SCONJ
aji-160	245	5	the	the	DET
aji-160	245	6	young	young	ADJ
aji-160	245	7	age	age	NOUN
aji-160	245	8	of	of	ADP
aji-160	245	9	patients	patient	NOUN
aji-160	245	10	,	,	PUNCT
aji-160	245	11	therapy	therapy	NOUN
aji-160	245	12	(	(	PUNCT
aji-160	245	13	primarily	primarily	ADV
aji-160	245	14	with	with	ADP
aji-160	245	15	glucocorticoids	glucocorticoid	NOUN
aji-160	245	16	,	,	PUNCT
aji-160	245	17	ha	ha	INTJ
aji-160	245	18	)	)	PUNCT
aji-160	245	19	and	and	CCONJ
aji-160	245	20	a	a	DET
aji-160	245	21	long	long	ADJ
aji-160	245	22	duration	duration	NOUN
aji-160	245	23	of	of	ADP
aji-160	245	24	certain	certain	ADJ
aji-160	245	25	sle	sle	NOUN
aji-160	245	26	are	be	AUX
aji-160	245	27	linked	link	VERB
aji-160	245	28	to	to	ADP
aji-160	245	29	a	a	DET
aji-160	245	30	higher	high	ADJ
aji-160	245	31	prevalence	prevalence	NOUN
aji-160	245	32	hazard	hazard	NOUN
aji-160	245	33	factors	factor	NOUN
aji-160	245	34	(	(	PUNCT
aji-160	245	35	hypertension	hypertension	NOUN
aji-160	245	36	,	,	PUNCT
aji-160	245	37	hypercholesterolemia	hypercholesterolemia	NOUN
aji-160	245	38	,	,	PUNCT
aji-160	245	39	overweight	overweight	NOUN
aji-160	245	40	)	)	PUNCT
aji-160	245	41	,	,	PUNCT
aji-160	245	42	and	and	CCONJ
aji-160	245	43	myocarditis	myocarditi	VERB
aji-160	245	44	a	a	DET
aji-160	245	45	practicing	practice	VERB
aji-160	245	46	rheumatologist	rheumatologist	NOUN
aji-160	245	47	should	should	AUX
aji-160	245	48	pay	pay	VERB
aji-160	245	49	attention	attention	NOUN
aji-160	245	50	to	to	ADP
aji-160	245	51	the	the	DET
aji-160	245	52	need	need	NOUN
aji-160	245	53	for	for	ADP
aji-160	245	54	joint	joint	ADJ
aji-160	245	55	management	management	NOUN
aji-160	245	56	of	of	ADP
aji-160	245	57	patients	patient	NOUN
aji-160	245	58	with	with	ADP
aji-160	245	59	sle	sle	PROPN
aji-160	245	60	with	with	ADP
aji-160	245	61	a	a	DET
aji-160	245	62	cardiologist	cardiologist	ADJ
aji-160	245	63	and	and	CCONJ
aji-160	245	64	immunological	immunological	ADJ
aji-160	245	65	,	,	PUNCT
aji-160	245	66	assessment	assessment	NOUN
aji-160	245	67	of	of	ADP
aji-160	245	68	markers	marker	NOUN
aji-160	245	69	of	of	ADP
aji-160	245	70	heart	heart	NOUN
aji-160	245	71	failure	failure	NOUN
aji-160	245	72	(	(	PUNCT
aji-160	245	73	hf	hf	NOUN
aji-160	245	74	)	)	PUNCT
aji-160	245	75	as	as	ADP
aji-160	245	76	a	a	DET
aji-160	245	77	potentially	potentially	ADV
aji-160	245	78	fatal	fatal	ADJ
aji-160	245	79	complication	complication	NOUN
aji-160	245	80	,	,	PUNCT
aji-160	245	81	especially	especially	ADV
aji-160	245	82	in	in	ADP
aji-160	245	83	patients	patient	NOUN
aji-160	245	84	with	with	ADP
aji-160	245	85	high	high	ADJ
aji-160	245	86	disease	disease	NOUN
aji-160	245	87	activity	activity	NOUN
aji-160	245	88	under	under	ADP
aji-160	245	89	medical	medical	ADJ
aji-160	245	90	control	control	NOUN
aji-160	245	91	of	of	ADP
aji-160	245	92	tfr	tfr	PROPN
aji-160	245	93	utilizing	utilize	VERB
aji-160	245	94	a	a	DET
aji-160	245	95	minimum	minimum	NOUN
aji-160	245	96	dose	dose	NOUN
aji-160	245	97	of	of	ADP
aji-160	245	98	ha	ha	INTJ
aji-160	245	99	during	during	ADP
aji-160	245	100	remission	remission	NOUN
aji-160	245	101	and	and	CCONJ
aji-160	245	102	low	low	ADJ
aji-160	245	103	activity	activity	NOUN
aji-160	245	104	.	.	PUNCT
aji-160	246	1	6	6	NUM
aji-160	246	2	.	.	X
aji-160	246	3	limitations	limitation	NOUN
aji-160	246	4	1	1	NUM
aji-160	246	5	.	.	PUNCT
aji-160	247	1	despite	despite	SCONJ
aji-160	247	2	the	the	DET
aji-160	247	3	extreme	extreme	ADJ
aji-160	247	4	importance	importance	NOUN
aji-160	247	5	of	of	ADP
aji-160	247	6	the	the	DET
aji-160	247	7	study	study	NOUN
aji-160	247	8	,	,	PUNCT
aji-160	247	9	we	we	PRON
aji-160	247	10	were	be	AUX
aji-160	247	11	unable	unable	ADJ
aji-160	247	12	to	to	PART
aji-160	247	13	include	include	VERB
aji-160	247	14	larger	large	ADJ
aji-160	247	15	shaker	shaker	NOUN
aji-160	247	16	;	;	PUNCT
aji-160	247	17	asian	asian	PROPN
aji-160	247	18	j.	j.	PROPN
aji-160	247	19	immunol	immunol	PROPN
aji-160	247	20	.	.	PROPN
aji-160	247	21	,	,	PUNCT
aji-160	247	22	vol	vol	NOUN
aji-160	247	23	.	.	PROPN
aji-160	247	24	8	8	NUM
aji-160	247	25	,	,	PUNCT
aji-160	247	26	no	no	INTJ
aji-160	247	27	.	.	NOUN
aji-160	247	28	1	1	NUM
aji-160	247	29	,	,	PUNCT
aji-160	247	30	pp	pp	ADJ
aji-160	247	31	.	.	PUNCT
aji-160	248	1	60	60	NUM
aji-160	248	2	-	-	SYM
aji-160	248	3	69	69	NUM
aji-160	248	4	,	,	PUNCT
aji-160	248	5	2025	2025	NUM
aji-160	248	6	;	;	PUNCT
aji-160	248	7	article	article	NOUN
aji-160	248	8	no.aji.134457	no.aji.134457	VERB
aji-160	248	9	68	68	NUM
aji-160	248	10	areas	area	NOUN
aji-160	248	11	,	,	PUNCT
aji-160	248	12	at	at	ADP
aji-160	248	13	least	least	ADJ
aji-160	248	14	in	in	ADP
aji-160	248	15	southern	southern	ADJ
aji-160	248	16	iraq	iraq	PROPN
aji-160	248	17	,	,	PUNCT
aji-160	248	18	due	due	ADP
aji-160	248	19	to	to	ADP
aji-160	248	20	legal	legal	ADJ
aji-160	248	21	restrictions	restriction	NOUN
aji-160	248	22	on	on	ADP
aji-160	248	23	allowing	allow	VERB
aji-160	248	24	data	datum	NOUN
aji-160	248	25	collection	collection	NOUN
aji-160	248	26	and	and	CCONJ
aji-160	248	27	involving	involve	VERB
aji-160	248	28	a	a	DET
aji-160	248	29	larger	large	ADJ
aji-160	248	30	study	study	NOUN
aji-160	248	31	sample	sample	NOUN
aji-160	248	32	.	.	PUNCT
aji-160	249	1	2	2	X
aji-160	249	2	.	.	X
aji-160	249	3	medical	medical	ADJ
aji-160	249	4	records	record	NOUN
aji-160	249	5	were	be	AUX
aji-160	249	6	used	use	VERB
aji-160	249	7	to	to	PART
aji-160	249	8	collect	collect	VERB
aji-160	249	9	information	information	NOUN
aji-160	249	10	for	for	ADP
aji-160	249	11	patients	patient	NOUN
aji-160	249	12	,	,	PUNCT
aji-160	249	13	especially	especially	ADV
aji-160	249	14	the	the	DET
aji-160	249	15	control	control	NOUN
aji-160	249	16	group	group	NOUN
aji-160	249	17	.	.	PUNCT
aji-160	250	1	3	3	X
aji-160	250	2	.	.	X
aji-160	250	3	there	there	PRON
aji-160	250	4	is	be	VERB
aji-160	250	5	no	no	DET
aji-160	250	6	similarity	similarity	NOUN
aji-160	250	7	between	between	ADP
aji-160	250	8	patients	patient	NOUN
aji-160	250	9	in	in	ADP
aji-160	250	10	the	the	DET
aji-160	250	11	severity	severity	NOUN
aji-160	250	12	and	and	CCONJ
aji-160	250	13	duration	duration	NOUN
aji-160	250	14	of	of	ADP
aji-160	250	15	the	the	DET
aji-160	250	16	injury	injury	NOUN
aji-160	250	17	4	4	NUM
aji-160	250	18	.	.	PUNCT
aji-160	250	19	limited	limit	VERB
aji-160	250	20	laboratory	laboratory	NOUN
aji-160	250	21	materials	material	NOUN
aji-160	250	22	and	and	CCONJ
aji-160	250	23	ct	ct	NOUN
aji-160	250	24	scan	scan	ADJ
aji-160	250	25	results	result	NOUN
aji-160	250	26	for	for	ADP
aji-160	250	27	patients	patient	NOUN
aji-160	250	28	prompted	prompt	VERB
aji-160	250	29	us	we	PRON
aji-160	250	30	to	to	PART
aji-160	250	31	communicate	communicate	VERB
aji-160	250	32	directly	directly	ADV
aji-160	250	33	with	with	ADP
aji-160	250	34	patients	patient	NOUN
aji-160	250	35	for	for	ADP
aji-160	250	36	reevaluation	reevaluation	NOUN
aji-160	250	37	.	.	PUNCT
aji-160	251	1	7	7	X
aji-160	251	2	.	.	X
aji-160	251	3	recommendations	recommendation	NOUN
aji-160	251	4	1	1	NUM
aji-160	251	5	.	.	X
aji-160	251	6	raising	raise	VERB
aji-160	251	7	awareness	awareness	NOUN
aji-160	251	8	among	among	ADP
aji-160	251	9	doctors	doctor	NOUN
aji-160	251	10	about	about	ADP
aji-160	251	11	the	the	DET
aji-160	251	12	risks	risk	NOUN
aji-160	251	13	of	of	ADP
aji-160	251	14	lupus	lupus	NOUN
aji-160	251	15	and	and	CCONJ
aji-160	251	16	its	its	PRON
aji-160	251	17	direct	direct	ADJ
aji-160	251	18	impact	impact	NOUN
aji-160	251	19	on	on	ADP
aji-160	251	20	heart	heart	NOUN
aji-160	251	21	function	function	NOUN
aji-160	251	22	,	,	PUNCT
aji-160	251	23	especially	especially	ADV
aji-160	251	24	in	in	ADP
aji-160	251	25	its	its	PRON
aji-160	251	26	early	early	ADJ
aji-160	251	27	stages	stage	NOUN
aji-160	251	28	.	.	PUNCT
aji-160	252	1	2	2	X
aji-160	252	2	.	.	X
aji-160	252	3	it	it	PRON
aji-160	252	4	is	be	AUX
aji-160	252	5	necessary	necessary	ADJ
aji-160	252	6	to	to	PART
aji-160	252	7	deepen	deepen	VERB
aji-160	252	8	the	the	DET
aji-160	252	9	studies	study	NOUN
aji-160	252	10	and	and	CCONJ
aji-160	252	11	establish	establish	VERB
aji-160	252	12	a	a	DET
aji-160	252	13	longitudinal	longitudinal	ADJ
aji-160	252	14	study	study	NOUN
aji-160	252	15	to	to	PART
aji-160	252	16	increase	increase	VERB
aji-160	252	17	understanding	understanding	NOUN
aji-160	252	18	of	of	ADP
aji-160	252	19	the	the	DET
aji-160	252	20	effect	effect	NOUN
aji-160	252	21	of	of	ADP
aji-160	252	22	lupus	lupus	NOUN
aji-160	252	23	on	on	ADP
aji-160	252	24	the	the	DET
aji-160	252	25	heart	heart	NOUN
aji-160	252	26	.	.	PUNCT
aji-160	253	1	3	3	X
aji-160	253	2	.	.	X
aji-160	253	3	encourage	encourage	VERB
aji-160	253	4	teamwork	teamwork	NOUN
aji-160	253	5	among	among	ADP
aji-160	253	6	cardiologists	cardiologist	NOUN
aji-160	253	7	,	,	PUNCT
aji-160	253	8	rheumatologists	rheumatologist	NOUN
aji-160	253	9	,	,	PUNCT
aji-160	253	10	and	and	CCONJ
aji-160	253	11	immunologists	immunologist	NOUN
aji-160	253	12	to	to	PART
aji-160	253	13	develop	develop	VERB
aji-160	253	14	an	an	DET
aji-160	253	15	early	early	ADJ
aji-160	253	16	picture	picture	NOUN
aji-160	253	17	of	of	ADP
aji-160	253	18	lupus	lupus	NOUN
aji-160	253	19	disease	disease	NOUN
aji-160	253	20	progression	progression	NOUN
aji-160	253	21	and	and	CCONJ
aji-160	253	22	the	the	DET
aji-160	253	23	potential	potential	NOUN
aji-160	253	24	for	for	ADP
aji-160	253	25	cardiac	cardiac	ADJ
aji-160	253	26	damage	damage	NOUN
aji-160	253	27	.	.	PUNCT
aji-160	254	1	4	4	X
aji-160	254	2	.	.	X
aji-160	254	3	requiring	require	VERB
aji-160	254	4	lupus	lupus	ADJ
aji-160	254	5	patients	patient	NOUN
aji-160	254	6	to	to	PART
aji-160	254	7	undergo	undergo	VERB
aji-160	254	8	heart	heart	NOUN
aji-160	254	9	function	function	NOUN
aji-160	254	10	tests	test	NOUN
aji-160	254	11	even	even	ADV
aji-160	254	12	if	if	SCONJ
aji-160	254	13	they	they	PRON
aji-160	254	14	do	do	AUX
aji-160	254	15	not	not	PART
aji-160	254	16	show	show	VERB
aji-160	254	17	heart	heart	NOUN
aji-160	254	18	symptoms	symptom	NOUN
aji-160	254	19	and	and	CCONJ
aji-160	254	20	making	make	VERB
aji-160	254	21	it	it	PRON
aji-160	254	22	a	a	DET
aji-160	254	23	mandatory	mandatory	ADJ
aji-160	254	24	work	work	NOUN
aji-160	254	25	routine	routine	ADJ
aji-160	254	26	consent	consent	NOUN
aji-160	254	27	as	as	ADP
aji-160	254	28	per	per	ADP
aji-160	254	29	international	international	ADJ
aji-160	254	30	standards	standard	NOUN
aji-160	254	31	or	or	CCONJ
aji-160	254	32	university	university	NOUN
aji-160	254	33	standards	standard	NOUN
aji-160	254	34	,	,	PUNCT
aji-160	254	35	patient(s	patient(s	PROPN
aji-160	254	36	)	)	PUNCT
aji-160	254	37	written	write	VERB
aji-160	254	38	consent	consent	NOUN
aji-160	254	39	has	have	AUX
aji-160	254	40	been	be	AUX
aji-160	254	41	collected	collect	VERB
aji-160	254	42	and	and	CCONJ
aji-160	254	43	preserved	preserve	VERB
aji-160	254	44	by	by	ADP
aji-160	254	45	the	the	DET
aji-160	254	46	author(s	author(s	NOUN
aji-160	254	47	)	)	PUNCT
aji-160	254	48	.	.	PUNCT
aji-160	255	1	ethical	ethical	ADJ
aji-160	255	2	approval	approval	NOUN
aji-160	255	3	as	as	ADP
aji-160	255	4	per	per	ADP
aji-160	255	5	international	international	ADJ
aji-160	255	6	standards	standard	NOUN
aji-160	255	7	or	or	CCONJ
aji-160	255	8	university	university	NOUN
aji-160	255	9	standards	standard	NOUN
aji-160	255	10	written	write	VERB
aji-160	255	11	ethical	ethical	ADJ
aji-160	255	12	approval	approval	NOUN
aji-160	255	13	has	have	AUX
aji-160	255	14	been	be	AUX
aji-160	255	15	collected	collect	VERB
aji-160	255	16	and	and	CCONJ
aji-160	255	17	preserved	preserve	VERB
aji-160	255	18	by	by	ADP
aji-160	255	19	the	the	DET
aji-160	255	20	author(s	author(s	NOUN
aji-160	255	21	)	)	PUNCT
aji-160	255	22	.	.	PUNCT
aji-160	256	1	disclaimer	disclaimer	NOUN
aji-160	256	2	(	(	PUNCT
aji-160	256	3	artificial	artificial	ADJ
aji-160	256	4	intelligence	intelligence	NOUN
aji-160	256	5	)	)	PUNCT
aji-160	256	6	author(s	author(s	NOUN
aji-160	256	7	)	)	PUNCT
aji-160	256	8	hereby	hereby	ADV
aji-160	256	9	declare	declare	VERB
aji-160	256	10	that	that	SCONJ
aji-160	256	11	no	no	DET
aji-160	256	12	generative	generative	NOUN
aji-160	256	13	ai	ai	VERB
aji-160	256	14	technologies	technology	NOUN
aji-160	256	15	such	such	ADJ
aji-160	256	16	as	as	ADP
aji-160	256	17	large	large	ADJ
aji-160	256	18	language	language	NOUN
aji-160	256	19	models	model	NOUN
aji-160	256	20	(	(	PUNCT
aji-160	256	21	chatgpt	chatgpt	NOUN
aji-160	256	22	,	,	PUNCT
aji-160	256	23	copilot	copilot	NOUN
aji-160	256	24	,	,	PUNCT
aji-160	256	25	etc	etc	X
aji-160	256	26	)	)	PUNCT
aji-160	256	27	and	and	CCONJ
aji-160	256	28	text	text	NOUN
aji-160	256	29	-	-	PUNCT
aji-160	256	30	to	to	ADP
aji-160	256	31	-	-	PUNCT
aji-160	256	32	image	image	NOUN
aji-160	256	33	generators	generator	NOUN
aji-160	256	34	have	have	AUX
aji-160	256	35	been	be	AUX
aji-160	256	36	used	use	VERB
aji-160	256	37	during	during	ADP
aji-160	256	38	writing	writing	NOUN
aji-160	256	39	or	or	CCONJ
aji-160	256	40	editing	editing	NOUN
aji-160	256	41	of	of	ADP
aji-160	256	42	this	this	DET
aji-160	256	43	manuscript	manuscript	NOUN
aji-160	256	44	.	.	PUNCT
aji-160	257	1	acknowledgement	acknowledgement	NOUN
aji-160	257	2	i	i	PRON
aji-160	257	3	would	would	AUX
aji-160	257	4	like	like	VERB
aji-160	257	5	to	to	PART
aji-160	257	6	extend	extend	VERB
aji-160	257	7	my	my	PRON
aji-160	257	8	sincere	sincere	ADJ
aji-160	257	9	gratitude	gratitude	NOUN
aji-160	257	10	and	and	CCONJ
aji-160	257	11	appreciation	appreciation	NOUN
aji-160	257	12	to	to	ADP
aji-160	257	13	professor	professor	PROPN
aji-160	257	14	dr	dr	PROPN
aji-160	257	15	.	.	PROPN
aji-160	257	16	fateh	fateh	PROPN
aji-160	257	17	shaker	shaker	PROPN
aji-160	257	18	abdul	abdul	PROPN
aji-160	257	19	hussein	hussein	PROPN
aji-160	257	20	,	,	PUNCT
aji-160	257	21	a	a	DET
aji-160	257	22	specialist	specialist	NOUN
aji-160	257	23	in	in	ADP
aji-160	257	24	cardiology	cardiology	NOUN
aji-160	257	25	and	and	CCONJ
aji-160	257	26	vascular	vascular	ADJ
aji-160	257	27	diseases	disease	NOUN
aji-160	257	28	,	,	PUNCT
aji-160	257	29	for	for	ADP
aji-160	257	30	his	his	PRON
aji-160	257	31	valuable	valuable	ADJ
aji-160	257	32	insightful	insightful	ADJ
aji-160	257	33	guidance	guidance	NOUN
aji-160	257	34	to	to	ADP
aji-160	257	35	completion	completion	NOUN
aji-160	257	36	of	of	ADP
aji-160	257	37	this	this	DET
aji-160	257	38	research	research	NOUN
aji-160	257	39	.	.	PUNCT
aji-160	258	1	competing	compete	VERB
aji-160	258	2	interests	interest	NOUN
aji-160	258	3	author	author	NOUN
aji-160	258	4	has	have	AUX
aji-160	258	5	declared	declare	VERB
aji-160	258	6	that	that	SCONJ
aji-160	258	7	no	no	DET
aji-160	258	8	competing	compete	VERB
aji-160	258	9	interests	interest	NOUN
aji-160	258	10	exist	exist	VERB
aji-160	258	11	.	.	PUNCT
aji-160	259	1	references	reference	NOUN
aji-160	259	2	adawi	adawi	PROPN
aji-160	259	3	,	,	PUNCT
aji-160	259	4	m.	m.	NOUN
aji-160	259	5	,	,	PUNCT
aji-160	259	6	abu	abu	PROPN
aji-160	259	7	-	-	PUNCT
aji-160	259	8	gabel	gabel	PROPN
aji-160	259	9	,	,	PUNCT
aji-160	259	10	t.	t.	PROPN
aji-160	259	11	,	,	PUNCT
aji-160	259	12	sabbah	sabbah	PROPN
aji-160	259	13	,	,	PUNCT
aji-160	259	14	f.	f.	PROPN
aji-160	259	15	,	,	PUNCT
aji-160	259	16	yehuda	yehuda	PROPN
aji-160	259	17	,	,	PUNCT
aji-160	259	18	i.	i.	PROPN
aji-160	259	19	,	,	PUNCT
aji-160	259	20	tamir	tamir	PROPN
aji-160	259	21	,	,	PUNCT
aji-160	259	22	s.	s.	PROPN
aji-160	259	23	,	,	PUNCT
aji-160	259	24	&	&	CCONJ
aji-160	259	25	blum	blum	PROPN
aji-160	259	26	,	,	PUNCT
aji-160	259	27	a.	a.	NOUN
aji-160	259	28	(	(	PUNCT
aji-160	259	29	2020	2020	NUM
aji-160	259	30	)	)	PUNCT
aji-160	259	31	.	.	PUNCT
aji-160	260	1	vascular	vascular	ADJ
aji-160	260	2	reactivity	reactivity	NOUN
aji-160	260	3	of	of	ADP
aji-160	260	4	adult	adult	NOUN
aji-160	260	5	-	-	PUNCT
aji-160	260	6	onset	onset	NOUN
aji-160	260	7	systemic	systemic	ADJ
aji-160	260	8	lupus	lupus	PROPN
aji-160	260	9	erythematosus	erythematosus	PROPN
aji-160	260	10	patients	patient	NOUN
aji-160	260	11	.	.	PUNCT
aji-160	261	1	israel	israel	PROPN
aji-160	261	2	medical	medical	PROPN
aji-160	261	3	association	association	PROPN
aji-160	261	4	journal	journal	PROPN
aji-160	261	5	,	,	PUNCT
aji-160	261	6	22	22	NUM
aji-160	261	7	,	,	PUNCT
aji-160	261	8	348–351	348–351	NUM
aji-160	261	9	.	.	PUNCT
aji-160	261	10	cieślik	cieślik	PROPN
aji-160	261	11	,	,	PUNCT
aji-160	261	12	p.	p.	NOUN
aji-160	261	13	,	,	PUNCT
aji-160	261	14	semik	semik	NOUN
aji-160	261	15	-	-	PUNCT
aji-160	261	16	grabarczyk	grabarczyk	NOUN
aji-160	261	17	,	,	PUNCT
aji-160	261	18	e.	e.	PROPN
aji-160	261	19	,	,	PUNCT
aji-160	261	20	hrycek	hrycek	PROPN
aji-160	261	21	,	,	PUNCT
aji-160	261	22	a.	a.	PROPN
aji-160	261	23	,	,	PUNCT
aji-160	261	24	&	&	CCONJ
aji-160	261	25	holecki	holecki	PROPN
aji-160	261	26	,	,	PUNCT
aji-160	261	27	m.	m.	NOUN
aji-160	261	28	(	(	PUNCT
aji-160	261	29	2022	2022	NUM
aji-160	261	30	)	)	PUNCT
aji-160	261	31	.	.	PUNCT
aji-160	262	1	the	the	DET
aji-160	262	2	impact	impact	NOUN
aji-160	262	3	of	of	ADP
aji-160	262	4	antiendothelial	antiendothelial	ADJ
aji-160	262	5	cell	cell	NOUN
aji-160	262	6	antibodies	antibodie	VERB
aji-160	262	7	(	(	PUNCT
aji-160	262	8	aecas	aeca	NOUN
aji-160	262	9	)	)	PUNCT
aji-160	262	10	on	on	ADP
aji-160	262	11	the	the	DET
aji-160	262	12	development	development	NOUN
aji-160	262	13	of	of	ADP
aji-160	262	14	blood	blood	NOUN
aji-160	262	15	vessel	vessel	NOUN
aji-160	262	16	damage	damage	NOUN
aji-160	262	17	in	in	ADP
aji-160	262	18	patients	patient	NOUN
aji-160	262	19	with	with	ADP
aji-160	262	20	systemic	systemic	ADJ
aji-160	262	21	lupus	lupus	PROPN
aji-160	262	22	erythematosus	erythematosus	NOUN
aji-160	262	23	:	:	PUNCT
aji-160	262	24	the	the	DET
aji-160	262	25	preliminary	preliminary	ADJ
aji-160	262	26	study	study	NOUN
aji-160	262	27	.	.	PUNCT
aji-160	263	1	rheumatology	rheumatology	PROPN
aji-160	263	2	international	international	PROPN
aji-160	263	3	,	,	PUNCT
aji-160	263	4	42	42	NUM
aji-160	263	5	,	,	PUNCT
aji-160	263	6	791	791	NUM
aji-160	263	7	–	–	PUNCT
aji-160	263	8	801	801	NUM
aji-160	263	9	.	.	PUNCT
aji-160	264	1	https://doi.org/10.1007/s00296-022-051045	https://doi.org/10.1007/s00296-022-051045	NOUN
aji-160	264	2	foret	foret	NOUN
aji-160	264	3	,	,	PUNCT
aji-160	264	4	t.	t.	PROPN
aji-160	264	5	,	,	PUNCT
aji-160	264	6	dufrost	dufrost	NOUN
aji-160	264	7	,	,	PUNCT
aji-160	264	8	v.	v.	ADV
aji-160	264	9	,	,	PUNCT
aji-160	264	10	heymonet	heymonet	PROPN
aji-160	264	11	,	,	PUNCT
aji-160	264	12	m.	m.	NOUN
aji-160	264	13	,	,	PUNCT
aji-160	264	14	risse	risse	PROPN
aji-160	264	15	,	,	PUNCT
aji-160	264	16	j.	j.	PROPN
aji-160	264	17	,	,	PUNCT
aji-160	264	18	faure	faure	PROPN
aji-160	264	19	,	,	PUNCT
aji-160	264	20	g.	g.	PROPN
aji-160	264	21	,	,	PUNCT
aji-160	264	22	louis	louis	PROPN
aji-160	264	23	,	,	PUNCT
aji-160	264	24	h.	h.	PROPN
aji-160	264	25	,	,	PUNCT
aji-160	264	26	et	et	PROPN
aji-160	264	27	al	al	PROPN
aji-160	264	28	.	.	PROPN
aji-160	264	29	(	(	PUNCT
aji-160	264	30	2022	2022	NUM
aji-160	264	31	)	)	PUNCT
aji-160	264	32	.	.	PUNCT
aji-160	265	1	circulating	circulate	VERB
aji-160	265	2	endothelial	endothelial	ADJ
aji-160	265	3	cells	cell	NOUN
aji-160	265	4	are	be	AUX
aji-160	265	5	associated	associate	VERB
aji-160	265	6	with	with	ADP
aji-160	265	7	thromboembolic	thromboembolic	ADJ
aji-160	265	8	events	event	NOUN
aji-160	265	9	in	in	ADP
aji-160	265	10	patients	patient	NOUN
aji-160	265	11	with	with	ADP
aji-160	265	12	antiphospholipid	antiphospholipid	NOUN
aji-160	265	13	antibodies	antibody	NOUN
aji-160	265	14	.	.	PUNCT
aji-160	266	1	thrombosis	thrombosis	NOUN
aji-160	266	2	and	and	CCONJ
aji-160	266	3	haemostasis	haemostasis	NOUN
aji-160	266	4	.	.	PUNCT
aji-160	267	1	advance	advance	VERB
aji-160	267	2	online	online	ADJ
aji-160	267	3	publication	publication	NOUN
aji-160	267	4	.	.	PUNCT
aji-160	268	1	https://doi.org/10.1055/a-1926-0453	https://doi.org/10.1055/a-1926-0453	NOUN
aji-160	268	2	gladman	gladman	NOUN
aji-160	268	3	,	,	PUNCT
aji-160	268	4	d.	d.	PROPN
aji-160	268	5	d.	d.	PROPN
aji-160	268	6	,	,	PUNCT
aji-160	268	7	ginzler	ginzler	NOUN
aji-160	268	8	,	,	PUNCT
aji-160	268	9	e.	e.	PROPN
aji-160	268	10	,	,	PUNCT
aji-160	268	11	goldsmith	goldsmith	PROPN
aji-160	268	12	,	,	PUNCT
aji-160	268	13	c.	c.	PROPN
aji-160	268	14	,	,	PUNCT
aji-160	268	15	et	et	PROPN
aji-160	268	16	al	al	PROPN
aji-160	268	17	.	.	PUNCT
aji-160	268	18	(	(	PUNCT
aji-160	268	19	1996	1996	NUM
aji-160	268	20	)	)	PUNCT
aji-160	268	21	.	.	PUNCT
aji-160	269	1	the	the	DET
aji-160	269	2	development	development	NOUN
aji-160	269	3	and	and	CCONJ
aji-160	269	4	initial	initial	ADJ
aji-160	269	5	validation	validation	NOUN
aji-160	269	6	of	of	ADP
aji-160	269	7	the	the	DET
aji-160	269	8	systemic	systemic	ADJ
aji-160	269	9	lupus	lupus	PROPN
aji-160	269	10	international	international	ADJ
aji-160	269	11	collaborating	collaborate	VERB
aji-160	269	12	clinics	clinic	NOUN
aji-160	269	13	/	/	SYM
aji-160	269	14	american	american	PROPN
aji-160	269	15	college	college	PROPN
aji-160	269	16	of	of	ADP
aji-160	269	17	rheumatology	rheumatology	NOUN
aji-160	269	18	damage	damage	NOUN
aji-160	269	19	index	index	NOUN
aji-160	269	20	for	for	ADP
aji-160	269	21	systemic	systemic	ADJ
aji-160	269	22	lupus	lupu	NOUN
aji-160	269	23	erythematous	erythematous	ADJ
aji-160	269	24	.	.	PUNCT
aji-160	270	1	arthritis	arthritis	NOUN
aji-160	270	2	&	&	CCONJ
aji-160	270	3	rheumatism	rheumatism	NOUN
aji-160	270	4	,	,	PUNCT
aji-160	270	5	39(3	39(3	NUM
aji-160	270	6	)	)	PUNCT
aji-160	270	7	,	,	PUNCT
aji-160	270	8	363–369	363–369	NUM
aji-160	270	9	.	.	PUNCT
aji-160	271	1	https://doi.org/10.1002/art.1780390303	https://doi.org/10.1002/art.1780390303	PROPN
aji-160	271	2	gladman	gladman	PROPN
aji-160	271	3	,	,	PUNCT
aji-160	271	4	d.	d.	PROPN
aji-160	271	5	d.	d.	PROPN
aji-160	271	6	,	,	PUNCT
aji-160	271	7	ibanez	ibanez	PROPN
aji-160	271	8	,	,	PUNCT
aji-160	271	9	d.	d.	PROPN
aji-160	271	10	,	,	PUNCT
aji-160	271	11	&	&	CCONJ
aji-160	271	12	urowitz	urowitz	PROPN
aji-160	271	13	,	,	PUNCT
aji-160	271	14	m.	m.	PROPN
aji-160	271	15	b.	b.	PROPN
aji-160	271	16	(	(	PUNCT
aji-160	271	17	2002	2002	NUM
aji-160	271	18	)	)	PUNCT
aji-160	271	19	.	.	PUNCT
aji-160	272	1	systemic	systemic	ADJ
aji-160	272	2	lupus	lupus	PROPN
aji-160	272	3	erythematous	erythematous	ADJ
aji-160	272	4	disease	disease	NOUN
aji-160	272	5	activity	activity	NOUN
aji-160	272	6	index	index	NOUN
aji-160	272	7	2000	2000	NUM
aji-160	272	8	.	.	PUNCT
aji-160	273	1	the	the	DET
aji-160	273	2	journal	journal	NOUN
aji-160	273	3	of	of	ADP
aji-160	273	4	rheumatology	rheumatology	NOUN
aji-160	273	5	,	,	PUNCT
aji-160	273	6	29(2	29(2	NUM
aji-160	273	7	)	)	PUNCT
aji-160	273	8	,	,	PUNCT
aji-160	273	9	288–291	288–291	NUM
aji-160	273	10	.	.	PUNCT
aji-160	274	1	hochberg	hochberg	PROPN
aji-160	274	2	,	,	PUNCT
aji-160	274	3	m.	m.	PROPN
aji-160	274	4	c.	c.	PROPN
aji-160	274	5	(	(	PUNCT
aji-160	274	6	1997	1997	NUM
aji-160	274	7	)	)	PUNCT
aji-160	274	8	.	.	PUNCT
aji-160	275	1	updating	update	VERB
aji-160	275	2	the	the	DET
aji-160	275	3	american	american	PROPN
aji-160	275	4	college	college	PROPN
aji-160	275	5	of	of	ADP
aji-160	275	6	rheumatology	rheumatology	NOUN
aji-160	275	7	revised	revise	VERB
aji-160	275	8	criteria	criterion	NOUN
aji-160	275	9	for	for	ADP
aji-160	275	10	the	the	DET
aji-160	275	11	classification	classification	NOUN
aji-160	275	12	of	of	ADP
aji-160	275	13	systemic	systemic	ADJ
aji-160	275	14	lupus	lupu	NOUN
aji-160	275	15	erythematous	erythematous	ADJ
aji-160	275	16	.	.	PUNCT
aji-160	276	1	arthritis	arthritis	NOUN
aji-160	276	2	&	&	CCONJ
aji-160	276	3	rheumatism	rheumatism	NOUN
aji-160	276	4	,	,	PUNCT
aji-160	276	5	40(9	40(9	NUM
aji-160	276	6	)	)	PUNCT
aji-160	276	7	,	,	PUNCT
aji-160	276	8	1725	1725	NUM
aji-160	276	9	.	.	PUNCT
aji-160	277	1	https://doi.org/10.1002/art.1780400928	https://doi.org/10.1002/art.1780400928	PROPN
aji-160	277	2	kim	kim	PROPN
aji-160	277	3	,	,	PUNCT
aji-160	277	4	c.	c.	PROPN
aji-160	277	5	h.	h.	PROPN
aji-160	277	6	,	,	PUNCT
aji-160	277	7	al	al	PROPN
aji-160	277	8	-	-	PUNCT
aji-160	277	9	kindi	kindi	NOUN
aji-160	277	10	,	,	PUNCT
aji-160	277	11	s.	s.	PROPN
aji-160	277	12	g.	g.	PROPN
aji-160	277	13	,	,	PUNCT
aji-160	277	14	jandali	jandali	PROPN
aji-160	277	15	,	,	PUNCT
aji-160	277	16	b.	b.	PROPN
aji-160	277	17	,	,	PUNCT
aji-160	277	18	et	et	PROPN
aji-160	277	19	al	al	PROPN
aji-160	277	20	.	.	PUNCT
aji-160	277	21	(	(	PUNCT
aji-160	277	22	2017	2017	NUM
aji-160	277	23	)	)	PUNCT
aji-160	277	24	.	.	PUNCT
aji-160	278	1	incidence	incidence	NOUN
aji-160	278	2	and	and	CCONJ
aji-160	278	3	hazard	hazard	NOUN
aji-160	278	4	of	of	ADP
aji-160	278	5	heart	heart	NOUN
aji-160	278	6	failure	failure	NOUN
aji-160	278	7	in	in	ADP
aji-160	278	8	systemic	systemic	ADJ
aji-160	278	9	lupus	lupu	NOUN
aji-160	278	10	erythematous	erythematous	ADJ
aji-160	278	11	.	.	PUNCT
aji-160	279	1	heart	heart	NOUN
aji-160	279	2	,	,	PUNCT
aji-160	279	3	103(3	103(3	NUM
aji-160	279	4	)	)	PUNCT
aji-160	279	5	,	,	PUNCT
aji-160	279	6	227–233	227–233	NUM
aji-160	279	7	.	.	PUNCT
aji-160	279	8	shaker	shaker	NOUN
aji-160	279	9	;	;	PUNCT
aji-160	279	10	asian	asian	PROPN
aji-160	279	11	j.	j.	PROPN
aji-160	279	12	immunol	immunol	PROPN
aji-160	279	13	.	.	PROPN
aji-160	279	14	,	,	PUNCT
aji-160	279	15	vol	vol	NOUN
aji-160	279	16	.	.	PROPN
aji-160	279	17	8	8	NUM
aji-160	279	18	,	,	PUNCT
aji-160	279	19	no	no	INTJ
aji-160	279	20	.	.	NOUN
aji-160	279	21	1	1	NUM
aji-160	279	22	,	,	PUNCT
aji-160	279	23	pp	pp	ADJ
aji-160	279	24	.	.	PUNCT
aji-160	280	1	60	60	NUM
aji-160	280	2	-	-	SYM
aji-160	280	3	69	69	NUM
aji-160	280	4	,	,	PUNCT
aji-160	280	5	2025	2025	NUM
aji-160	280	6	;	;	PUNCT
aji-160	280	7	article	article	NOUN
aji-160	280	8	no.aji.134457	no.aji.134457	VERB
aji-160	280	9	69	69	NUM
aji-160	280	10	https://doi.org/10.1136/heartjnl-2016309561	https://doi.org/10.1136/heartjnl-2016309561	NOUN
aji-160	280	11	mazurek	mazurek	PROPN
aji-160	280	12	,	,	PUNCT
aji-160	280	13	a.	a.	NOUN
aji-160	280	14	,	,	PUNCT
aji-160	280	15	gryga	gryga	NOUN
aji-160	280	16	,	,	PUNCT
aji-160	280	17	k.	k.	PROPN
aji-160	280	18	,	,	PUNCT
aji-160	280	19	bugala	bugala	INTJ
aji-160	280	20	,	,	PUNCT
aji-160	280	21	k.	k.	PROPN
aji-160	280	22	,	,	PUNCT
aji-160	280	23	iwaniec	iwaniec	PROPN
aji-160	280	24	,	,	PUNCT
aji-160	280	25	t.	t.	NOUN
aji-160	280	26	,	,	PUNCT
aji-160	280	27	musial	musial	ADJ
aji-160	280	28	,	,	PUNCT
aji-160	280	29	j.	j.	PROPN
aji-160	280	30	,	,	PUNCT
aji-160	280	31	podolec	podolec	NOUN
aji-160	280	32	,	,	PUNCT
aji-160	280	33	p.	p.	PROPN
aji-160	280	34	,	,	PUNCT
aji-160	280	35	et	et	PROPN
aji-160	280	36	al	al	PROPN
aji-160	280	37	.	.	PROPN
aji-160	281	1	(	(	PUNCT
aji-160	281	2	2022	2022	NUM
aji-160	281	3	)	)	PUNCT
aji-160	281	4	.	.	PUNCT
aji-160	282	1	influence	influence	NOUN
aji-160	282	2	of	of	ADP
aji-160	282	3	statin	statin	PROPN
aji-160	282	4	therapy	therapy	NOUN
aji-160	282	5	on	on	ADP
aji-160	282	6	antiphospholipid	antiphospholipid	NOUN
aji-160	282	7	antibodies	antibody	NOUN
aji-160	282	8	and	and	CCONJ
aji-160	282	9	endothelial	endothelial	ADJ
aji-160	282	10	dysfunction	dysfunction	NOUN
aji-160	282	11	in	in	ADP
aji-160	282	12	young	young	ADJ
aji-160	282	13	patients	patient	NOUN
aji-160	282	14	with	with	ADP
aji-160	282	15	coronary	coronary	ADJ
aji-160	282	16	artery	artery	NOUN
aji-160	282	17	disease	disease	NOUN
aji-160	282	18	and	and	CCONJ
aji-160	282	19	systemic	systemic	ADJ
aji-160	282	20	lupus	lupus	PROPN
aji-160	282	21	erythematosus	erythematosus	PROPN
aji-160	282	22	.	.	PUNCT
aji-160	283	1	archives	archive	NOUN
aji-160	283	2	of	of	ADP
aji-160	283	3	medical	medical	ADJ
aji-160	283	4	science	science	NOUN
aji-160	283	5	,	,	PUNCT
aji-160	283	6	18(1	18(1	NUM
aji-160	283	7	)	)	PUNCT
aji-160	283	8	,	,	PUNCT
aji-160	283	9	18–24	18–24	NUM
aji-160	283	10	.	.	PUNCT
aji-160	284	1	https://doi.org/10.5114/aoms.2019.90271	https://doi.org/10.5114/aoms.2019.90271	PROPN
aji-160	284	2	mcmurray	mcmurray	PROPN
aji-160	284	3	,	,	PUNCT
aji-160	284	4	j.	j.	PROPN
aji-160	284	5	j.	j.	PROPN
aji-160	284	6	v.	v.	PROPN
aji-160	284	7	,	,	PUNCT
aji-160	284	8	adamopoulos	adamopoulos	PROPN
aji-160	284	9	,	,	PUNCT
aji-160	284	10	s.	s.	PROPN
aji-160	284	11	,	,	PUNCT
aji-160	284	12	anker	anker	PROPN
aji-160	284	13	,	,	PUNCT
aji-160	284	14	s.	s.	PROPN
aji-160	284	15	d.	d.	PROPN
aji-160	284	16	,	,	PUNCT
aji-160	284	17	et	et	PROPN
aji-160	284	18	al	al	PROPN
aji-160	284	19	.	.	PUNCT
aji-160	284	20	(	(	PUNCT
aji-160	284	21	2012	2012	NUM
aji-160	284	22	)	)	PUNCT
aji-160	284	23	.	.	PUNCT
aji-160	285	1	esc	esc	NOUN
aji-160	285	2	guidelines	guideline	VERB
aji-160	285	3	for	for	ADP
aji-160	285	4	the	the	DET
aji-160	285	5	diagnosis	diagnosis	NOUN
aji-160	285	6	and	and	CCONJ
aji-160	285	7	treatment	treatment	NOUN
aji-160	285	8	of	of	ADP
aji-160	285	9	acute	acute	ADJ
aji-160	285	10	and	and	CCONJ
aji-160	285	11	chronic	chronic	ADJ
aji-160	285	12	heart	heart	NOUN
aji-160	285	13	failure	failure	NOUN
aji-160	285	14	2012	2012	NUM
aji-160	285	15	.	.	PUNCT
aji-160	286	1	journal	journal	NOUN
aji-160	286	2	of	of	ADP
aji-160	286	3	cardiology	cardiology	NOUN
aji-160	286	4	,	,	PUNCT
aji-160	286	5	17(4s3	17(4s3	NUM
aji-160	286	6	)	)	PUNCT
aji-160	286	7	,	,	PUNCT
aji-160	286	8	1–68	1–68	NOUN
aji-160	286	9	.	.	PUNCT
aji-160	287	1	https://doi.org/10.15829/1560-4071-20124s3	https://doi.org/10.15829/1560-4071-20124s3	NOUN
aji-160	287	2	miyakis	miyaki	NOUN
aji-160	287	3	,	,	PUNCT
aji-160	287	4	s.	s.	PROPN
aji-160	287	5	,	,	PUNCT
aji-160	287	6	lockshin	lockshin	PROPN
aji-160	287	7	,	,	PUNCT
aji-160	287	8	m.	m.	NOUN
aji-160	287	9	d.	d.	PROPN
aji-160	287	10	,	,	PUNCT
aji-160	287	11	atsumi	atsumi	PROPN
aji-160	287	12	,	,	PUNCT
aji-160	287	13	t.	t.	PROPN
aji-160	287	14	,	,	PUNCT
aji-160	287	15	et	et	PROPN
aji-160	287	16	al	al	PROPN
aji-160	287	17	.	.	PUNCT
aji-160	287	18	(	(	PUNCT
aji-160	287	19	2006	2006	NUM
aji-160	287	20	)	)	PUNCT
aji-160	287	21	.	.	PUNCT
aji-160	288	1	international	international	ADJ
aji-160	288	2	consensus	consensus	NOUN
aji-160	288	3	statement	statement	NOUN
aji-160	288	4	on	on	ADP
aji-160	288	5	an	an	DET
aji-160	288	6	update	update	NOUN
aji-160	288	7	of	of	ADP
aji-160	288	8	the	the	DET
aji-160	288	9	classification	classification	NOUN
aji-160	288	10	criteria	criterion	NOUN
aji-160	288	11	for	for	ADP
aji-160	288	12	definite	definite	ADJ
aji-160	288	13	antiphospholipid	antiphospholipid	NOUN
aji-160	288	14	syndrome	syndrome	NOUN
aji-160	288	15	(	(	PUNCT
aji-160	288	16	aps	aps	PROPN
aji-160	288	17	)	)	PUNCT
aji-160	288	18	.	.	PUNCT
aji-160	289	1	journal	journal	NOUN
aji-160	289	2	of	of	ADP
aji-160	289	3	thrombosis	thrombosis	NOUN
aji-160	289	4	and	and	CCONJ
aji-160	289	5	haemostasis	haemostasis	NOUN
aji-160	289	6	,	,	PUNCT
aji-160	289	7	4(2	4(2	NUM
aji-160	289	8	)	)	PUNCT
aji-160	289	9	,	,	PUNCT
aji-160	289	10	295–306	295–306	NUM
aji-160	289	11	.	.	PUNCT
aji-160	290	1	https://doi.org/10.1111/j.15387836.2006.01753.x	https://doi.org/10.1111/j.15387836.2006.01753.x	X
aji-160	290	2	nasonov	nasonov	PROPN
aji-160	290	3	,	,	PUNCT
aji-160	290	4	e.	e.	PROPN
aji-160	290	5	l.	l.	PROPN
aji-160	290	6	(	(	PUNCT
aji-160	290	7	ed	ed	NOUN
aji-160	290	8	.	.	PUNCT
aji-160	290	9	)	)	PUNCT
aji-160	290	10	.	.	PUNCT
aji-160	291	1	(	(	PUNCT
aji-160	291	2	2010	2010	NUM
aji-160	291	3	)	)	PUNCT
aji-160	291	4	.	.	PUNCT
aji-160	292	1	rheumatology	rheumatology	NOUN
aji-160	292	2	.	.	PUNCT
aji-160	293	1	clinical	clinical	ADJ
aji-160	293	2	guidelines	guideline	NOUN
aji-160	293	3	(	(	PUNCT
aji-160	293	4	pp	pp	ADJ
aji-160	293	5	.	.	PUNCT
aji-160	293	6	429–481	429–481	NUM
aji-160	293	7	)	)	PUNCT
aji-160	293	8	.	.	PUNCT
aji-160	294	1	geotar	geotar	NOUN
aji-160	294	2	-	-	PUNCT
aji-160	294	3	media	medium	NOUN
aji-160	294	4	.	.	PUNCT
aji-160	295	1	petri	petri	ADJ
aji-160	295	2	,	,	PUNCT
aji-160	295	3	m.	m.	NOUN
aji-160	295	4	,	,	PUNCT
aji-160	295	5	orbai	orbai	NOUN
aji-160	295	6	,	,	PUNCT
aji-160	295	7	a.-m	a.-m	PROPN
aji-160	295	8	.	.	PUNCT
aji-160	295	9	,	,	PUNCT
aji-160	295	10	alarcón	alarcón	PROPN
aji-160	295	11	,	,	PUNCT
aji-160	295	12	g.	g.	PROPN
aji-160	295	13	s.	s.	PROPN
aji-160	295	14	,	,	PUNCT
aji-160	295	15	et	et	PROPN
aji-160	295	16	al	al	PROPN
aji-160	295	17	.	.	PUNCT
aji-160	296	1	(	(	PUNCT
aji-160	296	2	2012	2012	NUM
aji-160	296	3	)	)	PUNCT
aji-160	296	4	.	.	PUNCT
aji-160	297	1	derivation	derivation	NOUN
aji-160	297	2	and	and	CCONJ
aji-160	297	3	validation	validation	NOUN
aji-160	297	4	of	of	ADP
aji-160	297	5	the	the	DET
aji-160	297	6	systemic	systemic	ADJ
aji-160	297	7	lupus	lupus	PROPN
aji-160	297	8	international	international	ADJ
aji-160	297	9	collaborating	collaborating	NOUN
aji-160	297	10	clinics	clinic	NOUN
aji-160	297	11	classification	classification	NOUN
aji-160	297	12	criteria	criterion	NOUN
aji-160	297	13	for	for	ADP
aji-160	297	14	systemic	systemic	ADJ
aji-160	297	15	lupus	lupu	NOUN
aji-160	297	16	erythematous	erythematous	ADJ
aji-160	297	17	.	.	PUNCT
aji-160	298	1	arthritis	arthritis	NOUN
aji-160	298	2	&	&	CCONJ
aji-160	298	3	rheumatism	rheumatism	NOUN
aji-160	298	4	,	,	PUNCT
aji-160	298	5	64(8	64(8	NOUN
aji-160	298	6	)	)	PUNCT
aji-160	298	7	,	,	PUNCT
aji-160	298	8	2677–2686	2677–2686	NUM
aji-160	298	9	.	.	PUNCT
aji-160	299	1	https://doi.org/10.1002/art.34473	https://doi.org/10.1002/art.34473	PROPN
aji-160	299	2	rebrova	rebrova	PROPN
aji-160	299	3	,	,	PUNCT
aji-160	299	4	o.	o.	PROPN
aji-160	299	5	yu	yu	PROPN
aji-160	299	6	.	.	PUNCT
aji-160	300	1	(	(	PUNCT
aji-160	300	2	2002	2002	NUM
aji-160	300	3	)	)	PUNCT
aji-160	300	4	.	.	PUNCT
aji-160	301	1	statistical	statistical	ADJ
aji-160	301	2	analysis	analysis	NOUN
aji-160	301	3	of	of	ADP
aji-160	301	4	medical	medical	ADJ
aji-160	301	5	data	datum	NOUN
aji-160	301	6	.	.	PUNCT
aji-160	302	1	use	use	NOUN
aji-160	302	2	of	of	ADP
aji-160	302	3	the	the	DET
aji-160	302	4	statistica	statistica	PROPN
aji-160	302	5	software	software	PROPN
aji-160	302	6	package	package	NOUN
aji-160	302	7	(	(	PUNCT
aji-160	302	8	p.	p.	NOUN
aji-160	302	9	312	312	NUM
aji-160	302	10	)	)	PUNCT
aji-160	302	11	.	.	PUNCT
aji-160	303	1	mediasfera	mediasfera	NOUN
aji-160	303	2	.	.	PUNCT
aji-160	304	1	tan	tan	PROPN
aji-160	304	2	,	,	PUNCT
aji-160	304	3	e.	e.	PROPN
aji-160	304	4	m.	m.	PROPN
aji-160	304	5	,	,	PUNCT
aji-160	304	6	cohen	cohen	PROPN
aji-160	304	7	,	,	PUNCT
aji-160	304	8	a.	a.	PROPN
aji-160	304	9	s.	s.	PROPN
aji-160	304	10	,	,	PUNCT
aji-160	304	11	fries	fry	NOUN
aji-160	304	12	,	,	PUNCT
aji-160	304	13	j.	j.	PROPN
aji-160	304	14	f.	f.	PROPN
aji-160	304	15	,	,	PUNCT
aji-160	304	16	et	et	PROPN
aji-160	304	17	al	al	PROPN
aji-160	304	18	.	.	PUNCT
aji-160	305	1	(	(	PUNCT
aji-160	305	2	1982	1982	NUM
aji-160	305	3	)	)	PUNCT
aji-160	305	4	.	.	PUNCT
aji-160	306	1	the	the	DET
aji-160	306	2	1982	1982	NUM
aji-160	306	3	revised	revise	VERB
aji-160	306	4	criteria	criterion	NOUN
aji-160	306	5	for	for	ADP
aji-160	306	6	the	the	DET
aji-160	306	7	classification	classification	NOUN
aji-160	306	8	of	of	ADP
aji-160	306	9	systemic	systemic	ADJ
aji-160	306	10	lupus	lupu	NOUN
aji-160	306	11	erythematous	erythematous	ADJ
aji-160	306	12	.	.	PUNCT
aji-160	307	1	arthritis	arthritis	NOUN
aji-160	307	2	&	&	CCONJ
aji-160	307	3	rheumatism	rheumatism	NOUN
aji-160	307	4	,	,	PUNCT
aji-160	307	5	25(11	25(11	NUM
aji-160	307	6	)	)	PUNCT
aji-160	307	7	,	,	PUNCT
aji-160	307	8	1271–1277	1271–1277	NUM
aji-160	307	9	.	.	PUNCT
aji-160	308	1	https://doi.org/10.1002/art.1780251101	https://doi.org/10.1002/art.1780251101	ADJ
aji-160	308	2	disclaimer	disclaimer	ADJ
aji-160	308	3	/	/	SYM
aji-160	308	4	publisher	publisher	NOUN
aji-160	308	5	’s	’s	PART
aji-160	308	6	note	note	NOUN
aji-160	308	7	:	:	PUNCT
aji-160	308	8	the	the	DET
aji-160	308	9	statements	statement	NOUN
aji-160	308	10	,	,	PUNCT
aji-160	308	11	opinions	opinion	NOUN
aji-160	308	12	and	and	CCONJ
aji-160	308	13	data	datum	NOUN
aji-160	308	14	contained	contain	VERB
aji-160	308	15	in	in	ADP
aji-160	308	16	all	all	DET
aji-160	308	17	publications	publication	NOUN
aji-160	308	18	are	be	AUX
aji-160	308	19	solely	solely	ADV
aji-160	308	20	those	those	PRON
aji-160	308	21	of	of	ADP
aji-160	308	22	the	the	DET
aji-160	308	23	individual	individual	ADJ
aji-160	308	24	author(s	author(s	PROPN
aji-160	308	25	)	)	PUNCT
aji-160	308	26	and	and	CCONJ
aji-160	308	27	contributor(s	contributor(s	NOUN
aji-160	308	28	)	)	PUNCT
aji-160	308	29	and	and	CCONJ
aji-160	308	30	not	not	PART
aji-160	308	31	of	of	ADP
aji-160	308	32	the	the	DET
aji-160	308	33	publisher	publisher	NOUN
aji-160	308	34	and/or	and/or	CCONJ
aji-160	308	35	the	the	DET
aji-160	308	36	editor(s	editor(s	NOUN
aji-160	308	37	)	)	PUNCT
aji-160	308	38	.	.	PUNCT
aji-160	309	1	this	this	DET
aji-160	309	2	publisher	publisher	NOUN
aji-160	309	3	and/or	and/or	CCONJ
aji-160	309	4	the	the	DET
aji-160	309	5	editor(s	editor(s	NOUN
aji-160	309	6	)	)	PUNCT
aji-160	309	7	disclaim	disclaim	VERB
aji-160	309	8	responsibility	responsibility	NOUN
aji-160	309	9	for	for	ADP
aji-160	309	10	any	any	DET
aji-160	309	11	injury	injury	NOUN
aji-160	309	12	to	to	ADP
aji-160	309	13	people	people	NOUN
aji-160	309	14	or	or	CCONJ
aji-160	309	15	property	property	NOUN
aji-160	309	16	resulting	result	VERB
aji-160	309	17	from	from	ADP
aji-160	309	18	any	any	DET
aji-160	309	19	ideas	idea	NOUN
aji-160	309	20	,	,	PUNCT
aji-160	309	21	methods	method	NOUN
aji-160	309	22	,	,	PUNCT
aji-160	309	23	instructions	instruction	NOUN
aji-160	309	24	or	or	CCONJ
aji-160	309	25	products	product	NOUN
aji-160	309	26	referred	refer	VERB
aji-160	309	27	to	to	ADP
aji-160	309	28	in	in	ADP
aji-160	309	29	the	the	DET
aji-160	309	30	content	content	NOUN
aji-160	309	31	.	.	PUNCT
aji-160	310	1	_	_	PUNCT
aji-160	311	1	_	_	PUNCT
aji-160	312	1	_	_	PUNCT
aji-160	313	1	_	_	PUNCT
aji-160	314	1	_	_	PUNCT
aji-160	315	1	_	_	PUNCT
aji-160	316	1	_	_	PUNCT
aji-160	317	1	_	_	PUNCT
aji-160	318	1	_	_	PUNCT
aji-160	319	1	_	_	PUNCT
aji-160	320	1	_	_	PUNCT
aji-160	321	1	_	_	PUNCT
aji-160	322	1	_	_	PUNCT
aji-160	323	1	_	_	PUNCT
aji-160	324	1	_	_	PUNCT
aji-160	325	1	_	_	PUNCT
aji-160	326	1	_	_	PUNCT
aji-160	327	1	_	_	PUNCT
aji-160	328	1	_	_	PUNCT
aji-160	329	1	_	_	PUNCT
aji-160	330	1	_	_	PUNCT
aji-160	331	1	_	_	PUNCT
aji-160	332	1	_	_	PUNCT
aji-160	333	1	_	_	PUNCT
aji-160	334	1	_	_	PUNCT
aji-160	335	1	_	_	PUNCT
aji-160	336	1	_	_	PUNCT
aji-160	337	1	_	_	PUNCT
aji-160	338	1	_	_	PUNCT
aji-160	339	1	_	_	PUNCT
aji-160	340	1	_	_	PUNCT
aji-160	341	1	_	_	PUNCT
aji-160	342	1	_	_	PUNCT
aji-160	343	1	_	_	PUNCT
aji-160	344	1	_	_	PUNCT
aji-160	345	1	_	_	PUNCT
aji-160	346	1	_	_	PUNCT
aji-160	347	1	_	_	PUNCT
aji-160	348	1	_	_	PUNCT
aji-160	349	1	_	_	PUNCT
aji-160	350	1	_	_	PUNCT
aji-160	351	1	_	_	PUNCT
aji-160	352	1	_	_	PUNCT
aji-160	353	1	_	_	PUNCT
aji-160	354	1	_	_	PUNCT
aji-160	355	1	_	_	PUNCT
aji-160	356	1	_	_	PUNCT
aji-160	357	1	_	_	PUNCT
aji-160	358	1	_	_	PUNCT
aji-160	359	1	_	_	PUNCT
aji-160	360	1	_	_	PUNCT
aji-160	361	1	_	_	PUNCT
aji-160	362	1	_	_	PUNCT
aji-160	363	1	_	_	PUNCT
aji-160	364	1	_	_	PUNCT
aji-160	365	1	_	_	PUNCT
aji-160	366	1	_	_	PUNCT
aji-160	367	1	_	_	PUNCT
aji-160	368	1	_	_	PUNCT
aji-160	369	1	_	_	PUNCT
aji-160	370	1	_	_	PUNCT
aji-160	371	1	_	_	PUNCT
aji-160	372	1	_	_	PUNCT
aji-160	373	1	_	_	PUNCT
aji-160	374	1	_	_	PUNCT
aji-160	375	1	_	_	PUNCT
aji-160	376	1	_	_	PUNCT
aji-160	377	1	_	_	PUNCT
aji-160	378	1	_	_	PUNCT
aji-160	379	1	_	_	PUNCT
aji-160	380	1	_	_	PUNCT
aji-160	381	1	_	_	PUNCT
aji-160	382	1	_	_	PUNCT
aji-160	383	1	_	_	PUNCT
aji-160	384	1	_	_	PUNCT
aji-160	385	1	_	_	PUNCT
aji-160	386	1	_	_	PUNCT
aji-160	387	1	_	_	PUNCT
aji-160	388	1	_	_	PUNCT
aji-160	389	1	_	_	PUNCT
aji-160	390	1	_	_	PUNCT
aji-160	391	1	©	©	PRON
aji-160	391	2	copyright	copyright	NOUN
aji-160	391	3	(	(	PUNCT
aji-160	391	4	2025	2025	NUM
aji-160	391	5	):	):	PUNCT
aji-160	391	6	author(s	author(s	NOUN
aji-160	391	7	)	)	PUNCT
aji-160	391	8	.	.	PUNCT
aji-160	392	1	the	the	DET
aji-160	392	2	licensee	licensee	NOUN
aji-160	392	3	is	be	AUX
aji-160	392	4	the	the	DET
aji-160	392	5	journal	journal	PROPN
aji-160	392	6	publisher	publisher	NOUN
aji-160	392	7	.	.	PUNCT
aji-160	393	1	this	this	PRON
aji-160	393	2	is	be	AUX
aji-160	393	3	an	an	DET
aji-160	393	4	open	open	ADJ
aji-160	393	5	access	access	NOUN
aji-160	393	6	article	article	NOUN
aji-160	393	7	distributed	distribute	VERB
aji-160	393	8	under	under	ADP
aji-160	393	9	the	the	DET
aji-160	393	10	terms	term	NOUN
aji-160	393	11	of	of	ADP
aji-160	393	12	the	the	DET
aji-160	393	13	creative	creative	ADJ
aji-160	393	14	commons	common	NOUN
aji-160	393	15	attribution	attribution	NOUN
aji-160	393	16	license	license	NOUN
aji-160	393	17	(	(	PUNCT
aji-160	393	18	http://creativecommons.org/licenses/by/4.0	http://creativecommons.org/licenses/by/4.0	NOUN
aji-160	393	19	)	)	PUNCT
aji-160	393	20	,	,	PUNCT
aji-160	393	21	which	which	PRON
aji-160	393	22	permits	permit	VERB
aji-160	393	23	unrestricted	unrestricted	ADJ
aji-160	393	24	use	use	NOUN
aji-160	393	25	,	,	PUNCT
aji-160	393	26	distribution	distribution	NOUN
aji-160	393	27	,	,	PUNCT
aji-160	393	28	and	and	CCONJ
aji-160	393	29	reproduction	reproduction	NOUN
aji-160	393	30	in	in	ADP
aji-160	393	31	any	any	DET
aji-160	393	32	medium	medium	NOUN
aji-160	393	33	,	,	PUNCT
aji-160	393	34	provided	provide	VERB
aji-160	393	35	the	the	DET
aji-160	393	36	original	original	ADJ
aji-160	393	37	work	work	NOUN
aji-160	393	38	is	be	AUX
aji-160	393	39	properly	properly	ADV
aji-160	393	40	cited	cite	VERB
aji-160	393	41	.	.	PUNCT
aji-160	394	1	peer	peer	NOUN
aji-160	394	2	-	-	PUNCT
aji-160	394	3	review	review	NOUN
aji-160	394	4	history	history	NOUN
aji-160	394	5	:	:	PUNCT
aji-160	394	6	the	the	DET
aji-160	394	7	peer	peer	NOUN
aji-160	394	8	review	review	NOUN
aji-160	394	9	history	history	NOUN
aji-160	394	10	for	for	ADP
aji-160	394	11	this	this	DET
aji-160	394	12	paper	paper	NOUN
aji-160	394	13	can	can	AUX
aji-160	394	14	be	be	AUX
aji-160	394	15	accessed	access	VERB
aji-160	394	16	here	here	ADV
aji-160	394	17	:	:	PUNCT
aji-160	394	18	https://pr.sdiarticle5.com/review-history/134457	https://pr.sdiarticle5.com/review-history/134457	NOUN
aji-160	394	19	https://pr.sdiarticle5.com/review-history/134457	https://pr.sdiarticle5.com/review-history/134457	NOUN